

Platinum-Based Chemotherapy plus Cetuximab in Head

New England Journal of Medicine

359, 1116-1127

DOI: [10.1056/nejmoa0802656](https://doi.org/10.1056/nejmoa0802656)

Citation Report

#	ARTICLE	IF	CITATIONS
3	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 937-944.	0.4	0
4	Molecularly Targeted Agents in the Treatment of Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck. Hematology/Oncology Clinics of North America, 2008, 22, 1209-1220.	0.9	10
5	Dose-Dependent New Bone Formation by Extracorporeal Shock Wave Application on the Intact Femur of Rabbits. European Surgical Research, 2008, 41, 44-53.	0.6	33
6	Cetuximab in Head and Neck Cancer. New England Journal of Medicine, 2008, 359, 2725-2726.	13.9	4
7	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 1024-1029.	0.4	1
8	Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck. OncoTargets and Therapy, 2009, 2, 243.	1.0	5
12	Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of Oncology, 2009, 2009, 1-14.	0.6	99
13	Update on Anti-EGFR Targeted Therapy. Journal of Oncology, 2009, 2009, 1-2.	0.6	2
14	Epidermal Growth Factor Receptor Inhibition Modulates the Microenvironment by Vascular Normalization to Improve Chemotherapy and Radiotherapy Efficacy. PLoS ONE, 2009, 4, e6539.	1.1	110
15	A review on the treatment of relapsed/metastatic head and neck cancer. Expert Opinion on Pharmacotherapy, 2009, 10, 2625-2632.	0.9	8
16	Pharmacotherapy of head and neck squamous cell carcinoma. Expert Opinion on Pharmacotherapy, 2009, 10, 2291-2302.	0.9	19
17	Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2009, 27, 6052-6069.	0.8	112
18	Role of Cell Cycle in Epidermal Growth Factor Receptor Inhibitor-Mediated Radiosensitization. Cancer Research, 2009, 69, 5108-5114.	0.4	49
19	The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. Cancer Research, 2009, 69, 3021-3031.	0.4	236
20	Phase I Drug Combination Trial Design: Walking the Tightrope. Journal of Clinical Oncology, 2009, 27, 4441-4443.	0.8	26
21	Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets, 2009, 13, 339-362.	1.5	77
22	Phase I Study of C-TPF in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2009, 27, 4448-4453.	0.8	54
23	Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nature Reviews Clinical Oncology, 2009, 6, 132-133.	12.5	10

#	ARTICLE	IF	CITATIONS
24	Strategies to improve drug delivery in bladder cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 727-744.	2.4	19
25	The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP. <i>Cancer Biology and Therapy</i> , 2009, 8, 1914-1921.	1.5	12
26	Monoclonal antibody therapies for solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 341-353.	1.4	19
27	Current situation of zalutumumab. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 667-674.	1.4	15
28	New trends in epidermal growth factor receptor-directed monoclonal antibodies. <i>Immunotherapy</i> , 2009, 1, 965-982.	1.0	10
29	Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium. <i>Journal of Clinical Oncology</i> , 2009, 27, 5102-5108.	0.8	42
30	Molecular therapy in head and neck oncology. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 266-277.	12.5	86
31	PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1116-1123.	2.8	104
32	Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2009, 20, 1275-1279.	0.6	127
33	Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv121-iv122.	0.6	61
34	Immunotherapy for head and neck cancer. <i>Oral Oncology</i> , 2009, 45, 747-751.	0.8	7
35	Advances in understanding of toxicities of treatment for head and neck cancer. <i>Oral Oncology</i> , 2009, 45, 844-848.	0.8	34
36	Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial. <i>Gynecologic Oncology</i> , 2009, 113, 16-20.	0.6	88
37	Targeting EGFR resistance networks in head and neck cancer. <i>Cellular Signalling</i> , 2009, 21, 1255-1268.	1.7	72
38	Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. <i>European Journal of Pharmacology</i> , 2009, 625, 6-22.	1.7	22
39	Targeted radionuclide therapy in head and neck cancer. <i>Head and Neck</i> , 2010, 32, 666-678.	0.9	11
40	A phase 2 study of cetuximab in combination with docetaxel in chemotherapyâ€refractory/resistant patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2009, 115, 1713-1722.	2.0	35
41	The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. <i>Cancer</i> , 2009, 115, 5723-5733.	2.0	210

#	ARTICLE	IF	CITATIONS
42	Molecular targeted therapies in epidermoid carcinoma of the upper aerodigestive tract. <i>Oncologie</i> , 2009, 11, 152-159.	0.2	2
43	Place de la chimiothérapie d'induction dans les carcinomes épidermoïdes de la tête et du cou localement avancés inopérables (hors préservation laryngée). <i>Oncologie</i> , 2009, 11, 133-139.	0.2	2
44	Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan®) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2009, 266, 1937-1944.	0.8	47
45	Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. <i>European Archives of Oto-Rhino-Laryngology</i> , 2009, 266, 1845-1855.	0.8	69
47	Tunicamycin suppresses cisplatin-induced HepG2 cell apoptosis via enhancing p53 protein nuclear export. <i>Molecular and Cellular Biochemistry</i> , 2009, 327, 171-182.	1.4	18
48	Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. <i>Clinical and Translational Oncology</i> , 2009, 11, 340-348.	1.2	53
49	Carcinoma of the anal canal. <i>Oncology Reviews</i> , 2009, 3, 27-40.	0.8	3
50	Recent advances of novel targeted therapy for squamous cell carcinoma of the head and neck. <i>Oncology Reviews</i> , 2009, 3, 149-160.	0.8	1
51	Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future. <i>Oncology Reviews</i> , 2009, 3, 137-148.	0.8	1
52	Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck. <i>Oncology Reviews</i> , 2009, 3, 247-256.	0.8	3
53	Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. <i>Current Oncology Reports</i> , 2009, 11, 156-162.	1.8	19
54	Skin toxicities associated with epidermal growth factor receptor inhibitors. <i>Targeted Oncology</i> , 2009, 4, 107-119.	1.7	240
55	Combined Cetuximab and Reirradiation for Locoregional Recurrent and Inoperable Squamous Cell Carcinoma of the Head and Neck. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 775-781.	1.0	43
57	HPV & head and neck cancer: a descriptive update. <i>Head & Neck Oncology</i> , 2009, 1, 36.	2.3	162
58	Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. <i>Head & Neck Oncology</i> , 2009, 1, 6.	2.3	98
59	Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions. <i>Current Problems in Cancer</i> , 2009, 33, 245-294.	1.0	9
60	Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). <i>British Journal of Cancer</i> , 2009, 101, 1261-1268.	2.9	130
61	Pharmaceutical Perspectives of Cancer Therapeutics. , 2009, , .		15

#	ARTICLE	IF	CITATIONS
62	Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. <i>Cancer Treatment Reviews</i> , 2009, 35, 354-363.	3.4	120
63	Transforming Growth Factor-alpha reduces carcinogen-induced DNA damage in mini-organ cultures from head-and-neck cancer patients. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2009, 677, 42-45.	0.9	7
65	PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2009, 50, 74S-88S.	2.8	172
66	Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 113.	3.5	34
67	Management of Head and Neck Cancer in Elderly Patients. <i>Drugs and Aging</i> , 2009, 26, 571-583.	1.3	22
68	Second-line chemotherapy in head and neck cancer: what should we expect?. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 269-273.	1.1	5
69	Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1421-1428.	1.1	99
70	Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors. <i>International Journal of Radiation Biology</i> , 2009, 85, 943-954.	1.0	38
71	Personalizing cancer care: updates on head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1219-1222.	1.1	0
72	Emerging molecular targeted therapies in the treatment of head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 299-310.	1.0	45
73	Novel therapies in metastatic head and neck squamous cell carcinoma. <i>Community Oncology</i> , 2009, 6, 310-316.	0.2	2
74	Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. <i>Lancet Oncology</i> , The, 2009, 10, 247-257.	5.1	263
75	Targeting the future in head and neck cancer. <i>Lancet Oncology</i> , The, 2009, 10, 204-205.	5.1	8
76	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. <i>Lancet</i> , The, 2009, 373, 1525-1531.	6.3	1,321
77	Docetaxel in the management of head and neck cancer. <i>Anti-Cancer Drugs</i> , 2009, 20, 639-645.	0.7	13
78	Role of molecular markers and gene profiling in head and neck cancers. <i>Current Opinion in Oncology</i> , 2009, 21, 206-211.	1.1	36
79	Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents. <i>Current Opinion in Oncology</i> , 2009, 21, 232-237.	1.1	11
80	Head and neck cancer emerging strategies: advances and new challenges. <i>Current Opinion in Oncology</i> , 2009, 21, 191-193.	1.1	8

#	ARTICLE	IF	CITATIONS
83	NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-5-S-21.	2.3	102
84	Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer. <i>Current Opinion in Oncology</i> , 2009, 21, 491-498.	1.1	4
85	Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Drug Targets</i> , 2009, 9, 931-937.	0.8	32
86	Design and performance of clinical trials in head and neck cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 184-185.	1.1	0
87	Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution. <i>Anti-Cancer Drugs</i> , 2010, 21, 553-558.	0.7	15
89	A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 229-235.	0.5	52
90	Gene alterations in head and neck carcinomas and their role in promoting malignant behavior (Review). <i>International Journal of Oncology</i> , 2010, 36, 525-32.	1.4	5
91	Hepatectomy for liver metastases from squamous cell laryngeal cancer. Is it worthy?. <i>Open Medicine (Poland)</i> , 2010, 5, 535-537.	0.6	0
92	IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. <i>Human Antibodies</i> , 2010, 19, 89-99.	0.6	73
93	Cetuximab-dependent ADCC in cancer: dream or reality?. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1607-1608.	2.0	7
94	Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 259-265.	1.1	4
95	A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 649-660.	1.1	61
96	Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 849-861.	1.1	23
97	Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 37-42.	1.1	28
98	Reirradiation with Alternating Docetaxel-Based Chemotherapy for Recurrent Head and Neck Squamous Cell Carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 255-261.	1.0	32
100	Fractionated Stereotactic Radiosurgery for Reirradiation of Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1411-1419.	0.4	117
101	Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 891-896.	1.2	7
102	SEOM clinical guidelines for the treatment of head and neck cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 742-748.	1.2	8

#	ARTICLE	IF	CITATIONS
104	Cetuximab in combination therapy: from bench to clinic. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 171-180.	2.7	27
105	Phase II study of sunitinib malate in head and neck squamous cell carcinoma. <i>Investigational New Drugs</i> , 2010, 28, 677-683.	1.2	83
106	Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib. <i>Oral Oncology</i> , 2010, 46, 172-177.	0.8	3
107	Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2010, 46, 694-697.	0.8	8
108	Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens. <i>Oral Oncology</i> , 2010, 46, 818-821.	0.8	11
109	Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas. <i>BMC Cancer</i> , 2010, 10, 189.	1.1	70
110	Mechanisms of resistance to HER family targeting antibodies. <i>Experimental Cell Research</i> , 2010, 316, 1083-1100.	1.2	136
111	Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapy. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 805-817.	1.6	3
112	Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2010, 32, 1412-1421.	0.9	109
113	Sorafenib: Where do we go from here?. <i>Hepatology</i> , 2010, 52, 360-369.	3.6	92
114	Induction chemotherapy in the management of head and neck cancer. <i>Journal of Surgical Oncology</i> , 2010, 101, 292-298.	0.8	11
115	Prognostic value of the sixth edition of the UICC's TNM classification and stage grouping for oral cancer. <i>Journal of Surgical Oncology</i> , 2010, 102, 443-449.	0.8	53
116	Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis. <i>Laryngoscope</i> , 2010, 120, 261-266.	1.1	35
117	Radiochemotherapy With Cetuximab, Cisplatin, and Amifostine for Locally Advanced Head and Neck Cancer: A Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 9-15.	0.4	29
118	A Retrospective, Multicenter Study of the Tolerance of Induction Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Radiotherapy With Concomitant Cetuximab in 46 Cases of Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 430-437.	0.4	18
119	Initial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1020-1025.	0.4	25
120	Significance of Interleukin-6 Signaling in the Resistance of Pharyngeal Cancer to Irradiation and the Epidermal Growth Factor Receptor Inhibitor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1214-1224.	0.4	54
121	Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report. <i>Head & Neck Oncology</i> , 2010, 2, 3.	2.3	5

#	ARTICLE	IF	CITATIONS
122	Complete Clinical Response to Cetuximab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma. <i>Dermatologic Surgery</i> , 2010, 36, 2069-2074.	0.4	25
123	Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>British Journal of Cancer</i> , 2010, 102, 500-505.	2.9	163
124	Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. <i>British Journal of Cancer</i> , 2010, 102, 1687-1691.	2.9	52
125	Epidermal Growth Factor Receptor Targeted Therapy in Stages III and IV Head and Neck Cancer. <i>Current Oncology</i> , 2010, 17, 37-48.	0.9	88
126	Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2010, 5, e12702.	1.1	128
127	Cetuximab in Locally Advanced Head-And-Neck Cancer: Defining the Population. <i>Current Oncology</i> , 2010, 17, 48-51.	0.9	6
128	The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. <i>Biologics: Targets and Therapy</i> , 2010, 4, 173.	3.0	39
129	Tracheal cancer treated with a short course of external and endoluminal radio-chemotherapy combined with cetuximab a. <i>Journal of Contemporary Brachytherapy</i> , 2010, 4, 160-162.	0.4	3
130	Squamous cell carcinoma of the head and neck: EHNSâ€“ESMOâ€“ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v184-v186.	0.6	493
131	EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 185-201.	1.0	32
132	Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 8-14.	0.8	234
133	Gain, but what, how much and at what cost?. <i>Annals of Oncology</i> , 2010, 21, 1562-1563.	0.6	0
134	Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2010, 21, 864-870.	0.6	51
135	Optimal treatment for recurrent/metastatic head and neck cancer. <i>Annals of Oncology</i> , 2010, 21, vii252-vii261.	0.6	286
136	Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment. <i>Clinical Cancer Research</i> , 2010, 16, 304-310.	3.2	60
137	Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2010, 16, 2095-2105.	3.2	92
138	Incidental Thyroid Cancer in Head and Neck Squamous Cell Carcinoma. , 2010, 20, 112-114.		0
139	Meta-Analysis of Incidence and Risk of Hypomagnesemia with Cetuximab for Advanced Cancer. <i>Chemotherapy</i> , 2010, 56, 459-465.	0.8	57

#	ARTICLE	IF	CITATIONS
140	Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy. <i>Oncologist</i> , 2010, 15, 976-986.	1.9	30
141	Stereotactic Radiotherapy of Hepatocellular Carcinoma: Preliminary Results. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 479-487.	0.8	107
142	Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: CORTEC 2006-01. <i>Journal of Clinical Oncology</i> , 2010, 28, 21-28.	0.8	172
143	Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2010, 21, 2284-2289.	0.6	25
144	Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin. <i>Chemotherapy</i> , 2010, 56, 268-274.	0.8	5
145	Emerging drugs to treat squamous cell carcinomas of the head and neck. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 355-373.	1.0	96
146	Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2010, 21, 1967-1973.	0.6	99
147	Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 709-722.	1.9	77
148	Understanding resistance to EGFR inhibitors—impact on future treatment strategies. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 493-507.	12.5	593
149	Quality-of-life considerations in treatment of unresectable, recurrent head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 345-352.	1.1	12
150	S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 659-662.	1.1	5
151	Tumor Antigen—Targeted, Monoclonal Antibody—Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape. <i>Journal of Clinical Oncology</i> , 2010, 28, 4390-4399.	0.8	285
152	Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non—Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099. <i>Journal of Clinical Oncology</i> , 2010, 28, 911-917.	0.8	419
153	Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. <i>Experimental Biology and Medicine</i> , 2010, 235, 907-920.	1.1	41
154	Epidermal Growth Factor Receptor Expression and Gene Copy Number in the Risk of Oral Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 800-809.	0.7	108
155	Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee. <i>Annals of Oncology</i> , 2010, 21, 1952-1960.	0.6	22
156	Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5294-5300.	0.8	132
157	Oropharyngeal Cancer, Human Papilloma Virus, and Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1-3.	0.8	78

#	ARTICLE	IF	CITATIONS
158	Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma. <i>Oncologist</i> , 2010, 15, 1320-1328.	1.9	109
159	Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents. <i>Indian Journal of Cancer</i> , 2010, 47, 248.	0.2	12
160	Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 358-365.	1.1	61
161	A Phase II Trial Evaluating Weekly Docetaxel and Capecitabine in Patients with Metastatic or Advanced, Locally Recurrent Head and Neck Cancers. <i>Cancer Investigation</i> , 2010, 28, 910-916.	0.6	5
162	Advances in the systemic treatment of head and neck cancers. <i>Current Opinion in Oncology</i> , 2010, 22, 200-205.	1.1	22
163	Molecular targeted therapies in all histologies of head and neck cancers: an update. <i>Current Opinion in Oncology</i> , 2010, 22, 212-220.	1.1	24
164	Advances in radiotherapy of head and neck cancers. <i>Current Opinion in Oncology</i> , 2010, 22, 194-199.	1.1	32
165	The Role of Chemotherapy in the Management of Patients with Head and Neck Cancer. <i>Seminars in Plastic Surgery</i> , 2010, 24, 137-147.	0.8	6
167	Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. <i>Current Cancer Drug Targets</i> , 2010, 10, 799-812.	0.8	28
168	The Epidermal Growth Factor Receptor Axis: Support for a New Target for Oral Premalignancy. <i>Cancer Prevention Research</i> , 2010, 3, 797-799.	0.7	4
169	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2363-2389.	0.9	19
170	Targeted Therapies for Solid Tumors. <i>BioDrugs</i> , 2010, 24, 303-316.	2.2	18
171	Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1471-1484.	1.1	29
172	Cetuximab. <i>Drugs</i> , 2010, 70, 1987-2010.	4.9	47
173	Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 198-203.	1.1	9
174	Survival comparison between glioblastoma multiforme and other incurable cancers. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 417-421.	0.8	145
175	Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance. <i>Biomedicine and Pharmacotherapy</i> , 2010, 64, 550-558.	2.5	13
176	Esophagogastric cancer: Targeted agents. <i>Cancer Treatment Reviews</i> , 2010, 36, 235-248.	3.4	52

#	ARTICLE	IF	CITATIONS
177	Nasopharyngeal carcinoma: The next challenges. <i>European Journal of Cancer</i> , 2010, 46, 1967-1978.	1.3	201
178	Cetuximab in the management of locoregionally advanced head and neck cancer: Expanding the treatment options?. <i>European Journal of Cancer</i> , 2010, 46, 1979-1989.	1.3	29
179	Relationship Between Environmental Carcinogens and EGFR Targeting Anti-tumor Agents in Head and Neck Cancer. <i>Journal of the Chinese Medical Association</i> , 2010, 73, 457-458.	0.6	0
180	The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers. <i>American Journal of Pathology</i> , 2010, 176, 2607-2615.	1.9	89
181	Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 918-927.	0.8	263
182	Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. <i>Lancet Oncology</i> , The, 2010, 11, 66-74.	5.1	92
183	Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis. <i>Neoplasia</i> , 2010, 12, 206-213.	2.3	16
185	Chemotherapy regimens and treatment protocols for laryngeal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1305-1316.	0.9	17
186	New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors. <i>Clinical Cancer Research</i> , 2010, 16, 2489-2495.	3.2	102
187	Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Pharmacoeconomics</i> , 2010, 28, 439-448.	1.7	45
188	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. <i>Annals of Oncology</i> , 2011, 22, 1535-1546.	0.6	696
189	Noncovalent Functionalization of Carbon Nanovectors with an Antibody Enables Targeted Drug Delivery. <i>ACS Nano</i> , 2011, 5, 6643-6650.	7.3	45
190	Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE. <i>Pharmacoeconomics Italian Research Articles</i> , 2011, 13, 101-110.	0.2	0
191	Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1433-1445.	1.4	15
192	Spotlight on Cetuximab in Squamous Cell Carcinoma of the Head and Neck. <i>BioDrugs</i> , 2011, 25, 129-133.	2.2	5
194	Cetuximab Therapy for Head and Neck Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2011, 144, 676-684.	1.1	38
195	Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 19024-19029.	3.3	91
196	Anti-HER agents in gastric cancer: from bench to bedside. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 369-383.	8.2	73

#	ARTICLE	IF	CITATIONS
197	Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status. <i>Journal of Clinical Oncology</i> , 2011, 29, 2011-2019.	0.8	1,713
198	Targeted Therapies for Thymic Malignancies. <i>Thoracic Surgery Clinics</i> , 2011, 21, 115-123.	0.4	9
200	Targeting the human EGFR family in esophagogastric cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 492-503.	12.5	132
202	Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective. <i>ISRN Oncology</i> , 2011, 2011, 1-13.	2.1	6
203	Management of Recurrent Head and Neck Cancer. <i>Drugs</i> , 2011, 71, 1551-1559.	4.9	46
204	Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated with Cetuximab. <i>Drugs in R and D</i> , 2011, 11, 317-326.	1.1	13
205	Principles of Anticancer Drug Development. , 2011, , .		0
206	Cancer Immunotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 1-64.	0.7	120
207	The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2011, 65, 168-174.	2.5	10
208	PGE2 targets squamous cell carcinoma cell with the activated epidermal growth factor receptor family for survival against 5-fluorouracil through NR4A2 induction. <i>Cancer Letters</i> , 2011, 307, 227-236.	3.2	20
210	The Role of Targeted Molecular Inhibitors in the Management of Advanced Nonmelanoma Skin Cancer. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2011, 30, 57-61.	1.6	11
211	Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 333-343.	5.1	222
212	Re-irradiation with scanned charged particle beams in recurrent tumours of the head and neck: Acute toxicity and feasibility. <i>Radiotherapy and Oncology</i> , 2011, 101, 383-387.	0.3	36
213	Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2011, 99, 339-343.	0.3	52
214	Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. <i>Radiotherapy and Oncology</i> , 2011, 100, 70-75.	0.3	74
215	Practical Considerations in the Re-Irradiation of Recurrent and Second Primary Head-and-Neck Cancer: Who, Why, How, and How Much?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1211-1219.	0.4	74
216	Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. <i>Drug Resistance Updates</i> , 2011, 14, 260-279.	6.5	30
217	EGFR pathway in advanced non-small cell lung cancer. <i>Frontiers in Bioscience - Scholar</i> , 2011, S3, 501-517.	0.8	15

#	ARTICLE	IF	CITATIONS
218	Application of Host Cell Reactivation in Evaluating the Effects of Anticancer Drugs and Environmental Toxicants on Cellular DNA Repair Activity in Head and Neck Cancer. , 0, , .		2
219	Advances in EGFR-directed therapy in head and neck cancer. <i>Frontiers in Bioscience - Scholar</i> , 2011, S3, 454-466.	0.8	10
221	Head and Neck Cancer Metastasis. , 0, , 294-312.		0
222	Evaluation of microRNA expression in head and neck squamous cell carcinoma cell lines and in primary culture of oral keratinocytes. <i>Einstein (Sao Paulo, Brazil)</i> , 2011, 9, 442-448.	0.3	1
223	Current Recommendations for Systemic Therapy of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 681-689.	2.3	27
224	Targeted therapy in head and neck cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2011, 19, 132-137.	0.8	12
225	Design issues in head and neck clinical trials. <i>Anti-Cancer Drugs</i> , 2011, 22, 682-687.	0.7	3
226	Novel therapeutic target for head and neck squamous cell carcinoma. <i>Anti-Cancer Drugs</i> , 2011, 22, 665-673.	0.7	19
227	Current chemotherapies for recurrent/metastatic head and neck cancer. <i>Anti-Cancer Drugs</i> , 2011, 22, 621-625.	0.7	40
228	Role of molecular markers in the management of head and neck cancers. <i>Current Opinion in Oncology</i> , 2011, 23, 259-264.	1.1	26
229	Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy. <i>Current Opinion in Oncology</i> , 2011, 23, 241-248.	1.1	21
230	Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Organ Preservation of Locoregionally Advanced Oral Cavity Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 356-361.	0.6	26
231	Bcl-2 Targeted-Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011, 6, 45-57.	0.8	15
232	Reirradiation in head and neck cancers. <i>Anti-Cancer Drugs</i> , 2011, 22, 634-638.	0.7	3
233	Induction chemotherapy in head and neck cancer. <i>Anti-Cancer Drugs</i> , 2011, 22, 613-620.	0.7	23
234	New advances in targeted therapies for squamous cell carcinoma of the head and neck. <i>Anti-Cancer Drugs</i> , 2011, 22, 626-633.	0.7	10
235	Emerging Therapies in the Treatment of Locally Advanced Squamous Cell Cancers of Head and Neck. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2011, 6, 246-257.	0.8	8
236	Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients. <i>Journal of Wound Care</i> , 2011, 20, 166-170.	0.5	16

#	ARTICLE	IF	CITATIONS
237	Surgical Treatment Is Recommended for Advanced Oral Squamous Cell Carcinoma. <i>Tohoku Journal of Experimental Medicine</i> , 2011, 223, 17-25.	0.5	3
238	Emerging therapies for head and neck cancer: review of the Phase II and III trials. <i>Clinical Investigation</i> , 2011, 1, 669-687.	0.0	0
239	Head and Neck Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 596-650.	2.3	213
240	Controversies in the Locoregional Management of Head and Neck Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 653-662.	2.3	12
241	Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. <i>Oncology Reports</i> , 2011, 27, 467-74.	1.2	13
242	Update on monoclonal antibodies for the treatment of cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 20-25.	0.7	0
243	The emerging era of personalized therapy in squamous cell carcinoma of the head and neck. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 236-251.	0.7	19
244	Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. <i>British Journal of Cancer</i> , 2011, 104, 1691-1696.	2.9	51
245	Antibodies in oncology. <i>New Biotechnology</i> , 2011, 28, 518-529.	2.4	62
246	Staging and Grading as Prognostic Factors in Maxillary Squamous Cell Carcinoma. <i>Journal of Oral and Maxillofacial Surgery</i> , 2011, 69, 3038-3044.	0.5	21
247	The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab+bevacizumab+irradiation combination on head and neck cancer xenografts. <i>Oral Oncology</i> , 2011, 47, 340-344.	0.8	34
248	Oral complications of targeted cancer therapies: A narrative literature review. <i>Oral Oncology</i> , 2011, 47, 441-448.	0.8	115
249	Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2011, 47, 714-719.	0.8	17
250	Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2011, 47, 984-987.	0.8	12
251	Optimizing treatments of locally advanced squamous cell carcinoma: Where to go from here?. <i>Oral Oncology</i> , 2011, 47, 931-933.	0.8	1
252	Antitumor activity of cetuximab associated with the taxotere+cisplatin+fluorouracil (TPF) combination on an orthotopic head and neck cancer model. <i>Oral Oncology</i> , 2011, 47, 940-945.	0.8	9
253	Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. <i>Oral Oncology</i> , 2011, 47, 961-966.	0.8	47
254	The impact of EGFR stimulation and inhibition on BPDE induced DNA fragmentation in oral/oropharyngeal mucosa in vitro. <i>Oral Oncology</i> , 2011, 47, 1141-1147.	0.8	4

#	ARTICLE	IF	CITATIONS
255	Efficacy and immune mechanisms of cetuximab for the treatment of metastatic colorectal cancer. <i>Clinical Oncology and Cancer Research</i> , 2011, 8, 207-214.	0.1	7
256	Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. <i>Investigational New Drugs</i> , 2011, 29, 352-359.	1.2	27
257	Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. <i>Supportive Care in Cancer</i> , 2011, 19, 1079-1095.	1.0	374
258	IMRT Reirradiation with Concurrent Cetuximab Immunotherapy in Recurrent Head and Neck Cancer. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 32-38.	1.0	36
259	Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 373-377.	1.0	24
261	Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 769-776.	1.1	30
262	Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1477-1484.	1.1	15
263	Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. <i>Immunologic Research</i> , 2011, 50, 248-254.	1.3	136
264	Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer. <i>Medical Oncology</i> , 2011, 28, 246-249.	1.2	1
265	Cetuximab concomitant with gemcitabine and radiotherapy in advanced squamous cell carcinomas of upper aerodigestive tract: a pilot study. <i>Clinical and Translational Oncology</i> , 2011, 13, 109-114.	1.2	5
266	Pulmonary toxicities from targeted therapies: a review. <i>Targeted Oncology</i> , 2011, 6, 235-243.	1.7	94
267	Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents. <i>Targeted Oncology</i> , 2011, 6, 227-233.	1.7	50
268	Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. <i>Molecular Cancer</i> , 2011, 10, 12.	7.9	770
269	EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2011, 9, 168.	1.8	17
270	Radiotherapy and "new" drugs-new side effects?. <i>Radiation Oncology</i> , 2011, 6, 177.	1.2	53
271	The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head & Neck Oncology</i> , 2011, 3, 11.	2.3	75
272	HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. <i>Journal of Cellular Physiology</i> , 2011, 226, 2378-2390.	2.0	139
273	Cetuximab as primary treatment for cutaneous squamous cell carcinoma to the neck. <i>Head and Neck</i> , 2011, 33, 286-288.	0.9	29

#	ARTICLE	IF	CITATIONS
274	Insulin-like growth factor-1 receptor inhibitor, AMG479, in cetuximab-refractory head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2011, 33, 1804-1808.	0.9	16
275	Reirradiation with intensity-modulated radiotherapy in recurrent head and neck cancer. <i>Head and Neck</i> , 2011, 33, 1695-1702.	0.9	31
276	A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. <i>Cancer</i> , 2011, 117, 795-801.	2.0	11
277	Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. <i>Cancer</i> , 2011, 117, 2112-2119.	2.0	93
278	Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. <i>Cancer</i> , 2011, 117, 3173-3181.	2.0	53
279	Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. <i>International Journal of Cancer</i> , 2011, 129, 870-878.	2.3	53
280	Gefitinib in Combination With Irradiation With or Without Cisplatin in Patients With Inoperable Stage III Non-Small Cell Lung Cancer: A Phase I Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 126-132.	0.4	46
281	ACR Appropriateness Criteria® Retreatment of Recurrent Head and Neck Cancer After Prior Definitive Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1292-1298.	0.4	107
282	Cellular and Tumor Radiosensitivity is Correlated to Epidermal Growth Factor Receptor Protein Expression Level in Tumors Without EGFR Amplification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1181-1188.	0.4	38
283	Targeted anti-cancer therapy in the elderly. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 227-242.	2.0	33
284	The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3619-3630.	3.2	46
285	Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?. <i>Current Medicinal Chemistry</i> , 2011, 18, 5528-5544.	1.2	51
286	A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2011, 22, 417-423.	0.6	17
287	Durable complete response induced by paclitaxel-nimotuzumab-methotrexate chemotherapy in a patient with metastatic head and neck squamous cell carcinoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2011, 4, 182-184.	0.6	8
288	Development of targeted therapy for squamous cell carcinomas of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 373-386.	1.1	9
289	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. <i>Cancer Biology and Therapy</i> , 2011, 11, 777-792.	1.5	209
290	Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. <i>Current Medical Research and Opinion</i> , 2011, 27, 2253-2259.	0.9	25
291	Specific targeting of nasopharyngeal carcinoma cell line CNE1 by C225-conjugated ultrasmall superparamagnetic iron oxide particles with magnetic resonance imaging. <i>Acta Biochimica Et Biophysica Sinica</i> , 2011, 43, 301-306.	0.9	16

#	ARTICLE	IF	CITATIONS
292	New advances in molecular approaches to head and neck squamous cell carcinoma. <i>Anti-Cancer Drugs</i> , 2011, 22, 656-664.	0.7	42
293	Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1140-1145.	0.8	112
294	The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab. <i>Clinical Cancer Research</i> , 2011, 17, 6766-6777.	3.2	30
295	Current status of experimental therapeutics for head and neck cancer. <i>Experimental Biology and Medicine</i> , 2011, 236, 375-389.	1.1	36
296	Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. <i>Cancer Biology and Therapy</i> , 2011, 12, 436-446.	1.5	15
297	ThÃ©rapeutiques ciblÃ©es dans le traitement des tumeurs solides. , 2011, , 55-89.		1
298	Expression of Amphiregulin and EGFRVIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab+Docetaxel Treatment. <i>Clinical Cancer Research</i> , 2011, 17, 5197-5204.	3.2	85
299	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. <i>Annals of Oncology</i> , 2011, 22, 1078-1087.	0.6	204
300	Targeted Therapy in Nonmelanoma Skin Cancers. <i>Cancers</i> , 2011, 3, 2255-2273.	1.7	18
301	Novel Phosphoinositide 3-Kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells <i>in Vitro</i> and <i>in Vivo</i> . <i>Clinical Cancer Research</i> , 2011, 17, 7116-7126.	3.2	107
302	Therapeutic Monoclonal Antibodies: Current Perspectives and Applications for the Treatment of Head and Neck Cancer. <i>International Journal of Head and Neck Surgery</i> , 2011, 2, 87-94.	0.1	0
303	Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1230-1237.	1.1	84
304	Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab. <i>Clinical Cancer Research</i> , 2011, 17, 4996-5004.	3.2	26
305	Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. <i>Science Translational Medicine</i> , 2011, 3, 99ra86.	5.8	543
306	A Study Using Ifosfamide and Etoposide in Patients with Cisplatin-refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 630-636.	0.6	6
307	Long-Term Survival in a Smoking Caucasian Male Patient Treated with Gefitinib for Spinal Cord Compression Secondary to Lung Cancer. <i>Onkologie</i> , 2011, 34, 326-328.	1.1	4
308	Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. <i>MAbs</i> , 2011, 3, 396-401.	2.6	45
309	The cetuximab experience: developing predictive biomarkers in oncology. <i>Personalized Medicine</i> , 2011, 8, 149-159.	0.8	1

#	ARTICLE	IF	CITATIONS
310	Durable Complete Remission Induced by Cetuximab Monotherapy in a Patient Infected With HIV and Diagnosed With Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2011, 29, e222-e225.	0.8	3
311	Reply to D. Herchenhorn et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e285-e287.	0.8	3
312	Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. <i>Oncologist</i> , 2011, 16, 228-238.	1.9	94
313	When Bad Things Happen to Good Studies. <i>Journal of Clinical Oncology</i> , 2011, 29, 3497-3499.	0.8	7
314	Cetuximab in the treatment of squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 511-524.	1.1	40
315	Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 359-371.	1.1	7
316	Possible case of levofloxacin-induced thrombocytopenia. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 43-46.	0.5	12
317	Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. <i>Annals of Oncology</i> , 2011, 22, 567-574.	0.6	14
319	Empowering induction therapy for locally advanced head and neck cancer. <i>Annals of Oncology</i> , 2011, 22, 773-781.	0.6	15
320	Lower ataxia telangiectasia mutated (ATM) mRNA expression is correlated with poor outcome of laryngeal and pharyngeal cancer patients. <i>Annals of Oncology</i> , 2011, 22, 1088-1093.	0.6	23
321	Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. <i>Annals of Oncology</i> , 2011, 22, 712-717.	0.6	67
322	HPV16E6-Dependent c-Fos Expression Contributes to AP-1 Complex Formation in SiHa Cells. <i>Mediators of Inflammation</i> , 2011, 2011, 1-7.	1.4	5
323	The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. <i>Annals of Oncology</i> , 2011, 22, 2366-2374.	0.6	24
324	Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>ISRN Oncology</i> , 2012, 2012, 1-6.	2.1	6
325	Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. <i>Annals of Oncology</i> , 2012, 23, 1016-1022.	0.6	196
326	Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. <i>Annals of Oncology</i> , 2012, 23, 1672-1679.	0.6	106
327	Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial. <i>Annals of Oncology</i> , 2012, 23, 1005-1009.	0.6	13
328	Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). <i>Annals of Oncology</i> , 2012, 23, 2153-2161.	0.6	66

#	ARTICLE	IF	CITATIONS
329	Biologic Therapy in Head and Neck Cancer: A Road with Hurdles. <i>ISRN Oncology</i> , 2012, 2012, 1-15.	2.1	17
330	Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: A retrospective analysis. <i>Indian Journal of Cancer</i> , 2012, 49, 1.	0.2	8
331	Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. <i>Annals of Oncology</i> , 2012, 23, 1010-1016.	0.6	20
332	The role of cetuximab in the management of head and neck cancers. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 517-528.	1.4	23
333	New Strategies in Squamous Cell Carcinoma of the Lung: Identification of Tumor Drivers to Personalize Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 3002-3007.	3.2	32
334	New promising molecular targets in head and neck squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2012, 24, 235-242.	1.1	31
335	Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy. <i>Current Opinion in Oncology</i> , 2012, 24, 211-217.	1.1	28
337	Evidence based and new developments in re-irradiation for recurrent or second primary head and neck cancers. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2012, 20, 137-141.	0.8	5
338	Epidermal Growth Factor Receptor Inhibitors for Treatment of Orbital Squamous Cell Carcinoma. <i>JAMA Ophthalmology</i> , 2012, 130, 1608.	2.6	42
339	Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3545-3551.	0.8	115
340	Prospective Trial of Synchronous Bevacizumab, Erlotinib, and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1404-1414.	3.2	77
344	Anti-cancer Effects of Curcumin on Head and Neck Cancers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 1110-1116.	0.9	28
345	Anti-Tumor Monoclonal Antibodies in Conjunction with β -Glucans: A Novel Anti- Cancer Immunotherapy. <i>Current Medicinal Chemistry</i> , 2012, 19, 4298-4305.	1.2	22
346	Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas. <i>Annals of Oncology</i> , 2012, 23, 3129-3137.	0.6	18
347	Disseminated <i>Mycobacterium chelonae</i> Infection in a Patient Receiving an Epidermal Growth Factor Receptor Inhibitor for Advanced Head and Neck Cancer. <i>Journal of Clinical Microbiology</i> , 2012, 50, 194-195.	1.8	12
348	Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors. <i>Current Clinical Pharmacology</i> , 2012, 7, 137-145.	0.2	36
349	Autophagic action of new targeting agents in head and neck oncology. <i>Cancer Biology and Therapy</i> , 2012, 13, 978-991.	1.5	21
350	Targeted Therapy at the End of Life in Advanced Cancer Patients. <i>Journal of Palliative Medicine</i> , 2012, 15, 991-997.	0.6	20

#	ARTICLE	IF	CITATIONS
351	Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. <i>Head and Neck</i> , 2013, 35, 1471-1474.	0.9	18
352	Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. <i>Cancer Gene Therapy</i> , 2012, 19, 181-191.	2.2	36
353	Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. <i>Cell Cycle</i> , 2012, 11, 963-973.	1.3	13
354	Zalutumumab in head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 119-125.	1.4	22
355	Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. <i>Expert Opinion on Drug Safety</i> , 2012, 11, S9-S19.	1.0	80
356	Reirradiation for recurrent head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1177-1189.	1.1	27
357	Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3 ¹² /snail signalling pathway. <i>British Journal of Cancer</i> , 2012, 106, 1196-1204.	2.9	105
358	Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients. <i>Journal of Medical Economics</i> , 2012, 15, 786-795.	1.0	18
359	Correlation between Gene Expression of IGF-1R Pathway Markers and Cetuximab Benefit in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1156-1166.	3.2	32
360	The Risk for Anemia with Targeted Therapies for Solid Tumors. <i>Oncologist</i> , 2012, 17, 715-724.	1.9	34
361	Recent Advances in Biomarkers and Potential Targeted Therapies in Head and Neck Squamous Cell Carcinoma. <i>ISRN Surgery</i> , 2012, 2012, 1-7.	1.4	4
362	The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck. <i>Chemotherapy Research and Practice</i> , 2012, 2012, 1-13.	1.6	12
363	Advances in Targeting HER3 as an Anticancer Therapy. <i>Chemotherapy Research and Practice</i> , 2012, 2012, 1-9.	1.6	36
364	EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab. <i>Chemotherapy Research and Practice</i> , 2012, 2012, 1-10.	1.6	7
365	Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review. <i>Oncologist</i> , 2012, 17, 555-568.	1.9	44
366	A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2012, 18, 2336-2343.	3.2	104
367	Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma. <i>Anti-Cancer Drugs</i> , 2012, 23, 996-1001.	0.7	42
368	Senior Adult Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 162-209.	2.3	105

#	ARTICLE	IF	CITATIONS
369	Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer. <i>Current Pharmaceutical Design</i> , 2012, 18, 5431-5441.	0.9	9
370	Making the Most of Pathological Specimens: Molecular Diagnosis in Formalin-Fixed, Paraffin Embedded Tissue. <i>Current Drug Targets</i> , 2012, 13, 1475-1487.	1.0	35
372	Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma. <i>Anti-Cancer Drugs</i> , 2012, 23, 1107-1111.	0.7	10
373	Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. <i>International Journal of Molecular Medicine</i> , 2012, 30, 126-32.	1.8	6
374	Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma. <i>Oncology Letters</i> , 2012, 4, 898-904.	0.8	1
375	A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m ² for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1391-1398.	2.3	32
377	ASCO 2012. <i>Oncology Times</i> , 2012, 34, 18-20.	0.1	0
378	Mechanisms of acquired resistance to anti-EGF receptor treatment in colorectal cancer. <i>Colorectal Cancer</i> , 2012, 1, 491-502.	0.8	1
379	Antitumor effect of cetuximab in combination with S-1 in EGFR-amplified gastric cancer cells. <i>International Journal of Oncology</i> , 2012, 40, 975-982.	1.4	17
380	RASSF1A and ERCC1 Expression Levels Might Be Predictive of Prognosis in Advanced, Recurrent, and Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with Docetaxel and Cisplatin. <i>Onkologie</i> , 2012, 35, 673-682.	1.1	8
381	Cisplatin and 5-Fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012, 110, E661-6.	1.3	76
382	Epigenetic and genetic alterations-based molecular classification of head and neck cancer. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 279-290.	1.5	17
383	Clinical trial design in head and neck cancer: what has the oncologist learned?. <i>Lancet Oncology</i> , The, 2012, 13, e318-e323.	5.1	4
384	Cancer-Associated Fibroblasts Induce Matrix Metalloproteinase-Mediated Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cells. <i>Molecular Cancer Research</i> , 2012, 10, 1158-1168.	1.5	99
385	Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature. <i>European Archives of Oto-Rhino-Laryngology</i> , 2012, 269, 2157-2167.	0.8	25
387	Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e67-e75.	0.4	192
388	Continuous-Course Reirradiation With Concurrent Carboplatin and Paclitaxel for Locally Recurrent, Nonmetastatic Squamous Cell Carcinoma of the Head-and-Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 690-695.	0.4	37
389	Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 203-209.	0.4	98

#	ARTICLE	IF	CITATIONS
390	Reirradiation With Cetuximab in Locoregional Recurrent and Inoperable Squamous Cell Carcinoma of the Head and Neck: Feasibility and First Efficacy Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e377-e383.	0.4	31
391	Monitoring of Circulating Tumor Cells and Their Expression of EGFR/Phospho-EGFR During Combined Radiotherapy Regimens in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e685-e690.	0.4	63
392	A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2012, 127, 456-461.	0.6	40
393	Chemioterapia e terapie mirate nel trattamento delle neoplasie delle vie aerodigestive superiori (escluso il linfoma maligno). <i>EMC - Otorinolaringoiatria</i> , 2012, 11, 1-16.	0.0	0
394	Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab. <i>Neoplasia</i> , 2012, 14, 1023-IN3.	2.3	90
395	Quimioterapia y terapias dirigidas en el tratamiento de los cánceres de las vías aerodigestivas superiores (excluido el linfoma maligno). <i>EMC - Otorrinolaringología</i> , 2012, 41, 1-18.	0.0	0
396	Novel targeted therapies in head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 281-295.	1.9	11
398	Noncovalent Assembly of Targeted Carbon Nanovectors Enables Synergistic Drug and Radiation Cancer Therapy <i>in Vivo</i> . <i>ACS Nano</i> , 2012, 6, 2497-2505.	7.3	26
399	Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. <i>Cancer Biology and Therapy</i> , 2012, 13, 935-945.	1.5	27
400	Why RECIST Works and Why It Should Stayâ€”Counterpoint. <i>Cancer Research</i> , 2012, 72, 5151-5157.	0.4	28
401	Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. <i>Cancer Letters</i> , 2012, 321, 120-127.	3.2	67
402	Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome. <i>Cancer Letters</i> , 2012, 321, 18-26.	3.2	23
403	Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. <i>Cancer Treatment Reviews</i> , 2012, 38, 505-514.	3.4	53
404	Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma. <i>BMC Genomics</i> , 2012, 13, 160.	1.2	29
405	Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. <i>BMC Cancer</i> , 2012, 12, 368.	1.1	49
406	A new analysis approach of epidermal growth factor receptor pathway activation patterns provides insights into cetuximab resistance mechanisms in head and neck cancer. <i>BMC Medicine</i> , 2012, 10, 43.	2.3	2
407	Therapeutic Drug Monitoring of Selected Anticancer Drugs. , 2012, , 291-321.		1
408	Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab. <i>Oncologist</i> , 2012, 17, 14-e34.	1.9	74

#	ARTICLE	IF	CITATIONS
409	Targeted Therapy for Gastric Adenocarcinoma. <i>Advances in Pharmacology</i> , 2012, 65, 437-470.	1.2	10
410	Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1149-1159.	1.1	51
411	From chemoprevention and organ preservation programs to post-operative management: major achievements and strategies of the EORTC Head and Neck Cancer Group. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 76-81.	2.2	0
412	Oropharynx Cancer. <i>Current Problems in Cancer</i> , 2012, 36, 334-415.	1.0	5
413	The interaction of EGFR and repair of DNA damage following chemotherapy and radiation. <i>Drug Discovery Today: Disease Models</i> , 2012, 9, e69-e73.	1.2	1
414	Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptor. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 612-620.	0.5	38
415	Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell-activating cytokines. <i>Surgery</i> , 2012, 152, 431-440.	1.0	58
416	Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment. <i>Oral Oncology</i> , 2012, 48, 787-793.	0.8	40
417	Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2012, 48, 887-892.	0.8	42
418	Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. <i>Oral Oncology</i> , 2012, 48, 1281-1288.	0.8	71
419	Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature. <i>Oral Oncology</i> , 2012, 48, 1085-1089.	0.8	75
420	Management of squamous cell carcinoma of the head and neck in the elderly: Review and recommendations. <i>Journal of Geriatric Oncology</i> , 2012, 3, 265-272.	0.5	2
421	Cetuximab in non-melanoma skin cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 949-956.	1.4	33
422	The expression of epidermal growth factor receptor and Ki67 in primary and relapse nasopharyngeal cancer: a micro-evidence for anti-EGFR targeted maintenance therapy. <i>Medical Oncology</i> , 2012, 29, 1448-1455.	1.2	15
423	New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). <i>Medical Oncology</i> , 2012, 29, 2481-2491.	1.2	55
424	New drugs for head and neck cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 236-241.	0.3	0
425	Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells. <i>Neoplasia</i> , 2012, 14, 463-IN3.	2.3	36
427	The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 539-546.	1.1	4

#	ARTICLE	IF	CITATIONS
428	Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies. <i>BioDrugs</i> , 2012, 26, 83-99.	2.2	33
429	Patient-derived tumour xenografts as models for oncology drug development. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 338-350.	12.5	1,091
430	The road to resistance: EGFR mutation and cetuximab. <i>Nature Medicine</i> , 2012, 18, 199-200.	15.2	56
431	Molecular Characterization of Head and Neck Cancer. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 209-222.	1.6	22
432	Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trial. <i>Radiation Oncology</i> , 2012, 7, 57.	1.2	5
433	Regulation of Epidermal Growth Factor Receptor Signaling and Erlotinib Sensitivity in Head and Neck Cancer Cells by miR-7. <i>PLoS ONE</i> , 2012, 7, e47067.	1.1	68
434	Ten Years of Progress in Head and Neck Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 806-810.	2.3	44
435	Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Oncology</i> , 2012, 2012, 1-11.	0.6	17
436	Angiogenesis in Head and Neck Cancer: A Review of the Literature. <i>Journal of Oncology</i> , 2012, 2012, 1-9.	0.6	33
437	The Management of Skin Toxicity during Cetuximab Treatment in Advanced Colorectal Cancer: How much does it Cost? A Retrospective Economic Assessment from a Single-Center Experience. <i>Tumori</i> , 2012, 98, 408-412.	0.6	8
438	Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas. <i>Current Angiogenesis</i> , 2012, 1, 26-38.	0.1	0
439	Advanced Squamous Cell Carcinoma of the Skin. , 2012, , .		1
442	Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab. <i>Clinical Medicine Insights Ear, Nose and Throat</i> , 2012, 5, CMENT.S5129.	1.5	17
443	Cetuximab for Head and Neck Cancer from bench to clinic. <i>Journal of Solid Tumors</i> , 2012, 2, .	0.1	0
444	The role of EGFR-targeting strategies in the treatment of head and neck cancer. <i>OncoTargets and Therapy</i> , 2012, 5, 127.	1.0	6
445	Tumor control versus adverse events with targeted anticancer therapies. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 98-109.	12.5	90
446	Targeted therapy in head and neck cancer. <i>Tumor Biology</i> , 2012, 33, 707-721.	0.8	75
447	Anti-EGFR targeting agents in recurrent or metastatic head and neck carcinoma: A meta-analysis. <i>Head and Neck</i> , 2012, 34, 1657-1664.	0.9	8

#	ARTICLE	IF	CITATIONS
448	Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2012, 34, 1517-1523.	0.9	20
449	A population-based study of therapy and survival for patients with head and neck cancer treated in the community. <i>Cancer</i> , 2012, 118, 4452-4461.	2.0	44
450	Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer. <i>Cancer</i> , 2012, 118, 4694-4705.	2.0	40
451	Modulation of the Tumor Microvasculature by Phosphoinositide-3 Kinase Inhibition Increases Doxorubicin Delivery <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2012, 18, 161-169.	3.2	41
452	Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. <i>Strahlentherapie Und Onkologie</i> , 2012, 188, 235-242.	1.0	14
453	Current Treatment Options for Metastatic Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 35-46.	1.3	197
454	Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 561-569.	0.8	17
455	A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 121-128.	1.1	34
456	Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1385-1394.	1.2	3
457	New developments and opportunities in oral mucosal drug delivery for local and systemic disease. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 16-28.	6.6	251
458	Recent advances in head and neck cancer. <i>Apollo Medicine</i> , 2012, 9, 96-103.	0.0	3
459	Molecular-Targeted Therapies in Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2012, 22, 207-213.	1.0	9
460	Relationship between epidermal growth factor receptor gene copy number and protein expression in oral cavity squamous cell carcinoma. <i>Oral Oncology</i> , 2012, 48, 67-72.	0.8	39
461	Therapeutic targets in head and neck squamous cell carcinoma: Identification, evaluation, and clinical translation. <i>Oral Oncology</i> , 2012, 48, 10-17.	0.8	20
462	CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. <i>Oral Oncology</i> , 2012, 48, 585-593.	0.8	54
464	Combined therapy for thyroid squamous cell carcinoma. <i>Head and Neck</i> , 2012, 34, 131-134.	0.9	9
465	Current trends in initial management of hypopharyngeal cancer: The declining use of open surgery. <i>Head and Neck</i> , 2012, 34, 270-281.	0.9	238
468	PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 300-308.	3.3	29

#	ARTICLE	IF	CITATIONS
469	Adding a combination of hydroxycitrate and lipoic acid (METABLOCA,®) to chemotherapy improves effectiveness against tumor development: experimental results and case report. <i>Investigational New Drugs</i> , 2012, 30, 200-211.	1.2	49
470	Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 491-499.	1.2	23
471	Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2013, 35, 443-453.	0.9	33
472	Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. <i>Head and Neck</i> , 2013, 35, 294-306.	0.9	32
473	Molecular targeting agents in the context of primary chemoradiation strategies. <i>Head and Neck</i> , 2013, 35, 738-746.	0.9	4
474	Early postoperative epidermal growth factor receptor inhibition: Safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. <i>Head and Neck</i> , 2013, 35, 321-328.	0.9	14
475	Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2013, 11, 67.	0.8	57
476	The Role of Systemic Treatment Before, During, and After Definitive Treatment. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, 645-656.	0.5	2
477	A gene expression profile test to resolve head & neck squamous versus lung squamous cancers. <i>Diagnostic Pathology</i> , 2013, 8, 44.	0.9	12
478	Systemic Therapy in Head and Neck Cancer: Changing Paradigm. <i>Indian Journal of Surgical Oncology</i> , 2013, 4, 19-26.	0.3	7
479	Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. <i>Biomaterials</i> , 2013, 34, 8690-8707.	5.7	408
480	Cancer Genomics. , 2013, , .		4
481	Foolâ€™s gold, lost treasures, and the randomized clinical trial. <i>BMC Cancer</i> , 2013, 13, 193.	1.1	42
482	Patientsâ€™ perspectives on palliative chemotherapy of colorectal and non - colorectal cancer: a prospective study in a chemotherapy- experienced population. <i>BMC Cancer</i> , 2013, 13, 66.	1.1	14
483	Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. <i>BMC Clinical Pathology</i> , 2013, 13, 1.	1.8	23
484	Impact of Genetic Targets on Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, v-vi.	0.8	1
485	Efficacy and safety of photodynamic therapy with temoporfin in curative treatment of recurrent carcinoma of the oral cavity and oropharynx. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 1433-1439.	0.8	18
486	Phase I clinical study of vascular targeting fluorescent cationic liposomes in head and neck cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 1481-1487.	0.8	5

#	ARTICLE	IF	CITATIONS
487	Skin Rash During Cetuximab Treatment in Advanced Colorectal Cancer: is Age a Clinical Predictor?. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 241-245.	0.6	7
488	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. <i>Supportive Care in Cancer</i> , 2013, 21, 3243-3254.	1.0	46
489	Molecularly targeted therapies for nonmelanoma skin cancers. <i>International Journal of Dermatology</i> , 2013, 52, 654-665.	0.5	21
490	A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 545-552.	1.1	17
491	Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1473-1483.	1.1	15
492	Promising New Molecular Targeted Therapies in Head and Neck Cancer. <i>Drugs</i> , 2013, 73, 315-325.	4.9	81
494	Reirradiation plus EGFR inhibition in locally recurrent and unresectable head and neck cancer. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 842-848.	1.0	13
495	Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. <i>Journal of Biomedical Science</i> , 2013, 20, 43.	2.6	29
496	Sarcoidosis Mimicking Metastatic Bone Disease in Head and Neck Cancer. <i>Seminars in Oncology</i> , 2013, 40, 529-534.	0.8	8
497	Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. <i>European Journal of Cancer</i> , 2013, 49, 1161-1168.	1.3	151
498	Targeting Receptor Tyrosine Kinases in Solid Tumors. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 685-703.	0.6	8
499	The quest to overcome resistance to EGFR-targeted therapies in cancer. <i>Nature Medicine</i> , 2013, 19, 1389-1400.	15.2	883
500	Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2013, 49, 2877-2883.	1.3	30
501	Pemetrexed in head and neck cancer: A systematic review. <i>Oral Oncology</i> , 2013, 49, 492-501.	0.8	12
502	Promising systemic immunotherapies in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2013, 49, 1089-1096.	0.8	101
503	SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013. <i>Clinical and Translational Oncology</i> , 2013, 15, 1018-1024.	1.2	12
504	Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. <i>Lancet Oncology</i> , The, 2013, 14, e302-e309.	5.1	76
505	Current status and future directions in induction chemotherapy for head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 57-74.	2.0	10

#	ARTICLE	IF	CITATIONS
506	Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 1326-1336.	5.1	66
507	Aurora kinases in head and neck cancer. <i>Lancet Oncology</i> , The, 2013, 14, e425-e435.	5.1	55
509	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. <i>Molecular Oncology</i> , 2013, 7, 776-790.	2.1	140
510	Treatment of metastatic cervical cancer: Future directions involving targeted agents. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 303-314.	2.0	71
511	A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2013, 49, 461-467.	0.8	81
512	Biomarkers in Oncology. , 2013, , .		1
513	p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: Correlation with outcomes following chemo-radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 109, 146-151.	0.3	65
514	Epidermal Growth Factor Receptor Targeting in Head and Neck Cancer: Have We Been Just Skimming the Surface?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1381-1383.	0.8	36
515	Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 663-676.	1.3	11
516	A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2013, 119, 766-773.	2.0	31
517	Monoclonal antibodies in lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 209-226.	1.4	17
518	Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2013, 49, 352-359.	1.3	23
519	HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer. <i>Oral Diseases</i> , 2013, 19, 206-211.	1.5	19
520	Consensus recommendations for management of head and neck cancer in Asian countries: A review of international guidelines. <i>Oral Oncology</i> , 2013, 49, 872-877.	0.8	67
521	EGFR-directed treatments in SCCHN. <i>Lancet Oncology</i> , The, 2013, 14, 672-673.	5.1	14
522	Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 627-637.	5.1	346
523	HSP90 Inhibitor SNX5422/ 2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma. <i>Translational Oncology</i> , 2013, 6, 429-435.	1.7	22
524	Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. <i>Radiotherapy and Oncology</i> , 2013, 109, 281-285.	0.3	157

#	ARTICLE	IF	CITATIONS
525	p16 post-hoc analyses and Simpson's paradox. <i>Lancet Oncology</i> , The, 2013, 14, e436.	5.1	2
526	Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: Prognostic value of MAGE-A subgroups for treatment success. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2013, 41, 623-629.	0.7	19
527	Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 112-120.	2.0	21
528	A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). <i>Oral Oncology</i> , 2013, 49, 835-841.	0.8	54
529	The clinical predictive factors for subsequent distant metastasis in patients with locoregionally advanced oral squamous cell carcinoma. <i>Oral Oncology</i> , 2013, 49, 367-373.	0.8	23
530	Squamous cell carcinoma of the head and neck in the elderly. <i>Reports of Practical Oncology and Radiotherapy</i> , 2013, 18, 16-25.	0.3	69
531	Linifanib (ABT-869) enhances radiosensitivity of head and neck squamous cell carcinoma cells. <i>Oral Oncology</i> , 2013, 49, 591-597.	0.8	13
532	Predisposing factors, management, and prognostic evaluation of acute carotid blowout syndrome. <i>Journal of Vascular Surgery</i> , 2013, 58, 1226-1235.	0.6	49
533	Targeted Therapy in Head and Neck Cancer. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2013, 25, 83-92.	0.4	3
535	Oral Metronomic Chemotherapy in Recurrent, Metastatic and Locally Advanced Head and Neck Cancers. <i>Clinical Oncology</i> , 2013, 25, 388.	0.6	18
536	mTHPC mediated photodynamic therapy (PDT) of squamous cell carcinoma in the head and neck: A systematic review. <i>Oral Oncology</i> , 2013, 49, 192-210.	0.8	49
537	Multidisciplinary Care of the Patient with Head and Neck Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 179-215.	0.6	23
538	Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes. <i>Oral Oncology</i> , 2013, 49, 482-491.	0.8	41
539	Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer. <i>Medical Oncology</i> , 2013, 30, 358.	1.2	8
540	Head and neck cancer: from anatomy to biology. <i>International Journal of Cancer</i> , 2013, 133, 2013-2023.	2.3	130
541	Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial. <i>Annals of Oncology</i> , 2013, 24, 448-453.	0.6	24
542	Malignant epithelial tumors: Part II. Therapy and prevention. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 9-27.	0.4	5
543	Maligne epitheliale Tumoren: Teil II. Therapie und Prävention. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 9-28.	0.4	14

#	ARTICLE	IF	CITATIONS
544	Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2013, 35, 1819-1828.	0.9	38
545	Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1405-1414.	0.8	188
546	Significance of circulating tumor cell detection using the CellSearch system in patients with locally advanced head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 2745-2749.	0.8	53
547	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 490-499.	5.1	740
548	Second Branchial Cleft Cyst. , 2013, , 2368-2368.		0
549	Impact of Genetic Targets on Therapy in Head and Neck Squamous Cell Carcinoma. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, 165-177.	0.8	6
550	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 233-247.	1.1	38
551	Monoclonal antibodies in oncology therapeutics: present and future indications. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 269-282.	1.4	22
552	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 697-710.	5.1	402
553	Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade. <i>Oncogene</i> , 2013, 32, 2873-2881.	2.6	32
554	Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Investigational New Drugs</i> , 2013, 31, 417-424.	1.2	75
555	The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases. <i>Human Pathology</i> , 2013, 44, 2690-2695.	1.1	42
556	Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Investigational New Drugs</i> , 2013, 31, 1207-1216.	1.2	32
557	Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: Systematic review and meta-analysis. <i>Head and Neck</i> , 2013, 35, 1048-1055.	0.9	59
558	Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy – Update of the EORTC QLQ-H&N35, Phase I. <i>Head and Neck</i> , 2013, 35, 1331-1338.	0.9	27
559	Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma. <i>International Journal of Cancer</i> , 2013, 132, 1042-1050.	2.3	19
560	Personalized Management of Head & Neck Cancer. , 2013, , .		0
561	Interstitial photodynamic therapy in combination with Cetuximab for recurrent head and neck squamous cell carcinoma. <i>Proceedings of SPIE</i> , 2013, , .	0.8	0

#	ARTICLE	IF	CITATIONS
562	Treatment of Advanced Cutaneous Squamous Cell Carcinomas with Epidermal Growth Factor Receptor Inhibitors. <i>Dermatology</i> , 2013, 227, 289-294.	0.9	23
563	Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 524-531.	0.6	67
566	A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade, Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. <i>Annals of Oncology</i> , 2013, 24, 769-776.	0.6	25
567	Treatment Strategy for Superficial Pharyngeal Squamous Cell Carcinoma Synchronously Combined with Esophageal Cancer. <i>Oncology</i> , 2013, 84, 57-64.	0.9	6
568	Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2013, 3, 5.	1.3	5
569	Role of Met Axis in Head and Neck Cancer. <i>Cancers</i> , 2013, 5, 1601-1618.	1.7	6
570	Analysis of the EGFR Mutation Status in Head and Neck Squamous Cell Carcinoma before Treatment with Gefitinib. <i>Onkologie</i> , 2013, 36, 161-166.	1.1	5
571	Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie. <i>Oncology</i> , 2013, 84, 284-289.	0.9	40
572	Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2013, 24, 2261-2266.	0.6	29
573	A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2013, 24, 761-769.	0.6	89
574	Effets secondaires, complications et s�quelles de la chimioth�rapie. , 2013, , 125-147.		0
575	Emerging tyrosine kinase inhibitors for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 445-459.	1.0	7
576	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 636-642.	0.7	13
577	Pharmacoeconomic issues in head and neck oncology. <i>Current Opinion in Oncology</i> , 2013, 25, 213-217.	1.1	3
578	Biomarker-Directed Therapy of Squamous Carcinomas of the Head and Neck: Targeting PI3K/PTEN/mTOR Pathway. <i>Journal of Clinical Oncology</i> , 2013, 31, e137-e140.	0.8	30
579	Would You Go Broke to Stay Alive in Singapore?. <i>American Journal of Hospice and Palliative Medicine</i> , 2013, 30, 541-547.	0.8	3
580	Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers. <i>Clinical Cancer Research</i> , 2013, 19, 6633-6643.	3.2	29
581	Preoperative Cetuximab, Irinotecan, Cisplatin, and Radiation Therapy for Patients With Locally Advanced Esophageal Cancer. <i>Oncologist</i> , 2013, 18, 281-287.	1.9	33

#	ARTICLE	IF	CITATIONS
582	Hedgehog Signaling Alters Reliance on EGF Receptor Signaling and Mediates Anti-EGFR Therapeutic Resistance in Head and Neck Cancer. <i>Cancer Research</i> , 2013, 73, 3381-3392.	0.4	84
584	Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer. <i>Oncologist</i> , 2013, 18, 460-466.	1.9	45
585	Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept. <i>Clinical Cancer Research</i> , 2013, 19, 4931-4940.	3.2	21
586	Early Detection of Recurrent Disease by FDG-PET/CT Leads to Management Changes in Patients With Squamous Cell Cancer of the Head and Neck. <i>Oncologist</i> , 2013, 18, 1108-1117.	1.9	57
587	The SPECTRUM of findings in treatment options for recurrent/metastatic head and neck cancer. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 533-535.	0.6	3
588	Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Cancer: Experience Outside of a Trial Setting. <i>Chemotherapy</i> , 2013, 59, 1-7.	0.8	1
589	NCIâ€”RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers. <i>Journal of the National Cancer Institute</i> , 2013, 105, 11-24.	3.0	60
590	Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. <i>Cancer Biology and Therapy</i> , 2013, 14, 481-491.	1.5	43
591	Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2013, 24, 220-225.	0.6	127
592	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. <i>Pharmacological Reviews</i> , 2013, 65, 1351-1395.	7.1	33
593	Pemetrexed in combination with cisplatin versus cisplatin monotherapy in Asian patients with recurrent or metastatic head and neck cancer: Results of an exploratory subgroup analysis of a phase III trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 331-341.	0.7	1
594	Phase II study of TAS 106 in patients with platinumâ€”failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. <i>Cancer Medicine</i> , 2013, 2, 351-359.	1.3	10
595	Randomized Phase II Study of the Antiâ€”Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2586-2592.	0.8	296
596	Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance. <i>Oncologist</i> , 2013, 18, 850-864.	1.9	82
597	Mechanisms of resistance to EGFR targeted therapies. <i>Cancer Biology and Therapy</i> , 2013, 14, 304-314.	1.5	56
598	Phosphorylation of eIF2 \pm Suppresses Cisplatin-Induced A549 Cell Apoptosis via p38 Inhibition. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 268-273.	0.7	7
599	Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1415-1421.	0.8	180
600	Can Erlotinib Ameliorate Cisplatin-Induced Toxicities?. <i>Journal of Clinical Oncology</i> , 2013, 31, 3442-3443.	0.8	12

#	ARTICLE	IF	CITATIONS
601	Complications et sÅ©quelles de la radiothÅ©rapie. , 2013, , 13-65.		1
602	Cost Effectiveness of Neoadjuvant Chemotherapy in Locally Advanced Operable Head and Neck Cancer Followed by Surgery and Postoperative Radiotherapy: A Markov Model-Based Decision Analysis. <i>Oncology</i> , 2013, 84, 336-341.	0.9	4
603	Cisplatin-Based Chemotherapy Options for Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck. <i>Clinical Medicine Insights Therapeutics</i> , 2013, 5, CMT.S10409.	0.4	46
604	Targeting HER Receptors in Cancer. <i>Current Pharmaceutical Design</i> , 2013, 19, 808-817.	0.9	39
605	Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. <i>International Journal of Oncology</i> , 2013, 42, 1151-1158.	1.4	80
606	Prevention of Barrett Esophagus and Esophageal Adenocarcinoma by Smoothened Inhibitor in a Rat Model of Gastroesophageal Reflux Disease. <i>Annals of Surgery</i> , 2013, 258, 82-88.	2.1	26
607	Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: A study based on SWOG protocol S0420. <i>Oncology Reports</i> , 2013, 29, 2095-2100.	1.2	7
608	Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck. <i>Experimental and Therapeutic Medicine</i> , 2013, 5, 1247-1253.	0.8	24
615	New Insights into Individualized Antimetastatic Therapy. <i>Advanced Techniques in Biology & Medicine</i> , 2013, 1, .	0.1	9
616	Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis. <i>Oncology Letters</i> , 2013, 5, 1915-1920.	0.8	36
617	Drug Combinations in Cancer Treatments. <i>Advances in Pharmacoepidemiology & Drug Safety</i> , 2013, 02, .	0.1	5
618	Targeting the EGFR family of receptor tyrosine kinases. , 0, , 843-853.		0
619	Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab. <i>PLoS ONE</i> , 2013, 8, e56112.	1.1	32
620	Incidence and Risk of Treatment-Related Mortality with Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Cancer Patients: A Meta-Analysis of 21 Randomized Controlled Trials. <i>PLoS ONE</i> , 2013, 8, e81897.	1.1	13
621	Cetuximab: its unique place in head and neck cancer treatment. <i>Biologics: Targets and Therapy</i> , 2013, 7, 77.	3.0	62
622	Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial. <i>OncoTargets and Therapy</i> , 2013, 6, 1589.	1.0	40
624	Antigen-specific immunotherapy in head and neck cancer. <i>Advances in Cellular and Molecular Otolaryngology</i> , 2013, 1, 21758.	0.4	7
625	Molecular markers of response and resistance to EGFR inhibitors in head and neck cancersÅ. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 520.	3.0	10

#	ARTICLE	IF	CITATIONS
626	Molecular Pathways in Head and Neck Cancer: EGFR, PI3K, and More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 246-255.	1.8	46
627	Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib. OncoTargets and Therapy, 2014, 7, 245.	1.0	8
628	Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution. PLoS ONE, 2014, 9, e86697.	1.1	36
629	Circulating Tumor Cells in Patients with Recurrent or Metastatic Head and Neck Carcinoma: Prognostic and Predictive Significance. PLoS ONE, 2014, 9, e103918.	1.1	69
630	Targeting Serum Glucocorticoid-Regulated Kinase-1 in Squamous Cell Carcinoma of the Head and Neck: A Novel Modality of Local Control. PLoS ONE, 2014, 9, e113795.	1.1	9
631	Salvage Stereotactic Re-irradiation with CyberKnife for Locally Recurrent Head and Neck Cancer: A Single Center Experience. Tumori, 2014, 100, 278-283.	0.6	8
632	Cost-Effectiveness Evaluation of Oncological Drugs Newly Marketed in Italy. Global & Regional Health Technology Assessment, 2014, 1, GRHTA.5000182.	0.2	9
633	Curative treatment can be an option for patients with metastatic squamous cell cancer of the head and neck. Drug Design, Development and Therapy, 2014, 8, 2549.	2.0	1
634	EGF and EGFR genetic polymorphisms predict prognosis in locally advanced pharyngolaryngeal squamous cell carcinoma patients receiving postoperative concurrent chemoradiotherapy. OncoTargets and Therapy, 2014, 7, 2197.	1.0	12
635	Molecular targeted therapy for head and neck cancer. Nihon Koku Geka Gakkai Zasshi, 2014, 60, 404-406.	0.0	0
636	Interferencia del receptor del factor de crecimiento epidermoide (EGFR) y su utilidad como adyuvante en el tratamiento del c�ncer avanzado de cabeza y cuello. Revista De Otorrinolaringolog�a Y Cirug�a De Cabeza Y Cuello, 2014, 74, 259-265.	0.0	0
637	Value Considerations in the Treatment of Head and Neck Cancer: Radiation, Chemotherapy, and Supportive Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e296-e303.	1.8	9
638	Response to concurrent cetuximab: radiotherapy following failure of platinum-based induction chemotherapy in squamous cell carcinoma of the larynx. Journal of Radiotherapy in Practice, 2014, 13, 93-97.	0.2	0
639	Risk factors associated with hypersensitivity reactions to cetuximab: anti-cetuximab IgE detection as screening test. Future Oncology, 2014, 10, 2133-2140.	1.1	14
640	Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials. Personalized Medicine, 2014, 11, 545-558.	0.8	8
641	The translational significance of epithelial�mesenchymal transition in head and neck cancer. Clinical and Translational Medicine, 2014, 3, 60.	1.7	18
642	Human Papillomavirus-Associated Oropharynx Cancer (HPV-OPC): Treatment Options. Current Treatment Options in Oncology, 2014, 15, 595-610.	1.3	16
643	Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer, 2014, 120, 3940-3951.	2.0	53

#	ARTICLE	IF	CITATIONS
644	mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	109
645	Best practices in the management of the psycho-oncologic aspects of head and neck cancer patients: recommendations from the European Head and Neck Cancer Society Make Sense Campaign. <i>Annals of Oncology</i> , 2014, 25, 2115-2124.	0.6	44
646	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. <i>Journal of Translational Medicine</i> , 2014, 12, 291.	1.8	32
647	Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy. <i>Cell Death and Disease</i> , 2014, 5, e1091-e1091.	2.7	24
648	Clinical update on cancer: molecular oncology of head and neck cancer. <i>Cell Death and Disease</i> , 2014, 5, e1018-e1018.	2.7	160
649	Combining Cetuximab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: Is More Better?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2929-2931.	0.8	6
650	The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2014, 25, 2101-2115.	0.6	70
651	Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1637-1654.	1.9	5
652	Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. <i>Neuro-Oncology</i> , 2014, 16, viii7-viii13.	0.6	85
653	Guidelines for treatment of recurrent or metastatic head and neck cancer. <i>Indian Journal of Cancer</i> , 2014, 51, 89.	0.2	24
654	Feasibility of Cisplatin/5-Fluorouracil and Panitumumab in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 661-669.	0.6	3
655	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma. <i>The Cochrane Library</i> , 2014, 2014, CD010271.	1.5	28
656	State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013. <i>Oncology</i> , 2014, 86, 212-229.	0.9	61
657	Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013. <i>Future Oncology</i> , 2014, 10, 1635-1648.	1.1	30
658	Sipuleucel-T and immunotherapy in the treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 709-719.	1.4	8
659	A prospective trial comparing FDG α -PET / CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck. <i>Cancer Medicine</i> , 2014, 3, 1493-1501.	1.3	13
661	Salvage surgery for local residual or recurrent pharyngeal cancer after radiotherapy or chemoradiotherapy. <i>Laryngoscope</i> , 2014, 124, 2075-2080.	1.1	23
662	Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. <i>Cancer</i> , 2014, 120, 1187-1193.	2.0	61

#	ARTICLE	IF	CITATIONS
663	Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. <i>Annals of Oncology</i> , 2014, 25, 2052-2058.	0.6	53
664	TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2014, 36, 1555-1561.	0.9	13
665	Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303. <i>Clinical Cancer Research</i> , 2014, 20, 3023-3032.	3.2	34
666	Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. <i>Cancer</i> , 2014, 120, 624-632.	2.0	51
667	Phase I/II clinical study on safety and antivasular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer. <i>Head and Neck</i> , 2014, 36, 976-984.	0.9	35
668	Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. <i>Head and Neck</i> , 2014, 36, 1712-1717.	0.9	10
669	Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). <i>Annals of Oncology</i> , 2014, 25, 682-688.	0.6	78
670	Molecular Determinants of Head and Neck Cancer. , 2014, , .		2
673	A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2014, 25, 1813-1820.	0.6	162
674	High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients. <i>Cell Communication and Signaling</i> , 2014, 12, 17.	2.7	37
675	Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 469.	0.7	26
676	Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2014, 12, 203.	2.3	20
677	Emerging combination therapies to overcome resistance in EGFR-driven tumors. <i>Anti-Cancer Drugs</i> , 2014, 25, 127-139.	0.7	15
678	Targeting the epidermal growth factor receptor in solid tumors: focus on safety. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 535-549.	1.0	30
679	The Cancer Genome Atlas findings in head and neck cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 245-246.	1.1	5
680	Cetuximab, Paclitaxel, Carboplatin, and Radiation for Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 162-166.	0.6	5
681	Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 409-416.	0.5	34
682	EGFR Inhibitors as Therapeutic Agents in Head and Neck Cancer. , 2014, , 55-90.		3

#	ARTICLE	IF	CITATIONS
683	Effects of the administration of epidermal growth factor receptor specific inhibitor cetuximab, alone and in combination with cisplatin, on proliferation and apoptosis of Hep-2 laryngeal cancer cells. <i>Journal of Laryngology and Otology</i> , 2014, 128, 902-908.	0.4	5
684	Unintended Consequences of Expensive Cancer Therapeuticsâ€”The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 1225.	1.2	263
685	Metastasis of Laryngeal Squamous Cell Carcinoma to Bilateral Thigh Muscles. <i>Case Reports in Oncological Medicine</i> , 2014, 2014, 1-3.	0.2	6
686	Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. <i>Pharmaceuticals</i> , 2014, 7, 311-338.	1.7	62
687	Management of lymph node metastases from an unknown primary site to the head and neck (Review). <i>Molecular and Clinical Oncology</i> , 2014, 2, 917-922.	0.4	33
688	Case Report about Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test. <i>Clinical Medicine Insights: Oncology</i> , 2014, 8, CMO.S13897.	0.6	13
689	Indian Council of Medical Research consensus document for the management of colorectal cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2014, 35, 192-196.	0.1	26
690	Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trialsâ€”an Economic Evaluation Context. <i>Medical Decision Making</i> , 2014, 34, 387-402.	1.2	72
691	Afatinib in the treatment of head and neck squamous cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 135-143.	1.9	20
692	Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2014, 10, 21-40.	1.1	12
694	The role of re-irradiation of secondary and recurrent head and neck carcinomas. Is it a potentially curative treatment? A practical approach. <i>Cancer Treatment Reviews</i> , 2014, 40, 178-189.	3.4	41
695	Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 636-647.	3.4	33
696	Decision making in the management of recurrent head and neck cancer. <i>Head and Neck</i> , 2014, 36, 144-151.	0.9	153
697	Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. <i>International Journal of Cancer</i> , 2014, 134, 497-507.	2.3	164
698	Outcome of patients treated with palliative weekly Paclitaxel plus Cetuximab in recurrent head and neck cancer after failure of platinum-based therapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2014, 271, 373-378.	0.8	29
699	Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?. <i>Open Medicine (Poland)</i> , 2014, 9, 279-284.	0.6	0
700	Is biomarker research advancing in the era of personalized medicine for head and neck cancer?. <i>International Journal of Clinical Oncology</i> , 2014, 19, 211-219.	1.0	21
701	Radiofrequency ablation in advanced head and neck cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2014, 271, 207-210.	0.8	3

#	ARTICLE	IF	CITATIONS
702	Multimodal treatment strategies for elderly patients with head and neck cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 465-475.	3.4	38
703	Improving the Efficacy of Chemoradiation with Targeted Agents. <i>Cancer Discovery</i> , 2014, 4, 280-291.	7.7	75
704	Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer. <i>International Journal of Clinical Oncology</i> , 2014, 19, 220-229.	1.0	8
707	Targeted therapies in gastroesophageal cancer. <i>European Journal of Cancer</i> , 2014, 50, 1247-1258.	1.3	45
708	Oropharyngeal cancers: Relationship between epidermal growth factor receptor alterations and human papillomavirus status. <i>European Journal of Cancer</i> , 2014, 50, 1100-1111.	1.3	61
709	Local ablative treatments of oligometastases from head and neck carcinomas. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 47-63.	2.0	56
710	ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. <i>Cancer Cell</i> , 2014, 25, 282-303.	7.7	817
712	An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1227-1239.	1.1	73
713	Combination antiangiogenic therapy and radiation in head and neck cancers. <i>Oral Oncology</i> , 2014, 50, 19-26.	0.8	90
714	Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. <i>Annals of Oncology</i> , 2014, 25, 1410-1416.	0.6	89
715	Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. <i>Annals of Oncology</i> , 2014, 25, 801-807.	0.6	190
716	Demystifying the role of tumor HPV status in recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2014, 25, 760-762.	0.6	7
717	Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). <i>Cancer Treatment Reviews</i> , 2014, 40, 567-577.	3.4	122
718	An "inâ€cell trial"™ to assess the efficacy of a monovalent antiâ€MET antibody as monotherapy and in association with standard cytotoxics. <i>Molecular Oncology</i> , 2014, 8, 378-388.	2.1	10
719	Targeted therapy-induced diarrhea: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 165-179.	2.0	47
720	A community computational challenge to predict the activity of pairs of compounds. <i>Nature Biotechnology</i> , 2014, 32, 1213-1222.	9.4	264
721	Clinical application of genetics to guide prevention and treatment of oral diseases. <i>Clinical Genetics</i> , 2014, 86, 44-49.	1.0	36
722	Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2014, 40, 1221-1229.	3.4	26

#	ARTICLE	IF	CITATIONS
723	Classifying squamous cell carcinoma of the head and neck: prognosis, prediction and implications for therapy. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 229-236.	1.1	13
724	Selection of Therapeutic Treatment with Alternating Chemoradiotherapy for Larynx Preservation in Laryngeal Carcinoma Patients. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1063-1069.	0.6	5
725	Liposomal nanoprobe that combine anti-EGFR antibodies and MRI contrast agents: synthesis and in vitro characterization. <i>RSC Advances</i> , 2014, 4, 33756.	1.7	1
726	Tumor Antigen-Specific Monoclonal Antibodies and Induction of T-Cell Immunity. <i>Seminars in Oncology</i> , 2014, 41, 678-684.	0.8	15
727	Synergistic Antitumor Activity of Cetuximab and Namitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR Gene Copy Number. <i>Clinical Cancer Research</i> , 2014, 20, 995-1006.	3.2	7
729	Head and Neck Squamous Cell Carcinomas Do Not Express EGFRvIII. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 454-462.	0.4	7
730	Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: A retrospective review. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 83-87.	0.5	5
731	Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies. <i>Journal of Immunological Methods</i> , 2014, 414, 69-81.	0.6	71
732	Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. <i>Journal of Clinical Oncology</i> , 2014, 32, 2940-2950.	0.8	697
733	High-dose reirradiation with intensity-modulated radiotherapy for recurrent head-and-neck cancer: Disease control, survival and toxicity. <i>Radiotherapy and Oncology</i> , 2014, 111, 388-392.	0.3	50
734	Economic Analyses in Squamous Cell Carcinoma of the Head and Neck: A Review of the Literature From a Clinical Perspective. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 989-996.	0.4	10
735	Human Papillomavirus (HPV)-associated Oral Cancers and Treatment Strategies. <i>Journal of Dental Research</i> , 2014, 93, 29S-36S.	2.5	70
736	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. <i>Genes and Diseases</i> , 2014, 1, 75-86.	1.5	78
737	Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice. <i>European Journal of Cancer</i> , 2014, 50, 2303-2308.	1.3	32
739	YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 832-839.	0.8	45
740	Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2014, 50, 895-900.	0.8	20
741	Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234. <i>Journal of Clinical Oncology</i> , 2014, 32, 2486-2495.	0.8	180
743	HPV-related oropharyngeal cancers: From pathogenesis to new therapeutic approaches. <i>Cancer Letters</i> , 2014, 351, 198-205.	3.2	37

#	ARTICLE	IF	CITATIONS
744	A 3' UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2014, 25, 2230-2236.	0.6	36
745	Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303. <i>Clinical Cancer Research</i> , 2014, 20, 5041-5051.	3.2	33
746	AXL Mediates Resistance to Cetuximab Therapy. <i>Cancer Research</i> , 2014, 74, 5152-5164.	0.4	170
747	Understanding the Pathobiology of Head and Neck Squamous Cell Carcinoma. <i>Current Oral Health Reports</i> , 2014, 1, 196-203.	0.5	2
748	Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. <i>BMC Cancer</i> , 2014, 14, 473.	1.1	20
749	An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents. <i>BMC Cancer</i> , 2014, 14, 504.	1.1	15
750	Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. <i>BMC Research Notes</i> , 2014, 7, 337.	0.6	35
751	Erlotinib, Erlotinib+Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3289-3298.	3.2	48
752	Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1629-1640.	1.2	24
753	Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). <i>Investigational New Drugs</i> , 2014, 32, 1278-1284.	1.2	50
754	A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Investigational New Drugs</i> , 2014, 32, 1197-1203.	1.2	22
755	Monoclonal antibodies as therapeutics in human malignancies. <i>Future Oncology</i> , 2014, 10, 609-636.	1.1	20
756	Head and Neck Cancer in the Older Adult: Approaches in Evaluation and Management. <i>Current Geriatrics Reports</i> , 2014, 3, 209-219.	1.1	1
757	Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. <i>Future Oncology</i> , 2014, 10, 1065-1080.	1.1	8
758	Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins. <i>Cancer Letters</i> , 2014, 354, 365-377.	3.2	53
759	Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. <i>Annals of Oncology</i> , 2014, 25, 2047-2052.	0.6	129
760	Temporal changes in the efficacy of chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2014, 40, 1073-1079.	3.4	9
761	Cáncer de la orofaringe. <i>EMC - Otorrinolaringología</i> , 2014, 43, 1-18.	0.0	0

#	ARTICLE	IF	CITATIONS
762	Development of TRAIL Resistance by Radiation-Induced Hypermethylation of DR4 CpG Island in Recurrent Laryngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1203-1211.	0.4	13
763	Chemotherapy for Oral and Maxillofacial Tumors: An Update. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2014, 26, 163-169.	0.4	6
764	Long-term survival after distant metastasis in patients with oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 208-212.	0.8	28
766	Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions. <i>Cancer Treatment Reviews</i> , 2014, 40, 390-404.	3.4	77
767	Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2014, 42, 1322-1328.	0.7	16
768	Therapy of Advanced Squamous Cell Carcinoma of the Skin. <i>Current Treatment Options in Oncology</i> , 2014, 15, 302-320.	1.3	28
769	Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1826-1836.	1.9	59
770	Prospects for enhancement of targeted radionuclide therapy of cancer using ultrasound. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 279-284.	0.5	1
771	Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. <i>Oral Oncology</i> , 2014, 50, 918-923.	0.8	21
772	²¹³ Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells. <i>Nuclear Medicine and Biology</i> , 2014, 41, 68-76.	0.3	7
773	Clinical Analysis of Laryngeal Carcinoma Over Ten Years. <i>Practica Otologica, Supplement</i> , 2014, 140, 88-89.	0.0	0
774	è™æ–ã•æ²»ç™, éé,éfç™CEã®âE–âç™,æ³•ã•æ”¾ã°,ç•šç™,æ³•. <i>Journal of Otolaryngology of Japan</i> , 2014, 117, 697-701.	0	0
775	Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency. <i>Oncology Reports</i> , 2014, 32, 780-786.	1.2	19
776	Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. <i>International Journal of Nanomedicine</i> , 2014, 9, 3719.	3.3	134
777	The Role of microRNA in Head and Neck Cancer: Current Knowledge and Perspectives. <i>Molecules</i> , 2014, 19, 5704-5716.	1.7	35
778	Health Related Quality of Life in Patients with Metastatic, Relapsed, or Inoperable Squamous Cell Carcinoma of the Head and Neck in India. <i>Value in Health</i> , 2014, 17, A95.	0.1	0
779	Epidermal Growth Factor Receptor Inhibitors: Coming of Age. <i>Cancer Control</i> , 2014, 21, 74-79.	0.7	56
780	Head and Neck Cancers, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1454-1487.	2.3	192

#	ARTICLE	IF	CITATIONS
782	The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway as a therapeutic target in head and neck cancer. <i>Clinical Investigation</i> , 2014, 4, 1123-1138.	0.0	0
783	Helper T-cell based immunotherapy combined with adjuvants in head and neck squamous cell carcinoma. <i>Journal of Japan Society of Immunology & Allergology in Otolaryngology</i> , 2014, 32, 185-190.	0.0	0
784	Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma. <i>Oncology Reports</i> , 2014, 32, 1188-1192.	1.2	11
785	Advances in Diagnosis and Treatment of Nonmelanoma Skin Cancer. <i>Annals of Plastic Surgery</i> , 2014, 73, 615-619.	0.5	11
786	Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF- κ B activity in human oral squamous cell carcinoma cell lines. <i>International Journal of Oncology</i> , 2014, 45, 2439-2445.	1.4	18
788	Nab [®] paclitaxel [®] based compared to docetaxel [®] based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck. <i>Cancer Medicine</i> , 2015, 4, 481-489.	1.3	18
789	Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (<sc>ETPF</sc>) in patients with resectable nonmetastatic stage <sc>III</sc> or <sc>IV</sc> squamous cell carcinoma of the oropharynx. A <sc>GERCOR</sc> phase <sc>II</sc> ECHO</sc> study. <i>Cancer Medicine</i> , 2015, 4, 721-731.	1.3	7
790	DIGRE: Drug-Induced Genomic Residual Effect Model for Successful Prediction of Multidrug Effects. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 91-97.	1.3	30
791	Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2015, 44, 734-745.	1.4	8
793	Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck. <i>Radiology and Oncology</i> , 2015, 49, 17-25.	0.6	14
795	A Case of an Elderly Patient of Hypopharyngeal Carcinoma Developed Thrombocytopenia during Radiotherapy with Cetuximab. <i>Practica Otologica, Supplement</i> , 2015, 144, 82-83.	0.0	0
796	éé,éf"ç™(Eâ@æ—°ãŸã²»ç™,æ^ ç•¥ â€•â†âæ™çš,,è—â€. <i>Journal of Otolaryngology of Japan</i> , 2015, 118, 1369-1374.	0	0
797	Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2015, 5, 16280.	1.6	22
798	Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, e37-e48.	2.3	16
799	Determinants for Aggressive End-of-Life Care for Oral Cancer Patients. <i>Medicine (United States)</i> , 2015, 94, e460.	0.4	23
801	Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 282.	1.8	66
802	Head and neck cancer: metronomic chemotherapy. <i>BMC Cancer</i> , 2015, 15, 677.	1.1	20
803	Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients. , 2015, 3, 54.		40

#	ARTICLE	IF	CITATIONS
804	Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck. <i>Oncologist</i> , 2015, 20, 1393-1403.	1.9	7
805	Investigation of expression of p16 and EGFRv III and its correlation with the effects of treatment with cetuximab in oral cancer. <i>Journal of Japanese Society of Oral Oncology</i> , 2015, 27, 67-74.	0.0	0
806	Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Case Reports in Oncology</i> , 2015, 8, 503-508.	0.3	4
807	A case of multiple oral cancer whose life was prolonged by radiotherapy with cetuximab for trachea invasion due to metastasis of the upper mediastinal lymph node: a case report. <i>Journal of Japanese Society of Oral Oncology</i> , 2015, 27, 135-139.	0.0	2
808	Successful chemotherapy with cetuximab for multiple pulmonary metastases of oropharyngeal and laryngeal cancers. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2015, 25, 215-221.	0.0	1
809	Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review. <i>Clinical Medicine Insights: Oncology</i> , 2015, 9, CMO.S18682.	0.6	19
810	Unresectable Recurrent Squamous Cell Carcinoma of the Temporal Bone Treated by Induction Chemotherapy Followed by Concurrent Chemo-Reirradiation. <i>Otology and Neurotology</i> , 2015, 36, 1543-1546.	0.7	3
811	Beyond peptides and mAbs—current status and future perspectives for biotherapeutics with novel constructs. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S4-20.	1.0	55
812	Factors predicting outcome after salvage treatment for stage IV oral squamous cell carcinoma: Evidence of the potential importance of the cyclooxygenase-2/prostaglandin E ₂ pathway. <i>Head and Neck</i> , 2015, 37, 1142-1149.	0.9	4
813	Anticancer Drug Combinations, A Big Momentum is Needed. <i>Metabolomics: Open Access</i> , 2015, 05, .	0.1	2
814	Management of cancer of the head and neck. , 0, , 132-169.		0
815	Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines. <i>OncoTargets and Therapy</i> , 2015, 8, 335.	1.0	16
816	Successful rapid desensitization for cetuximab-induced anaphylaxis. <i>Allergy Asthma & Respiratory Disease</i> , 2015, 3, 294.	0.3	2
817	Cesium-131 brachytherapy in high risk and recurrent head and neck cancers: first report of long-term outcomes. <i>Journal of Contemporary Brachytherapy</i> , 2015, 6, 445-452.	0.4	14
818	Advancements in the Management of HPV-Associated Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2015, 4, 822-831.	1.0	1
819	Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors. <i>Frontiers in Immunology</i> , 2015, 6, 202.	2.2	130
820	Epidermal Growth Factor Receptor Inhibition Reduces Angiogenesis via Hypoxia-Inducible Factor-1 α and Notch1 in Head Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0119723.	1.1	41
821	An Inducible TGF- β 2-TGF β 2R Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. <i>PLoS ONE</i> , 2015, 10, e0123600.	1.1	5

#	ARTICLE	IF	CITATIONS
822	Use of Cetuximab in Combination with Cisplatin and Adjuvant Pelvic Radiation for Stage IIIB Vulvar Carcinoma. Case Reports in Obstetrics and Gynecology, 2015, 2015, 1-4.	0.2	4
823	The Tip of the Iceberg: Clinical Implications of Genomic Sequencing Projects in Head and Neck Cancer. Cancers, 2015, 7, 2094-2109.	1.7	19
825	Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e323-e328.	1.8	5
826	Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer. Oncotarget, 2015, 6, 34288-34299.	0.8	52
827	Many Questions Awaiting Answers: Clinical Trials in HPV-Associated Oropharyngeal Squamous Cell Carcinoma. Current Otorhinolaryngology Reports, 2015, 3, 73-78.	0.2	0
828	Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology, 2015, 26, 1476-1480.	0.6	71
829	Genomic medicine and targeted therapy for solid tumors. Journal of Surgical Oncology, 2015, 111, 38-42.	0.8	13
830	A new finite element approach for near real-time simulation of light propagation in locally advanced head and neck tumors. Lasers in Surgery and Medicine, 2015, 47, 60-67.	1.1	38
832	Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT). Investigational New Drugs, 2015, 33, 895-900.	1.2	11
833	Phase 1 Trial of Bevacizumab With Concurrent Chemoradiation Therapy for Squamous Cell Carcinoma of the Head and Neck With Exploratory Functional Imaging of Tumor Hypoxia, Proliferation, and Perfusion. International Journal of Radiation Oncology Biology Physics, 2015, 91, 942-951.	0.4	44
834	Genomic Applications in Head and Neck Cancers. , 2015, , 341-358.		0
835	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncology, 2015, 11, 2175-2191.	1.1	5
836	Adverse skin reactions during treatment with cetuximab plus radiotherapy: Multidisciplinary approach to minimize radio-chemotherapy interruption. Journal of Dermatological Treatment, 2015, 26, 183-187.	1.1	4
837	Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial. Head and Neck, 2015, 37, 1081-1087.	0.9	22
838	Reply to D. Adkins et al. Journal of Clinical Oncology, 2015, 33, 1225-1226.	0.8	1
839	Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck. Hematology/Oncology Clinics of North America, 2015, 29, 1011-1032.	0.9	8
840	Immunotherapy for Head and Neck Squamous Cell Carcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 1033-1043.	0.9	30
841	HPV-Associated Head and Neck Cancer. Journal of the National Cancer Institute, 2015, 107, djv344.	3.0	153

#	ARTICLE	IF	CITATIONS
842	Personalized Oral Health Care. , 2015, , .		8
843	Identification of Akt1 as a potent therapeutic target for oral squamous cell carcinoma. International Journal of Oncology, 2015, 47, 1273-1281.	1.4	16
844	Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway. International Journal of Oncology, 2015, 47, 2165-2172.	1.4	17
845	Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma. International Journal of Oncology, 2015, 46, 1971-1977.	1.4	19
846	Biological and therapeutic activities, and anticancer properties of curcumin. Experimental and Therapeutic Medicine, 2015, 10, 1615-1623.	0.8	222
847	<scp>KRAS</scp> and <scp>BRAF</scp> mutations in anal carcinoma. Apmis, 2015, 123, 53-59.	0.9	20
848	Hematologic toxicity assessment in solid tumor patients treated with cetuximab: A pooled analysis of 18 randomized controlled trials. International Journal of Cancer, 2015, 136, 936-944.	2.3	13
849	Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate. Head and Neck, 2015, 37, 134-150.	0.9	106
850	Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck. Oral Oncology, 2015, 51, 291-298.	0.8	136
851	Barriers to clinical trial recruitment in head and neck cancer. Oral Oncology, 2015, 51, 203-211.	0.8	27
852	A Prospective Phase 2 Trial of Reirradiation With Stereotactic Body Radiation Therapy Plus Cetuximab in Patients With Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2015, 91, 480-488.	0.4	123
853	Immunotherapy for head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 299-304.	0.8	19
854	Individualized cancer chemotherapy via cancer biomarkers or bioinformatics detection. , 2015, , 13-19.		0
855	Individualized antimetastatic therapy [1â€²2]. , 2015, , 29-36.		0
856	Drug combinations. , 2015, , 37-41.		5
857	TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). Annals of Oncology, 2015, 26, 561-567.	0.6	55
858	AKT and MET signalling mediates antiapoptotic radioresistance in head neck cancer cell lines. Oral Oncology, 2015, 51, 158-163.	0.8	25
859	A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncology, 2015, 51, 279-286.	0.8	65

#	ARTICLE	IF	CITATIONS
860	Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 221-232.	5.1	153
861	Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. <i>Targeted Oncology</i> , 2015, 10, 501-508.	1.7	22
862	Immunity in Head and Neck Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 12-17.	1.6	53
863	EGFR-based bioradiotherapy in SCCHN. <i>Lancet Oncology</i> , The, 2015, 16, 129-130.	5.1	5
864	Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. <i>Clinical Cancer Research</i> , 2015, 21, 544-552.	3.2	56
865	Correlations Between Prognosis and Regional Biomarker Profiles in Head and Neck Squamous Cell Carcinomas. <i>Pathology and Oncology Research</i> , 2015, 21, 643-650.	0.9	30
866	Expression of magnesium transporter genes in head and neck cancer patients underwent neoadjuvant cisplatin-based chemotherapy. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 3051-3057.	0.8	8
867	Systemic Chemotherapy. , 2015, , 307-318.		0
868	HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1343-1351.	1.2	30
869	The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 2015, 51, 423-430.	0.8	39
870	Weekly paclitaxel plus cetuximab reduces the lung metastasis of adenoid cystic carcinoma arising from the salivary gland. <i>Oral Science International</i> , 2015, 12, 67-71.	0.3	1
871	Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2015, 42, 396-400.	0.5	14
872	Prise en charge globale des carcinomes "pidermo" des de la t"ete et du cou (CETEC) en 2015. <i>Oncologie</i> , 2015, 17, 215-219.	0.2	1
874	Panitumumab for locally advanced head and neck squamous-cell carcinoma. <i>Lancet Oncology</i> , The, 2015, 16, e156.	5.1	0
875	Radiotherapy for management of basal and squamous cell carcinoma. <i>Current Problems in Cancer</i> , 2015, 39, 237-247.	1.0	9
876	A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies. <i>Cancer</i> , 2015, 121, 1645-1653.	2.0	29
877	Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. <i>Annals of Oncology</i> , 2015, 26, 1941-1947.	0.6	113
879	Carboplatin-Pemetrexed in Treatment of Patients with Recurrent/Metastatic Cancers of the Head and Neck; Superior Outcomes in Oropharyngeal Primaries. <i>Frontiers in Oncology</i> , 2014, 4, 362.	1.3	2

#	ARTICLE	IF	CITATIONS
881	Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 1252-1258.	1.5	36
882	Oral Cavity Cancer: Risk Factors, Pathology, and Management. <i>Oncology</i> , 2015, 89, 187-195.	0.9	40
883	Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. <i>Cancer</i> , 2015, 121, 1977-1984.	2.0	116
884	Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. <i>British Dental Journal</i> , 2015, 218, 671-677.	0.3	15
885	Targeted Therapy in Advanced Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 253-262.	0.8	14
886	A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 376-382.	0.8	50
887	EGFR inhibition for recurrent or metastatic HNSCC. <i>Lancet Oncology</i> , The, 2015, 16, 488-489.	5.1	14
888	Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). <i>Oral Oncology</i> , 2015, 51, 399-408.	0.8	19
889	Epidermal Growth Factor Receptor Expression in Spindle Cell Carcinomas of the Head and Neck. <i>Head and Neck Pathology</i> , 2015, 9, 360-368.	1.3	8
890	Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. <i>Tumor Biology</i> , 2015, 36, 3471-3482.	0.8	42
891	Reirradiation and stereotactic body radiotherapy for recurrent or second primary squamous cell carcinoma of the head and neck. <i>Journal of Radiation Oncology</i> , 2015, 4, 117-128.	0.7	0
892	A case of fatal interstitial pneumonia during treatment of radiotherapy plus cetuximab for patient with head and neck carcinoma. <i>International Cancer Conference Journal</i> , 2015, 4, 162-166.	0.2	4
893	Chemoprevention targets for tobacco-related head and neck cancer: Past lessons and future directions. <i>Oral Oncology</i> , 2015, 51, 557-564.	0.8	23
894	Emerging drugs for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 313-329.	1.0	39
895	EGFR-directed antibodies increase the risk of severe infection in cancer patients. <i>BMC Medicine</i> , 2015, 13, 37.	2.3	3
896	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 583-594.	5.1	358
897	Cancer of the Oropharynx. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 509-520.	0.6	13
898	A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 13-20.	1.1	30

#	ARTICLE	IF	CITATIONS
899	Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial. <i>Targeted Oncology</i> , 2015, 10, 255-265.	1.7	9
900	Systemic Therapy for Squamous Cell Carcinoma of the Head and Neck. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 437-454.	0.6	11
901	Feasibility and safety of dose-dense modified docetaxel+cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1086-1092.	1.0	8
903	Cetuximab in patients with esophageal cancer: a systematic review and meta-analysis of randomized controlled trials. <i>Medical Oncology</i> , 2015, 32, 127.	1.2	16
905	The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 179-190.	2.0	48
906	MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1750-1760.	1.9	46
907	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. <i>Annals of Oncology</i> , 2015, 26, 943-949.	0.6	130
909	Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384. <i>Clinical Cancer Research</i> , 2015, 21, 2792-2801.	3.2	62
910	The Expanding Role of Therapeutic Antibodies. <i>International Reviews of Immunology</i> , 2015, 34, 202-264.	1.5	22
911	The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Treatment outcome in a single institution cohort. <i>Acta Oncologica</i> , 2015, 54, 1071-1075.	0.8	11
912	AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2601-2612.	3.2	94
913	Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. <i>British Journal of Dermatology</i> , 2015, 173, 527-534.	1.4	58
914	Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. <i>Cancer Biology and Therapy</i> , 2015, 16, 790-798.	1.5	11
915	AXL Mediates Resistance to PI3K± Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. <i>Cancer Cell</i> , 2015, 27, 533-546.	7.7	263
916	Targeting HER (ERBB) signaling in head and neck cancer: An essential update. <i>Molecular Aspects of Medicine</i> , 2015, 45, 74-86.	2.7	22
918	Molecular Aspects of Head and Neck Cancer Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 971-992.	0.9	45
921	Pharmacotherapy of head and neck cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2409-2422.	0.9	11
922	RTOC 0522: Huge Investment in Patients and Resources and No Benefit With Addition of Cetuximab to Radiotherapy—Why Did This Occur?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1223-1224.	0.8	6

#	ARTICLE	IF	CITATIONS
924	Oral cancer breaks out at ASCO. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 120, 421-423.	0.2	1
925	Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancer. <i>Applied Radiation and Isotopes</i> , 2015, 106, 237-241.	0.7	9
926	Oligoclonal antibodies to target the ErbB family. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1015-1021.	1.4	6
927	Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 656-664.	1.0	25
929	Human Papillomavirus-Associated Negative Pharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3251-3261.	0.8	47
930	Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3305-3313.	0.8	269
931	Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3227-3234.	0.8	125
932	Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach. <i>MAbs</i> , 2015, 7, 1058-1071.	2.6	26
934	Renal toxicity of anticancer agents targeting HER2 and EGFR. <i>Journal of Nephrology</i> , 2015, 28, 647-657.	0.9	33
935	Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. <i>Lancet Oncology</i> , 2015, 16, e611-e621.	5.1	63
936	Organization of primary care pathway in head and neck oncology (short version): Organization of chemotherapy in head and neck oncology. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2015, 132, 209-212.	0.4	0
937	Breakthrough targeted therapeutic approaches to squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2015, 11, 9-12.	1.1	2
938	Prevention of head and neck squamous cell carcinoma: Removing the "chemo" from "chemoprevention". <i>Oral Oncology</i> , 2015, 51, 112-118.	0.8	32
939	Anti- or pro-proliferation Conditional options for TGF- β and cetuximab in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 46-52.	0.8	3
940	Elevation in 5-FU-induced apoptosis in Head and Neck Cancer Stem Cells by a combination of CDHP and GSK-3 β inhibitors. <i>Journal of Oral Pathology and Medicine</i> , 2015, 44, 201-207.	1.4	17
941	Treatment outcomes of postradiation second head and neck malignancies managed by a multidisciplinary approach. <i>Head and Neck</i> , 2015, 37, 815-822.	0.9	9
942	Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. , 2015, , .		7
943	Effect of multimodality treatment on overall survival for patients with metastatic or recurrent HPV-positive head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 630-635.	0.9	21

#	ARTICLE	IF	CITATIONS
944	When is chemotherapy in head and neck squamous cell carcinoma not indicated?. European Archives of Oto-Rhino-Laryngology, 2015, 272, 781-787.	0.8	6
945	Radiation Therapy for Head and Neck Cancers. , 2015, , .		6
946	Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head and Neck, 2015, 37, 386-392.	0.9	31
947	Defining the genomic landscape of head and neck cancers through next-generation sequencing. Oral Diseases, 2015, 21, e11-24.	1.5	23
948	Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. Expert Opinion on Biological Therapy, 2015, 15, 45-59.	1.4	8
949	The Molecular Pathogenesis of Head and Neck Cancer. , 2015, , 491-498.e2.		3
950	Genomic Applications in Pathology. , 2015, , .		1
951	Survivin expression correlates with nodal metastasis in T1-T2 squamous cell carcinoma of the tongue. European Archives of Oto-Rhino-Laryngology, 2015, 272, 689-694.	0.8	7
952	Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab. International Journal of Clinical Oncology, 2015, 20, 282-289.	1.0	26
953	Monoclonal Antibodies as Therapeutic Agents. , 2016, , 157-196.		1
954	Some considerations about the value based pricing in oncology: an analysis on metastatic first line medicinal products. Global & Regional Health Technology Assessment, 2016, 3, 9-15.	0.2	1
955	CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network. Oncotarget, 2016, 7, 73845-73864.	0.8	16
956	Antibody Therapy. , 2016, , 550-559.		2
957	Treatment of Locally Recurrent and Metastatic Squamous Cell Carcinoma of Head & Neck. Head and Neck Cancer Research, 2016, 01, .	0.1	0
958	Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight. OncoTargets and Therapy, 2016, 9, 705.	1.0	3
959	New advances in targeted gastric cancer treatment. World Journal of Gastroenterology, 2016, 22, 6776.	1.4	74
960	Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, , e277-e282.	1.8	2
961	Genetic determinants in head and neck squamous cell carcinoma and their influence on global personalized medicine. Genes and Cancer, 2016, 7, 182-200.	0.6	41

#	ARTICLE	IF	CITATIONS
962	Locoregional Recurrent or Second Primary Head and Neck Cancer: Management Strategies and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e284-e292.	1.8	22
963	Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. OncoTargets and Therapy, 2016, 9, 1927.	1.0	43
964	Esophageal cancer: comparative effectiveness of treatment options. Comparative Effectiveness Research, 0, , 1.	0.2	1
965	Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab. Frontiers in Oncology, 2016, 6, 196.	1.3	7
966	Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck. Frontiers in Oncology, 2016, 6, 199.	1.3	73
967	Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Frontiers in Oncology, 2016, 6, 232.	1.3	82
968	Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC). Cancers, 2016, 8, 27.	1.7	42
969	Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. Cancers, 2016, 8, 87.	1.7	30
970	Safety of Combination Treatment with Imatinib Mesylate, Carboplatin, and Cetuximab in a Patient with Multiple Cancers: A Case Report. Tumori, 2016, 102, S1-S2.	0.6	1
971	Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo. International Journal of Molecular Sciences, 2016, 17, 272.	1.8	37
972	HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. Cancers, 2016, 8, 41.	1.7	100
973	The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Annals of Translational Medicine, 2016, 4, 173-173.	0.7	84
974	Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy. Critical Reviews in Therapeutic Drug Carrier Systems, 2016, 33, 363-400.	1.2	130
975	Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 407-415.	0.6	28
976	Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Head and Neck, 2016, 38, 1759-1764.	0.9	50
977	Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention. Future Oncology, 2016, 12, 2379-2386.	1.1	18
978	Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma. Anti-Cancer Drugs, 2016, 27, 66-70.	0.7	20
979	An enhanced role for palliative care in the multidisciplinary approach to high-risk head and neck cancer. Cancer, 2016, 122, 340-343.	2.0	29

#	ARTICLE	IF	CITATIONS
980	HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2016, 22, 4005-4013.	3.2	75
981	Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomographyâ€“CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. <i>Head and Neck</i> , 2016, 38, 347-354.	0.9	24
982	Molecular targeting in combination with platinumâ€“based chemoradiotherapy in head and neck cancer treatment. <i>Head and Neck</i> , 2016, 38, E2173-81.	0.9	6
983	Getting personal: Head and neck cancer management in the era of genomic medicine. <i>Head and Neck</i> , 2016, 38, E2250-8.	0.9	19
984	Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer. <i>Laryngoscope</i> , 2016, 126, E156-63.	1.1	24
985	Health careâ€“associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. <i>Head and Neck</i> , 2016, 38, E1009-13.	0.9	6
986	Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. <i>Head and Neck</i> , 2016, 38, E1618-24.	0.9	7
987	Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. <i>Supportive Care in Cancer</i> , 2016, 24, 4057-4074.	1.0	21
988	The promise of immunotherapy in head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2016, 27, 1675-1685.	0.6	95
989	Capecitabine and lapatinib for the firstâ€“line treatment of metastatic/recurrent head and neck squamous cell carcinoma. <i>Cancer</i> , 2016, 122, 2350-2355.	2.0	20
990	Endothelial growth factor receptor inhibitors in recurrent metastatic cancer of the head and neck. <i>Head and Neck</i> , 2016, 38, E2221-8.	0.9	2
991	Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by shortâ€“term culture of tumor slices. <i>Head and Neck</i> , 2016, 38, E911-5.	0.9	15
992	Phase II study of erlotinib and docetaxel with concurrent intensityâ€“modulated radiotherapy in locally advanced head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1770-6.	0.9	12
993	Preoperative Chemotherapy and Metronomic Scheduling of Chemotherapy in Locally Advanced Oral Cancers. <i>Oncology</i> , 2016, 91, 35-40.	0.9	17
994	è€³é¼»â€š¼â–%çš“è“ç™,ã«ãšãšã, G-CSF é©æš¼¼½ç”“ã,ã,ã,f%ãf ©ã,ãf³. <i>Journal of Otolaryngology of Japan</i> , 2016, 119, d097-1104		
995	Early detection and personalized treatment in oral cancer: the impact of omics approaches. <i>Molecular Cytogenetics</i> , 2016, 9, 85.	0.4	33
997	The tumor-suppressive microRNA-23b/27b cluster regulates the MET oncogene in oral squamous cell carcinoma. <i>International Journal of Oncology</i> , 2016, 49, 1119-1129.	1.4	35
998	No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). <i>Scientific Reports</i> , 2016, 6, 37621.	1.6	7

#	ARTICLE	IF	CITATIONS
999	Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population. <i>Oral Oncology</i> , 2016, 63, 38-43.	0.8	21
1000	A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 379-385.	0.4	5
1001	Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors. <i>Oncologist</i> , 2016, 21, 1483-1491.	1.9	64
1002	Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer. <i>Scientific Reports</i> , 2016, 6, 32946.	1.6	16
1003	Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. <i>BMC Cancer</i> , 2016, 16, 918.	1.1	60
1004	Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab. <i>Orl</i> , 2016, 78, 320-333.	0.6	4
1005	Emergence of long-term surviving patients with the introduction of Cetuximab in recurrent/metastatic disease of squamous cell carcinoma of head and neck. <i>Oral Oncology</i> , 2016, 55, e4.	0.8	10
1006	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. <i>Lancet Oncology, The</i> , 2016, 17, 956-965.	5.1	1,369
1007	The promise of immunostimulatory antibodies in head and neck cancer. <i>Lancet Oncology, The</i> , 2016, 17, 856-857.	5.1	7
1008	Aggregated adverse-events outcomes in oncology phase III reports: A systematic review. <i>European Journal of Cancer</i> , 2016, 52, 26-32.	1.3	4
1009	Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 5229-5237.	3.2	107
1010	Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 413-426.	2.7	44
1011	Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 58, 41-48.	0.8	78
1012	Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon. <i>Clinical Cancer Research</i> , 2016, 22, 3710-3712.	3.2	3
1013	Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines. <i>Journal of Laryngology and Otology</i> , 2016, 130, S181-S190.	0.4	70
1014	Chemotherapy: United Kingdom National Multidisciplinary Guidelines. <i>Journal of Laryngology and Otology</i> , 2016, 130, S71-S74.	0.4	5
1015	Hypopharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. <i>Journal of Laryngology and Otology</i> , 2016, 130, S104-S110.	0.4	50
1016	Evaluation of Weekly Paclitaxel, Carboplatin, and Cetuximab in Head and Neck Cancer Patients With Incurable Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 933-934.	0.4	2

#	ARTICLE	IF	CITATIONS
1017	Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 21-29.	0.4	29
1018	Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic <i>HER4</i> Mutations in HNSCC. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1988-1997.	1.9	16
1019	Outcome of heavily pretreated recurrent oral squamous cell carcinoma after salvage resection: A monocentric retrospective analysis. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2016, 44, 1061-1066.	0.7	11
1020	Systemic therapy for metastatic bladder cancer in 2016 and beyond. <i>Future Oncology</i> , 2016, 12, 1179-1192.	1.1	5
1021	Current Role of Dacomitinib in Head and Neck Cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 735-742.	1.9	5
1022	Molecular Signaling in Oral Cancer Invasion and Metastasis. , 2016, , 71-99.		1
1023	Investigational drugs for head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 797-810.	1.9	12
1024	Modeling head and neck cancer stem cell-mediated tumorigenesis. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 3279-3289.	2.4	7
1025	High-Risk Cutaneous Squamous Cell Carcinoma. , 2016, , .		5
1026	Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 2016, 56, 62-70.	0.8	13
1028	Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study. <i>Oncologist</i> , 2016, 21, 537.	1.9	3
1029	Application of nano-surface and molecular-orientation limited proteolysis to LC-MS bioanalysis of cetuximab. <i>Bioanalysis</i> , 2016, 8, 1009-1020.	0.6	10
1030	Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3803-3811.	2.0	34
1031	Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. <i>Cancer Letters</i> , 2016, 382, 32-43.	3.2	25
1033	DNA-based immunotherapy for HPV-associated head and neck cancer. <i>Immunotherapy</i> , 2016, 8, 1187-1192.	1.0	5
1034	Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study. <i>Oral Oncology</i> , 2016, 62, 54-59.	0.8	14
1035	Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. , 2016, , 711-729.		5
1036	Salivary Gland Malignancies. , 2016, , 698-714.e3.		0

#	ARTICLE	IF	CITATIONS
1037	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	0.8	715
1039	Genomic insights into head and neck cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, .	6.2	65
1040	nab -Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 61, 1-7.	0.8	18
1041	Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 457-474.	2.7	48
1042	Treatment of head and neck cancer in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1903-1921.	0.9	15
1043	Efficacy, outcomes, and complication rates of different surgical and nonsurgical treatment modalities for recurrent/residual oropharyngeal carcinoma: A systematic review and meta-analysis. <i>Head and Neck</i> , 2016, 38, 1855-1861.	0.9	54
1044	PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2016, 61, 31-40.	0.8	23
1045	Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease. <i>Medical Oncology</i> , 2016, 33, 107.	1.2	6
1046	Employing dynamical computational models for personalizing cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1373-1385.	1.4	29
1047	Cost-Effectiveness Analysis of Elective Neck Dissection in Patients With Clinically Node-Negative Oral Cavity Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3886-3891.	0.8	34
1048	Safety of drug treatments for head and neck cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1527-1539.	1.0	5
1049	Reirradiation of Recurrent and Second Primary Head and Neck Cancer With Proton Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 808-819.	0.4	80
1050	Cetuximab for the treatment of locally advanced and recurrent/metastatic oral cancer: An investigation of distant metastasis. <i>Molecular and Clinical Oncology</i> , 2016, 5, 246-252.	0.4	39
1051	Re-irradiation in Head and Neck Cancer. <i>Medical Radiology</i> , 2016, , 151-168.	0.0	0
1052	Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1614-1626.	1.9	16
1053	Targeted Therapy of Head and Neck Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 780-786.	0.8	17
1054	Expectations and preferences for palliative chemotherapy in head and neck cancers patients. <i>Oral Oncology</i> , 2016, 63, 10-15.	0.8	16
1055	Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 995-1002.	1.1	7

#	ARTICLE	IF	CITATIONS
1056	Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. Expert Opinion on Biological Therapy, 2016, 16, 1075-1078.	1.4	13
1057	Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Review of Anticancer Therapy, 2016, 16, 847-858.	1.1	8
1058	The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 898.	1.2	16
1059	The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer. Journal of Surgical Oncology, 2016, 114, 323-328.	0.8	4
1060	Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer. Annals of Oncology, 2016, 27, 2257-2262.	0.6	29
1061	The prospect of patritumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy, 2016, 16, 1549-1555.	1.4	5
1063	Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition. Oncology Reports, 2016, 36, 3139-3144.	1.2	19
1065	A multicenter retrospective observational study on the safety and efficacy of cetuximab for patients with oral cancer. Original Article. Journal of Japanese Society of Oral Oncology, 2016, 28, 169-179.	0.0	9
1066	Management of BCC and SCC of the Head and Neck. Cancer Control, 2016, 23, 220-227.	0.7	14
1067	Stereotactic Body Radiotherapy for Recurrent Unresectable Head and Neck Cancers. Cancer Control, 2016, 23, 6-11.	0.7	12
1068	Genomically personalized therapy in head and neck cancer. Cancers of the Head & Neck, 2016, 1, 2.	6.2	22
1069	Systemic therapy for recurrent or metastatic salivary gland malignancies. Cancers of the Head & Neck, 2016, 1, 11.	6.2	34
1070	Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. Therapeutic Drug Monitoring, 2016, 38, 567-572.	1.0	19
1071	Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma. Medicine (United States), 2016, 95, e4926.	0.4	16
1072	Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer. Cancer Journal (Sudbury, Tj ETQqO 0 0 rgBT /Overlock 10 Tf 10	0.0	10
1073	Histopathological analysis of oral squamous cell carcinoma in nonsmokers and nondrinkers. Translational Research in Oral Oncology, 2016, 1, 2057178X1664797.	2.3	3
1074	Phase II trial of bevacizumab+cetuximab+cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head and Neck, 2016, 38, E566-70.	0.9	35
1075	Brachytherapy after salvage surgery in cases with large isolated cervical recurrence of squamous cell carcinoma in the previously irradiated neck. Head and Neck, 2016, 38, E2490-4.	0.9	3

#	ARTICLE	IF	CITATIONS
1076	Efficacy and safety of vinorelbine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma patients. <i>Anti-Cancer Drugs</i> , 2016, 27, 349-352.	0.7	1
1077	Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 533-539.	0.7	4
1078	<scp>CD</scp>44^{high}/<scp>ALDH</scp>1^{high} head and neck squamous cell carcinoma cells exhibit mesenchymal characteristics and <scp>GSK</scp>3 β -dependent cancer stem cell properties. <i>Journal of Oral Pathology and Medicine</i> , 2016, 45, 180-188.	1.4	27
1079	Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy. <i>Clinical Cancer Research</i> , 2016, 22, 2453-2461.	3.2	8
1080	Progress in Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, , .	0.8	6
1081	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. <i>Clinical Cancer Research</i> , 2016, 22, 3961-3970.	3.2	65
1082	Treatment in elderly patients with head and neck cancer. <i>Hno</i> , 2016, 64, 217-220.	0.4	12
1083	Induction Chemotherapy. , 2016, , .		3
1084	Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. <i>Journal of Cancer Policy</i> , 2016, 7, 12-22.	0.6	4
1085	Image guided volumetric response during chemoradiotherapy for head and neck squamous cell carcinoma as a predictor of disease outcomes. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2016, 37, 304-310.	0.6	2
1086	Overexpression of ErbB4 is an independent marker for lymph node metastasis in Japanese patients with oral squamous cell carcinoma. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 122, 313-321.	0.2	4
1087	IL-10 and integrin signaling pathways are associated with head and neck cancer progression. <i>BMC Genomics</i> , 2016, 17, 38.	1.2	43
1088	Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. <i>BMC Cancer</i> , 2016, 16, 116.	1.1	31
1089	Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies. <i>BMC Cancer</i> , 2016, 16, 273.	1.1	15
1090	Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol. <i>Radiation Oncology</i> , 2016, 11, 6.	1.2	12
1091	Loss of epidermal growth factor receptor expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition. <i>Oncology Letters</i> , 2016, 11, 201-207.	0.8	40
1092	Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. <i>Annals of Oncology</i> , 2016, 27, 1585-1593.	0.6	41
1093	Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen. <i>BMC Cancer</i> , 2016, 16, 19.	1.1	10

#	ARTICLE	IF	CITATIONS
1094	Afatinib in squamous cell carcinoma of the head and neck. Expert Opinion on Pharmacotherapy, 2016, 17, 1295-1301.	0.9	15
1095	Palliative treatment standards for head and neck squamous cell carcinoma. Hno, 2016, 64, 487-493.	0.4	4
1096	Detection of subclinical recurrence or second primary cancer using ¹⁸ F-FDG PET/CT in patients treated curatively for head and neck squamous cell carcinoma. Head and Neck, 2016, 38, E511-8.	0.9	5
1097	Accuracy of ¹⁸ F-FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up. Head and Neck, 2016, 38, E1271-6.	0.9	14
1098	PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head and Neck, 2016, 38, E1756-61.	0.9	20
1099	ACR Appropriateness criteria® for nasopharyngeal carcinoma. Head and Neck, 2016, 38, 979-986.	0.9	17
1100	Letter to the editor. International Journal of Cancer, 2016, 138, 2763-2770.	2.3	0
1101	A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Investigational New Drugs, 2016, 34, 481-489.	1.2	30
1102	Prognostic factors and outcomes for salvage surgery in patients with recurrent squamous cell carcinoma of the tongue. Asia-Pacific Journal of Clinical Oncology, 2016, 12, e141-8.	0.7	18
1103	Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands. European Archives of Oto-Rhino-Laryngology, 2016, 273, 455-464.	0.8	18
1104	Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. Oral Oncology, 2016, 53, 10-16.	0.8	86
1105	Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models. Clinical Cancer Research, 2016, 22, 633-643.	3.2	20
1106	Chemotherapy in locally advanced head and neck squamous cell carcinoma. Cancer Treatment Reviews, 2016, 44, 10-16.	3.4	32
1107	Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. Cancer Treatment Reviews, 2016, 43, 113-123.	3.4	9
1108	Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer. European Archives of Oto-Rhino-Laryngology, 2016, 273, 4073-4080.	0.8	9
1109	Antibodies as stratagems against cancer. Molecular BioSystems, 2016, 12, 2047-2055.	2.9	14
1110	Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab. European Archives of Oto-Rhino-Laryngology, 2016, 273, 1629-1636.	0.8	6
1111	Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. Journal of Clinical Oncology, 2016, 34, e34-e37.	0.8	12

#	ARTICLE	IF	CITATIONS
1112	Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. <i>Tumor Biology</i> , 2016, 37, 127-140.	0.8	9
1113	Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 37-46.	2.0	219
1114	Predictive factors for long-term survival in head and neck squamous cell carcinoma patients with distant metastasis after initial definitive treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 295-304.	1.2	10
1115	Immunotherapy for head and neck cancer: latest developments and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 168-175.	1.4	18
1116	A genetic view of laryngeal cancer heterogeneity. <i>Cell Cycle</i> , 2016, 15, 1202-1212.	1.3	27
1117	Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 507-516.	0.6	11
1118	A novel approach to predict cetuximab-induced hypersensitivity reaction: detection of drug-specific IgE on basophils. <i>Cancer Medicine</i> , 2016, 5, 1004-1012.	1.3	15
1119	Cetuximab in Human Papillomavirus-Positive Oropharynx Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1289-1291.	0.8	8
1120	Treatment results and prognostic factors for advanced squamous cell carcinoma of the head and neck treated with salvage surgery after concurrent chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , 2016, 21, 869-874.	1.0	39
1121	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 4-31.	1.4	40
1122	A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Fluorouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 289-296.	0.4	24
1123	A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 53, 54-59.	0.8	10
1124	Erlotinib and the Risk of Oral Cancer. <i>JAMA Oncology</i> , 2016, 2, 209.	3.4	111
1125	The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma. <i>Clinical and Translational Oncology</i> , 2016, 18, 592-598.	1.2	16
1126	Oral squamous cell carcinoma: Key clinical questions, biomarker discovery, and the role of proteomics. <i>Archives of Oral Biology</i> , 2016, 63, 53-65.	0.8	69
1127	Tongue cancer during pregnancy: Surgery and more, a multidisciplinary challenge. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 1-11.	2.0	11
1128	Oropharyngeal Cancer. , 2016, , 597-628.e6.		1
1129	Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India. <i>Supportive Care in Cancer</i> , 2016, 24, 1595-1602.	1.0	14

#	ARTICLE	IF	CITATIONS
1130	Erlotinib and gefitinib responsiveness in head and neck cancer cell lines—a comparing analysis with cetuximab. <i>Clinical Oral Investigations</i> , 2016, 20, 759-769.	1.4	7
1131	Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma: an open question. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 263-265.	0.8	1
1132	Adjusting for treatment switching in randomised controlled trials — A simulation study and a simplified two-stage method. <i>Statistical Methods in Medical Research</i> , 2017, 26, 724-751.	0.7	70
1133	HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. <i>Clinical Cancer Research</i> , 2017, 23, 677-686.	3.2	58
1134	Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma. <i>Journal of Human Genetics</i> , 2017, 62, 113-121.	1.1	52
1135	Cetuximab as treatment for head and neck cancer patients with a previous liver transplant: report of two cases. <i>Journal of Chemotherapy</i> , 2017, 29, 310-313.	0.7	1
1136	Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2017, 2, 10-18.	0.6	54
1137	The paradoxical functions of EGFR during breast cancer progression. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, .	7.1	95
1138	Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer. <i>Japanese Dental Science Review</i> , 2017, 53, 61-77.	2.0	8
1139	Retrospective study of treatment outcomes after postoperative chemoradiotherapy in Japanese oral squamous cell carcinoma patients with risk factors of recurrence. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 123, 524-530.	0.2	7
1140	Development of oncolytic virotherapy for the treatment of oral cancer — At the waiting stage for clinical use. <i>Oral Science International</i> , 2017, 14, 1-12.	0.3	7
1141	CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. <i>Nature Communications</i> , 2017, 8, 13897.	5.8	54
1142	The latest prospects of investigational drugs for head and neck cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 265-268.	1.9	3
1143	How to treat recurrent/metastatic head and neck cancer: the economic issue in real-world practice. <i>Current Medical Research and Opinion</i> , 2017, 33, 779-780.	0.9	0
1144	Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel. <i>Medical Oncology</i> , 2017, 34, 28.	1.2	9
1145	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017, 54, 43-57.	3.4	28
1146	Buparlisib—and the continued quest for the ideal cure. <i>Lancet Oncology</i> , The, 2017, 18, 273-274.	5.1	0
1147	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 323-335.	5.1	173

#	ARTICLE	IF	CITATIONS
1148	Head and neck cancers in India. Journal of Surgical Oncology, 2017, 115, 555-563.	0.8	30
1150	State of the art in anti-cancer mAbs. Journal of Biomedical Science, 2017, 24, 15.	2.6	64
1151	Activity of weekly paclitaxel+cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors. Clinical and Translational Oncology, 2017, 19, 769-776.	1.2	15
1152	Cetuximab in the Context of Current Treatment of Squamous Cell Carcinoma of the Anus. Journal of Clinical Oncology, 2017, 35, 699-701.	0.8	1
1153	Lymphotoxin- β^2 Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer. Clinical Cancer Research, 2017, 23, 4388-4401.	3.2	24
1154	E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx" ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology, 2017, 35, 490-497.	0.8	359
1155	Response Evaluation in Head and Neck Oncology: Definition and Prediction. Orl, 2017, 79, 14-23.	0.6	7
1156	Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line. Pathology and Oncology Research, 2017, 23, 829-835.	0.9	2
1157	Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and Beyond. Orl, 2017, 79, 24-33.	0.6	6
1158	<i>In Vitro</i> and <i>In Vivo</i> Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance. Molecular Cancer Therapeutics, 2017, 16, 729-738.	1.9	23
1159	PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma. Clinical Epigenetics, 2017, 9, 12.	1.8	13
1160	Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab. JAMA Dermatology, 2017, 153, 291.	2.0	29
1161	Glucose transporter 4 promotes head and neck squamous cell carcinoma metastasis through the TRIM24-DDX58 axis. Journal of Hematology and Oncology, 2017, 10, 11.	6.9	41
1162	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. Oral Oncology, 2017, 69, 33-37.	0.8	16
1163	Tyrosine kinase-targeting drugs-associated heart failure. British Journal of Cancer, 2017, 116, 1366-1373.	2.9	28
1166	Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study. Head and Neck, 2017, 39, 1333-1342.	0.9	8
1167	Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 2). Oral Oncology, 2017, 70, 65-72.	0.8	8
1168	CXCR4: A New Player in an Old Scene?. Orl, 2017, 79, 34-42.	0.6	4

#	ARTICLE	IF	CITATIONS
1169	Zinc oxide nanoparticles antagonize the effect of Cetuximab on head and neck squamous cell carcinoma <i>in vitro</i> . <i>Cancer Biology and Therapy</i> , 2017, 18, 513-518.	1.5	12
1170	Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 32.	1.3	40
1171	Using a semi-conductor sequencing-based panel for genotyping of HPV-positive and HPV-negative oropharyngeal cancer: a retrospective pilot study. <i>Clinical Otolaryngology</i> , 2017, 42, 681-686.	0.6	1
1172	Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 50-58.	2.0	38
1173	Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2017, 28, 1605-1611.	0.6	474
1174	Potential for low-value palliative care of patients with recurrent head and neck cancer. <i>Lancet Oncology</i> , The, 2017, 18, e284-e289.	5.1	26
1175	Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey. <i>Oncology</i> , 2017, 93, 11-17.	0.9	7
1177	Do patient access schemes for high-cost cancer drugs deliver value to society? Lessons from the NHS Cancer Drugs Fund. <i>Annals of Oncology</i> , 2017, 28, 1738-1750.	0.6	102
1178	An update on larynx cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 31-50.	157.7	454
1179	Retrospective analysis of premedication, glucocorticosteroids, and H ₁ -antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer. <i>Journal of International Medical Research</i> , 2017, 45, 1378-1385.	0.4	11
1180	Does chemoselection open the door for immunotherapy?. <i>Annals of Oncology</i> , 2017, 28, 1697-1699.	0.6	0
1181	Quality of life and functional status of terminally ill head and neck cancer patients: a nation-wide, prospective observational study at tertiary cancer centers in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 47-53.	0.6	12
1182	Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. <i>Oncologist</i> , 2017, 22, 680-693.	1.9	23
1183	EGFR, <i>Immunology</i> , 2017, , 199-208.		0
1184	Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 733-741.	1.0	6
1185	p16, HPV, and Cetuximab: What Is the Evidence?. <i>Oncologist</i> , 2017, 22, 811-822.	1.9	19
1187	Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs. <i>Laryngoscope</i> , 2017, 127, 2565-2569.	1.1	25
1189	An overall review of targeted therapy in solid cancers. <i>Current Medicine Research and Practice</i> , 2017, 7, 99-105.	0.1	9

#	ARTICLE	IF	CITATIONS
1190	Small cell carcinoma of the head and neck: An analysis of the National Cancer Database. <i>Oral Oncology</i> , 2017, 69, 92-98.	0.8	59
1191	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 70, 34-42.	0.8	38
1192	A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26621.	0.8	17
1194	Receptor tyrosine kinase amplification is predictive of distant metastasis in patients with oral squamous cell carcinoma. <i>Cancer Science</i> , 2017, 108, 256-266.	1.7	17
1195	Salvage surgery for oropharyngeal squamous cell carcinomas: A retrospective study from 2005 to 2013. <i>Head and Neck</i> , 2017, 39, 1744-1750.	0.9	21
1196	Influence of photodynamic therapy on peripheral immune cell populations and cytokine concentrations in head and neck cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2017, 19, 194-201.	1.3	41
1197	Efficacy and safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for high-risk head and neck cancer patients in Japan. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 203-207.	1.1	9
1199	Blockage of EGFR Pathway for Anticancer Therapy in Squamous Cell Carcinoma of the Head and Neck. , 2017, , 135-161.		1
1200	Palliative systemic therapy for recurrent or metastatic nasopharyngeal carcinoma – How far have we achieved?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 13-23.	2.0	39
1201	Anti-epidermal growth factor receptor (anti-EGFR) agents as adjuncts to conventional treatment for head and neck squamous cell carcinomas. <i>The Cochrane Library</i> , 0, , .	1.5	0
1202	Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. <i>Drugs</i> , 2017, 77, 843-857.	4.9	40
1203	Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEX) as first-line treatment followed by cetuximab maintenance. <i>Oral Oncology</i> , 2017, 68, 114-118.	0.8	18
1204	Chemotherapy for recurrent/metastatic head and neck cancers. <i>Anti-Cancer Drugs</i> , 2017, 28, 357-361.	0.7	15
1206	Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 915-922.	1.1	9
1207	Genetics of Gastric Cancer. <i>Surgical Clinics of North America</i> , 2017, 97, 345-370.	0.5	34
1208	Utility of clinico-biological data for long-term prognosis of head and neck terminal cancer. <i>Acta Oto-Laryngologica</i> , 2017, 137, 895-898.	0.3	6
1209	Japanese Clinical Practice Guideline for Head and Neck Cancer. <i>Auris Nasus Larynx</i> , 2017, 44, 375-380.	0.5	44
1210	Radiotherapy plus EGFR inhibitors: synergistic modalities. <i>Cancers of the Head & Neck</i> , 2017, 2, 2.	6.2	8

#	ARTICLE	IF	CITATIONS
1212	Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2017, 127, 1583-1588.	1.1	8
1214	The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer. <i>JAMA Oncology</i> , 2017, 3, 483.	3.4	51
1215	Genomic sequencing and precision medicine in head and neck cancers. <i>European Journal of Surgical Oncology</i> , 2017, 43, 884-892.	0.5	12
1216	Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2017, 11, 338-345.	1.3	9
1217	Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism. <i>Cancer Research</i> , 2017, 77, 1188-1199.	0.4	71
1218	Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 368.	1.2	19
1219	Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 220.	3.4	64
1220	Critical Issues in Head and Neck Oncology. , 2017, , .		0
1221	Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2017, 6, 142-153.	1.3	27
1222	Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. <i>Clinical Cancer Research</i> , 2017, 23, 3072-3083.	3.2	45
1223	The Biology of Head and Neck Cancer. , 2017, , 51-66.		0
1224	Current mouse models of oral squamous cell carcinoma: Genetic and chemically induced models. <i>Oral Oncology</i> , 2017, 73, 16-20.	0.8	72
1225	Rapid occurrence of left ventricular thrombus associated with platinum-based chemotherapy plus cetuximab for the treatment of metastatic squamous cell carcinoma of the head and neck: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 7, 833-836.	0.4	7
1226	Genomic predictive model for recurrence and metastasis development in head and neck squamous cell carcinoma patients. <i>Scientific Reports</i> , 2017, 7, 13897.	1.6	38
1227	A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2017, 28, 2820-2826.	0.6	66
1228	Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 225-231.	0.3	33
1229	Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 4583-4593.	2.0	23
1230	mTOR co-targeting strategies for head and neck cancer therapy. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 491-502.	2.7	46

#	ARTICLE	IF	CITATIONS
1232	AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis. <i>Cancer Letters</i> , 2017, 408, 33-42.	3.2	31
1233	Resistance to dasatinib is associated with the activation of Akt in oral squamous cell carcinoma. <i>Translational Research in Oral Oncology</i> , 2017, 2, 2057178X1770292.	2.3	1
1234	Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. <i>Nature Medicine</i> , 2017, 23, 1167-1175.	15.2	141
1235	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 229-238.	0.7	15
1236	Identification of prognostic genes through expression differentiation during metastatic process in lung adenocarcinoma. <i>Scientific Reports</i> , 2017, 7, 11119.	1.6	3
1237	Liquid Biopsies in Head and Neck Cancer Patients. <i>Current Clinical Pathology</i> , 2017, , 195-200.	0.0	0
1238	EGFR-targeted therapies in the post-genomic era. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 463-473.	2.7	182
1239	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. <i>Oral Oncology</i> , 2017, 73, 138-146.	0.8	90
1240	Collagen gel droplet-embedded culture drug sensitivity testing in hard palate cancer-predicted antitumor efficacy of cetuximab: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 7, 637-641.	0.4	4
1241	Simple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 146, 266-272.	1.4	29
1242	nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2017, 72, 26-31.	0.8	12
1243	A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). <i>Annals of Oncology</i> , 2017, 28, 2533-2538.	0.6	33
1245	Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. <i>American Journal of Roentgenology</i> , 2017, 209, 289-303.	1.0	103
1246	Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 775-782.	0.5	12
1247	Immunotherapy. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 867-874.	0.5	4
1248	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. <i>ESMO Open</i> , 2017, 2, e000166.	2.0	4
1249	Survival of Head and Neck Cancer Cells Relies upon LZK Kinase-Mediated Stabilization of Mutant p53. <i>Cancer Research</i> , 2017, 77, 4961-4972.	0.4	22
1250	Four PTEN-targeting co-expressed miRNAs and ACTN4-targeting miR-548b are independent prognostic biomarkers in human squamous cell carcinoma of the oral tongue. <i>International Journal of Cancer</i> , 2017, 141, 2318-2328.	2.3	20

#	ARTICLE	IF	CITATIONS
1251	Stereotactic radiosurgery for brain metastases from primary head and neck carcinomas: a retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2017, 134, 197-203.	1.4	7
1252	A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma. <i>Oral Oncology</i> , 2017, 73, 21-26.	0.8	20
1253	Changes in cell junctions induced by inhibition of epidermal growth factor receptor in oral squamous cell carcinoma cells. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 953-960.	0.8	2
1254	Characterization of KIF11 as a novel prognostic biomarker and therapeutic target for oral cancer. <i>International Journal of Oncology</i> , 2018, 52, 155-165.	1.4	39
1255	Distant metastases in head and neck cancer. <i>Head and Neck</i> , 2017, 39, 1733-1743.	0.9	169
1256	Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 969-973.	0.4	3
1257	Palliative treatment of patients with inoperable locally advanced, recurrent or metastatic head and neck squamous cell cancer, using a low-dose and personalized chemotherapeutic regimen. <i>Oncology Letters</i> , 2017, 13, 4633-4640.	0.8	3
1259	DeSigN: connecting gene expression with therapeutics for drug repurposing and development. <i>BMC Genomics</i> , 2017, 18, 934.	1.2	62
1260	Immunotherapy in head and neck cancer: aiming at EXTREME precision. <i>BMC Medicine</i> , 2017, 15, 110.	2.3	64
1261	A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. <i>Investigational New Drugs</i> , 2017, 35, 68-78.	1.2	19
1262	Metronomic chemotherapy in head and neck cancer. <i>Cancer Letters</i> , 2017, 400, 219-222.	3.2	5
1263	Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study. <i>Current Medical Research and Opinion</i> , 2017, 33, 401-407.	0.9	9
1264	Salvage surgery after head and neck squamous cell carcinoma treated with bioradiotherapy. <i>Head and Neck</i> , 2017, 39, 116-121.	0.9	10
1265	Genomic alterations in human epidermal growth factor receptor 2 (<i>HER2/ERBB2</i>) in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, E15-E19.	0.9	12
1266	Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 623-631.	1.1	16
1267	Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2017, 38, 52-56.	0.6	1
1268	Synthetic Lethality in Cancer Therapeutics. <i>Annual Review of Cancer Biology</i> , 2017, 1, 141-161.	2.3	36
1269	Bioelectrics. , 2017, , .		13

#	ARTICLE	IF	CITATIONS
1270	Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC. Recent Results in Cancer Research, 2017, 206, 149-160.	1.8	2
1271	Medical Applications. , 2017, , 275-388.		2
1272	Inhibition of epithelialâ€mesenchymal transition by cetuximab via the EGFRâ€GEP100â€Arf6â€AMAP1 pathway in head and neck cancer. Head and Neck, 2017, 39, 476-485.	0.9	15
1273	Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population. Medicine (United States), 2017, 96, e9519.	0.4	5
1274	Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells. Oncology Reports, 2018, 39, 367-375.	1.2	6
1276	The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer. Oncology, 2017, 93, 75-82.	0.9	11
1277	Update on squamous cell carcinoma of the head and neck. Memo - Magazine of European Medical Oncology, 2017, 10, 220-223.	0.3	22
1278	A Case of Successful Treatment with Kampo Medicine to the Adverse Skin Reactions Induced by Cetuximab. Kampo Medicine, 2017, 68, 333-338.	0.1	1
1279	Title is missing!. Journal of Otolaryngology of Japan, 2017, 120, 866-872.	0.1	0
1280	Brain metastasis from oral cancer. Journal of Japanese Society of Oral Oncology, 2017, 29, 66-70.	0.0	0
1281	Chemotherapy for the older patient with oral cancer. Journal of Japanese Society of Oral Oncology, 2017, 29, 182-188.	0.0	0
1282	The management of sphenoidal metastasis from intraosseous squamous cell carcinoma of the mandible. Journal of Japanese Society of Oral Oncology, 2017, 29, 84-91.	0.0	0
1283	Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma. Molecular and Clinical Oncology, 2017, 7, 1021-1026.	0.4	4
1284	Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape. ESMO Open, 2017, 2, e000272.	2.0	2
1285	Liver metastasis of oral squamous cell carcinoma. Journal of Japanese Society of Oral Oncology, 2017, 29, 71-77.	0.0	0
1286	OP118 Cost-Effectiveness Analysis Of Molecular Profile Selection For Advanced Head And Neck Cancer. International Journal of Technology Assessment in Health Care, 2017, 33, 53-54.	0.2	0
1287	Re-irradiation for Recurrent Head and Neck Cancer. , 0, , .		0
1288	Alternative Imaging Response Criteria with the Use of Axitinib in Head and Neck Cancer: An Exploratory Analysis Utilizing the Choi Criteria. Otolaryngology (Sunnyvale, Calif), 2017, 07, .	0.0	1

#	ARTICLE	IF	CITATIONS
1289	Conspectus on Nanotechnology in Oral Cancer Diagnosis and Treatment. , 2017, , 31-49.		3
1290	Chemotherapy and Targeted Agents. , 2017, , 339-354.		3
1291	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 2537-2549.	2.0	6
1292	Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Management and Research, 2017, Volume 9, 363-371.	0.9	150
1293	Metronomic Cordycepin Therapy Prolongs Survival of Oral Cancer-Bearing Mice and Inhibits Epithelial-Mesenchymal Transition. Molecules, 2017, 22, 629.	1.7	24
1294	Reversing EGFR Mediated Immunescape by Targeted Monoclonal Antibody Therapy. Frontiers in Pharmacology, 2017, 8, 332.	1.6	25
1295	Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. Journal of Gastrointestinal Oncology, 2017, 8, 418-429.	0.6	20
1296	Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers, 2017, 9, 39.	1.7	47
1297	Activated HGF-c-Met Axis in Head and Neck Cancer. Cancers, 2017, 9, 169.	1.7	51
1298	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Frontiers in Oncology, 2017, 7, 72.	1.3	122
1299	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. Disease Markers, 2017, 2017, 1-9.	0.6	4
1300	Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay. Oncotarget, 2017, 8, 72127-72132.	0.8	14
1301	Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report. Molecular and Clinical Oncology, 2017, 6, 886-892.	0.4	8
1302	Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up. Theranostics, 2017, 7, 2314-2324.	4.6	61
1303	Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy. PLoS ONE, 2017, 12, e0180995.	1.1	15
1304	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. PLoS ONE, 2017, 12, e0183639.	1.1	2
1305	A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer, 2017, 17, 684.	1.1	125
1306	Clinical outcomes of retrograde intra-arterial chemotherapy concurrent with radiotherapy for elderly oral squamous cell carcinoma patients aged over 80 years old. Radiation Oncology, 2017, 12, 112.	1.2	14

#	ARTICLE	IF	CITATIONS
1307	An alternative approach with a low dose and prolonged chemotherapy for palliative treatment of locally advanced, metastatic or recurrent squamous cell head and neck cancer. <i>Applied Cancer Research</i> , 2017, 37, .	1.0	3
1309	Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing. <i>Oncotarget</i> , 2017, 8, 59113-59122.	0.8	52
1310	Palliative Radiotherapy for Advanced and Metastatic Head and Neck Cancers and Skin Metastases. , 2017, , 275-296.		0
1311	Cancer Immunotherapy. , 2017, , 32-65.		1
1312	Surgical Treatment for Pulmonary Metastasis of Head and Neck Cancer: Study of 58 Cases. <i>Annals of Thoracic and Cardiovascular Surgery</i> , 2017, 23, 169-174.	0.3	12
1313	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?. <i>Oncotarget</i> , 2017, 8, 100863-100898.	0.8	16
1314	Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes. <i>Oncotarget</i> , 2017, 8, 55600-55612.	0.8	133
1315	How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?. <i>Journal of Clinical Oncology</i> , 2017, 35, 2229-2231.	0.8	18
1316	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1542-1549.	0.8	527
1317	The Team Approach in the Management of Head and Neck Cancer. , 2017, , 285-291.		0
1319	Assessment of quality of life in phase III trials of radiotherapy in localized or locally advanced head and neck cancer over the past 17 years. <i>Annals of Palliative Medicine</i> , 2017, 6, 73-80.	0.5	4
1320	The Molecular Biology of Head and Neck Cancer. , 2017, , 243-256.		1
1321	Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway. <i>Oral Oncology</i> , 2018, 79, 55-63.	0.8	54
1322	Multidisciplinary Care of the Head and Neck Cancer Patient. <i>Cancer Treatment and Research</i> , 2018, , .	0.2	10
1323	Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. <i>Cancer Science</i> , 2018, 109, 771-776.	1.7	48
1324	Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer. <i>Future Oncology</i> , 2018, 14, 1547-1558.	1.1	4
1325	Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. <i>ESMO Open</i> , 2018, 3, e000303.	2.0	12
1326	GENIPAC: A Genomic Information Portal for Head and Neck Cancer Cell Systems. <i>Journal of Dental Research</i> , 2018, 97, 909-916.	2.5	6

#	ARTICLE	IF	CITATIONS
1327	Targeting the DNA Damage Response in OSCC with <i>TP53</i> Mutations. <i>Journal of Dental Research</i> , 2018, 97, 635-644.	2.5	92
1328	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Current Oncology Reports</i> , 2018, 20, 22.	1.8	131
1329	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. <i>Cancer Treatment Reviews</i> , 2018, 65, 54-64.	3.4	51
1330	Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Cancer Science</i> , 2018, 109, 1609-1616.	1.7	11
1331	New Therapies in Head and Neck Cancer. <i>Trends in Cancer</i> , 2018, 4, 385-396.	3.8	50
1332	Reirradiation of head and neck cancer using modern highly conformal techniques. <i>Head and Neck</i> , 2018, 40, 2078-2093.	0.9	39
1333	Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC. <i>Future Oncology</i> , 2018, 14, 877-889.	1.1	31
1334	Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 80, 104-107.	0.8	19
1335	Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis. <i>BMC Cancer</i> , 2018, 18, 323.	1.1	18
1336	Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. <i>Molecular Oncology</i> , 2018, 12, 830-854.	2.1	36
1337	Head and neck cancer in Hong Kong. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 13-21.	0.6	10
1338	Immunotherapy for recurrent/metastatic head and neck cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2018, 26, 152-156.	0.8	28
1339	Restoration of Facial Form and Lip Competence in a Patient with a Midfacial Defect. <i>Journal of Prosthodontics</i> , 2018, 27, 496-500.	1.7	1
1340	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. <i>Seminars in Cancer Biology</i> , 2018, 52, 228-240.	4.3	314
1341	Targeted cancer therapies. <i>Journal of the American Dental Association</i> , 2018, 149, 100-111.	0.7	12
1342	Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 549-554.	1.1	20
1343	Salvage of recurrence after surgery and adjuvant therapy: A systematic review. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2018, 39, 223-227.	0.6	15
1345	Induction chemotherapy with the EXTREME regimen in frail patients with locally advanced head and neck squamous cell carcinoma. <i>Targeted Oncology</i> , 2018, 13, 247-252.	1.7	3

#	ARTICLE	IF	CITATIONS
1346	Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. <i>Medical Oncology</i> , 2018, 35, 37.	1.2	52
1347	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 710-716.	1.9	25
1348	Monocle tumor as tonsillar squamous cell carcinoma metastasis: resolution after chemotherapy treatment. <i>International Journal of Dermatology</i> , 2018, 57, 498-500.	0.5	1
1349	Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas. <i>Oncologist</i> , 2018, 23, 526-e49.	1.9	15
1350	Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). <i>Annals of Oncology</i> , 2018, 29, 1004-1009.	0.6	68
1351	Leveraging Genomics for Head and Neck Cancer Treatment. <i>Journal of Dental Research</i> , 2018, 97, 603-613.	2.5	8
1352	Modified biweekly cisplatin, docetaxel plus cetuximab (TPEX) as first-line treatment for patients with recurrent/metastatic head and neck cancer. <i>Medical Oncology</i> , 2018, 35, 32.	1.2	12
1353	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors) <i>Tj ETQq1 1 0284314 rgt /Ov</i>	2.8	14
1354	Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN). <i>Annals of Oncology</i> , 2018, 29, 794-796.	0.6	7
1356	Perspectives in Head and Neck Medical Oncology. <i>Cancer Treatment and Research</i> , 2018, 174, 163-185.	0.2	5
1357	Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 509-521.	2.9	25
1358	Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). <i>Annals of Oncology</i> , 2018, 29, 985-991.	0.6	36
1359	Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2018, 46, 492-497.	0.7	6
1360	Molecularly-targeted therapy for the oral cancer stem cells. <i>Japanese Dental Science Review</i> , 2018, 54, 88-103.	2.0	16
1361	Establishment of Synergistic Chemoimmunotherapy for Head and Neck Cancer Using Peritumoral Immature Dendritic Cell Injections and Low-Dose Chemotherapies. <i>Translational Oncology</i> , 2018, 11, 132-139.	1.7	5
1362	Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 5.	2.7	33
1363	Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells. <i>Phytomedicine</i> , 2018, 39, 33-41.	2.3	33
1364	Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Caseâ€“Control Study of Patients with Head and Neck Squamous Cell Carcinoma. <i>Translational Oncology</i> , 2018, 11, 168-174.	1.7	8

#	ARTICLE	IF	CITATIONS
1365	Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. <i>Molecular Cancer</i> , 2018, 17, 60.	7.9	27
1366	Expression Differentiation Is Not Helpful in Identifying Prognostic Genes Based on TCGA Datasets. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 292-299.	2.3	14
1367	The Impact of Metronomic Adjuvant Chemotherapy in Patients with Advanced Oral Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2091-2097.	0.7	22
1368	A case of lateral retropharyngeal node metastasis from carcinoma of the tongue. <i>Journal of Japanese Society of Oral Oncology</i> , 2018, 30, 7-13.	0.0	0
1369	The importance of greater speed in drug development for advanced malignancies. <i>Cancer Medicine</i> , 2018, 7, 1824-1836.	1.3	23
1370	Genomics Reloaded: Rise of the Expression Profiles. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1-3.	0.4	2
1371	Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 80, 33-39.	0.8	5
1372	STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner. <i>Clinical Cancer Research</i> , 2018, 24, 2665-2677.	3.2	69
1373	Clonal evolution and heterogeneity in metastatic head and neck cancer – An analysis of the Austrian Study Group of Medical Tumour Therapy study group. <i>European Journal of Cancer</i> , 2018, 93, 69-78.	1.3	25
1374	Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC. <i>Oral Oncology</i> , 2018, 80, 23-32.	0.8	210
1375	Nivolumab in squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 409-420.	1.1	9
1376	Feasibility study on adaptive 18F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territory. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 727-736.	1.0	7
1377	Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. <i>Oncologist</i> , 2018, 23, 764-e86.	1.9	6
1378	Effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. <i>Head and Neck</i> , 2018, 40, 1743-1751.	0.9	7
1379	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
1380	AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2018, 40, 676-686.	0.9	16
1381	A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 595-605.	0.4	101
1382	Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 441-446.	0.6	12

#	ARTICLE	IF	CITATIONS
1384	Head and Neck Carcinoma Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 6-13.	3.2	71
1385	The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. <i>Pharmacogenomics Journal</i> , 2018, 18, 474-479.	0.9	20
1386	Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2018, 23, 225-233.	1.9	30
1387	Chemotherapy for Oral Cancer. <i>Dental Clinics of North America</i> , 2018, 62, 87-97.	0.8	88
1388	Role of Immunotherapy in Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2018, 28, 12-16.	1.0	62
1389	Nivolumab in recurrent/metastatic head and neck cancers. <i>Future Oncology</i> , 2018, 14, 603-609.	1.1	3
1390	Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and an Experimental Organometallic Drug for Melanoma Treatment. <i>Molecular Pharmaceutics</i> , 2018, 15, 116-126.	2.3	16
1391	Salvage surgery for recurrence of laryngeal and hypopharyngeal squamous cell carcinoma: A retrospective study from 2005 to 2013. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2018, 135, 111-117.	0.4	14
1392	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018, 63, 48-60.	3.4	134
1393	Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cancer</i> , 2018, 142, 2198-2206.	2.3	24
1394	Inhibition of BMP signaling overcomes acquired resistance to cetuximab in oral squamous cell carcinomas. <i>Cancer Letters</i> , 2018, 414, 181-189.	3.2	15
1395	SEOM clinical guidelines for the treatment of head and neck cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 75-83.	1.2	27
1396	A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. <i>Targeted Oncology</i> , 2018, 13, 69-78.	1.7	0
1397	Two cases of combination therapy with cetuximab, paclitaxel, and cisplatin for advanced head and neck cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 553-554.	0.5	5
1398	Update 2018. <i>Clinical Nuclear Medicine</i> , 2018, 43, e439-e452.	0.7	15
1399	Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3084-3090.	0.8	55
1400	Boron neutron capture therapy in the treatment of lung cancer. <i>Journal of Xiangya Medicine</i> , 0, 3, 29-29.	0.2	2
1401	Is more the better? cetuximab in non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2018, 7, S195-S197.	1.3	1

#	ARTICLE	IF	CITATIONS
1403	Exosomeâ€ delivered TRPP2 siRNA inhibits the epithelialâ€ mesenchymal transition of FaDu cells. <i>Oncology Letters</i> , 2018, 17, 1953-1961.	0.8	29
1404	Nasal administration of mesenchymal stem cells restores cisplatin-induced cognitive impairment and brain damage in mice. <i>Oncotarget</i> , 2018, 9, 35581-35597.	0.8	55
1406	Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma. <i>Medicine (United States)</i> , 2018, 97, e13717.	0.4	2
1407	Receptor Tyrosine Kinase-Targeted Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3491.	1.8	187
1408	lncRNA Expression after Irradiation and Chemoexposure of HNSCC Cell Lines. <i>Non-coding RNA</i> , 2018, 4, 33.	1.3	15
1409	HPV Assessment in Oropharynx Cancer: What is the Gold Standard?. , 2018, , 119-147.		1
1410	Prognostic analysis of patients with locally advanced nasopharyngeal carcinoma following intensity modulated radiation therapy. <i>Oncology Letters</i> , 2018, 15, 4445-4450.	0.8	4
1411	Treatment of Elderly Patients with Head and Neck Cancer. , 2018, , 285-307.		0
1412	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1197-1209.	1.0	11
1413	Persistent Head and Neck Cancer Following First-Line Treatment. <i>Cancers</i> , 2018, 10, 421.	1.7	14
1414	Are There Alternative Chemotherapy Regimens for EXTREME in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M-SCCHN)?. , 2018, , 267-276.		0
1415	Tumor Immunology, Immunotherapy and Its Application to Head and Neck Squamous Cell Carcinoma (HNSCC). , 2018, , 341-355.		2
1417	Potential application of tumor suppressor microRNAs for targeted therapy in head and neck cancer: A mini-review. <i>Oral Oncology</i> , 2018, 87, 165-169.	0.8	9
1418	Optimal Cetuximab Contact Concentration Using a Collagen Gel Droplet- Embedded Culture Drug Chemosensitivity Test in Human Oral Squamous Carcinoma Cell Lines. <i>Chemotherapy</i> , 2018, 07, .	0.0	2
1419	Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials. <i>BMC Cancer</i> , 2018, 18, 1170.	1.1	32
1420	Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 130-138.	0.9	9
1421	Targeted Next-Generation Sequencing in Head and Neck Cancer. , 2018, , 37-50.		0
1422	Lower gingival squamous cell carcinoma with brain metastasis during long-term cetuximab treatment: A case report. <i>Oncology Letters</i> , 2018, 15, 7158-7162.	0.8	4

#	ARTICLE	IF	CITATIONS
1423	Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma. <i>International Journal of Oncology</i> , 2018, 54, 283-294.	1.4	21
1424	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. <i>JCI Insight</i> , 2018, 3, .	2.3	110
1425	Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK. <i>Frontiers in Oncology</i> , 2018, 8, 616.	1.3	17
1426	Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?. <i>Cancer</i> , 2018, 124, 4163-4164.	2.0	6
1427	Introduction to Head and Neck Cancer. , 2018, , 191-193.		0
1428	Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer. <i>Oncology</i> , 2018, 95, 353-359.	0.9	6
1429	Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status. <i>Life Sciences</i> , 2018, 212, 182-193.	2.0	4
1430	TRKB tyrosine kinase receptor is a potential therapeutic target for poorly differentiated oral squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 25225-25243.	0.8	28
1431	A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2018, 104, 1-8.	1.3	10
1432	Chemoprevention of Head and Neck Cancers: Does It Have Only One Face?. <i>BioMed Research International</i> , 2018, 2018, 1-15.	0.9	9
1433	Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab. <i>Oral Oncology</i> , 2018, 86, 251-257.	0.8	78
1434	Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab. <i>Head and Neck</i> , 2018, 40, 2424-2431.	0.9	14
1435	Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer. <i>Bioconjugate Chemistry</i> , 2018, 29, 3817-3832.	1.8	14
1436	Irradiance controls photodynamic efficacy and tissue heating in experimental tumours: implication for interstitial PDT of locally advanced cancer. <i>British Journal of Cancer</i> , 2018, 119, 1191-1199.	2.9	33
1437	Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits. <i>Current Treatment Options in Oncology</i> , 2018, 19, 68.	1.3	14
1438	The G-quadruplex fluorescent probe 3,6-bis(1-methyl-2-vinyl-pyridinium) carbazole diiodide as a biosensor for human cancers. <i>Scientific Reports</i> , 2018, 8, 16082.	1.6	36
1439	Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 432.	1.3	12
1440	Oral cancers: Current status. <i>Oral Oncology</i> , 2018, 87, 64-69.	0.8	68

#	ARTICLE	IF	CITATIONS
1441	Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. <i>Annals of Oncology</i> , 2018, 29, 2313-2327.	0.6	47
1443	Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus. <i>Oral Oncology</i> , 2018, 87, 207-209.	0.8	3
1444	Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. <i>Annals of Oncology</i> , 2018, 29, 2247-2253.	0.6	101
1445	ASO Author Reflections: Tegafur-Uracil in Advanced Oral Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 899-900.	0.7	2
1447	An update: emerging drugs to treat squamous cell carcinomas of the head and neck. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 283-299.	1.0	44
1448	Underexpression of β -1-microglobulin/bikunin precursor predicts a poor prognosis in oral squamous cell carcinoma. <i>International Journal of Oncology</i> , 2018, 53, 2605-2614.	1.4	13
1449	HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. <i>Oral Oncology</i> , 2018, 86, 69-74.	0.8	4
1450	Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2018, 8, 339.	1.3	21
1451	Successful cisplatin-etoposide chemotherapy-based treatment of a primary small cell neuroendocrine carcinoma of the tonsil with multiple metastases: a case report. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5391-5395.	1.0	3
1452	High incidence of cetuximab-related infusion reactions in head and neck patients. <i>ESMO Open</i> , 2018, 3, e000346.	2.0	8
1453	A gene expression profile associated with perineural invasion identifies a subset of HNSCC at risk of post-surgical recurrence. <i>Oral Oncology</i> , 2018, 86, 53-60.	0.8	35
1454	The Role of Palliative Care in Oral Cavity Carcinoma. <i>Current Otorhinolaryngology Reports</i> , 2018, 6, 276-284.	0.2	0
1455	Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCMS system in a quaternary oncology centre. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 865-876.	1.1	8
1456	Effectiveness Outcomes in Patients With Recurrent or Refractory Head and Neck Cancers: Retrospective Analysis of Data From a Community Oncology Database. <i>Clinical Therapeutics</i> , 2018, 40, 1522-1537.	1.1	5
1457	Head and Neck Tumors. , 2018, , 1-136.		1
1458	Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial. <i>Acta Oncologica</i> , 2018, 57, 1159-1164.	0.8	7
1459	Oligometastatic status as predictor of survival in metastatic human papillomavirus-positive oropharyngeal carcinoma. <i>Head and Neck</i> , 2018, 40, 1685-1690.	0.9	25
1460	Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization. <i>International Journal of Radiation Biology</i> , 2018, 94, 628-644.	1.0	15

#	ARTICLE	IF	CITATIONS
1461	Evaluation of Reirradiation in Locally Advanced Head and Neck Cancers: Toxicity and Early Clinical Outcomes. <i>Journal of Oncology</i> , 2018, 2018, 1-5.	0.6	4
1462	Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma. <i>Surgical Oncology</i> , 2018, 27, 259-265.	0.8	14
1463	Checkpoint Inhibitors in Head and Neck Cancer: Current Knowledge and Perspectives. <i>Journal of Investigative Medicine</i> , 2018, 66, 1023-1030.	0.7	26
1464	Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2018, 4, 1583.	3.4	84
1465	The human papillomavirus (HPV)-related cancer biology: An overview. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 1537-1556.	2.5	96
1466	Update on Keratinocyte Carcinomas. <i>New England Journal of Medicine</i> , 2018, 379, 363-374.	13.9	216
1467	Importance of magnesium sulfate supplementation in the prevention of hypomagnesemia and hypocalcemia during chemoradiation in head and neck cancer. <i>Journal of Trace Elements in Medicine and Biology</i> , 2018, 50, 327-331.	1.5	3
1468	Modulation of Exposure to Static Magnetic Field Affects Targeted Therapy of Solid Tumors <i>In Vivo</i> . <i>Anticancer Research</i> , 2018, 38, 4549-4555.	0.5	8
1469	Screening for long noncoding RNAs associated with oral squamous cell carcinoma reveals the potentially oncogenic actions of DLEU1. <i>Cell Death and Disease</i> , 2018, 9, 826.	2.7	46
1471	A Non Platinum Regimen for the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Region. Results From an Extended Phase II Study With Paclitaxel and Capecitabine. <i>Frontiers in Oncology</i> , 2018, 8, 243.	1.3	5
1472	Electrochemotherapy: a well-accepted palliative treatment by patients with head and neck tumours. <i>Acta Otorhinolaryngologica Italica</i> , 2018, 38, 181-187.	0.7	17
1473	Skin Reaction to Cetuximab as a Criterion for Treatment Selection in Head and Neck Cancer. <i>Anticancer Research</i> , 2018, 38, 4213-4220.	0.5	4
1474	Bosutinib Inhibits EGFR Activation in Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1824.	1.8	12
1475	Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 13488-13500.	0.8	28
1476	Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. <i>Lancet Oncology</i> , The, 2018, 19, 1082-1093.	5.1	21
1477	Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer. <i>PLoS ONE</i> , 2018, 13, e0200509.	1.1	6
1478	Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 901-915.	1.1	40
1479	Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1267-1272.	1.0	51

#	ARTICLE	IF	CITATIONS
1480	Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review). <i>Oncology Letters</i> , 2018, 15, 7497-7505.	0.8	50
1481	Mechanisms of receptor tyrosine kinase activation in cancer. <i>Molecular Cancer</i> , 2018, 17, 58.	7.9	580
1484	Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds. <i>Scientific Reports</i> , 2018, 8, 12163.	1.6	24
1485	Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review. <i>Oral Oncology</i> , 2018, 84, 108-120.	0.8	67
1486	The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. <i>European Journal of Cancer</i> , 2018, 93, 89-98.	1.3	14
1487	Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?. <i>ESMO Open</i> , 2018, 3, e000404.	2.0	0
1488	Cancers of the Oral Cavity: Diagnosis and Treatment. , 2018, , .		0
1489	New developments in the management of head and neck cancer – impact of pembrolizumab. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 295-303.	0.9	55
1490	Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT) Tj ETQq0 0 0 rgBT /Overlock 1 cyclophosphamide. <i>Clinical and Translational Radiation Oncology</i> , 2018, 12, 47-52.	0.9	12
1491	Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). <i>Cancers of the Head & Neck</i> , 2018, 3, 3.	6.2	58
1492	CheckMate 141: 1â€Year Update and Subgroup Analysis of Nivolumab as Firstâ€Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018, 23, 1079-1082.	1.9	70
1493	Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. <i>Oral Oncology</i> , 2018, 82, 144-151.	0.8	13
1495	Soft Palate Cancer. , 2018, , 761-773.		0
1496	Advanced Larynx Cancer. , 2018, , 818-829.		0
1497	Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. <i>Current Opinion in Pharmacology</i> , 2018, 41, 114-121.	1.7	97
1498	Synthesis and antitumor activity of bis(hydroxymethyl)propionate analogs of pterostilbene in cisplatin-resistant human oral cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3909-3916.	1.4	10
1499	Severe Pain Due to Paraspinal Abscess Formation in Two Patients with Squamous-Cell Carcinoma of the Head and Neck after Multimodal Treatment Including Cetuximab. <i>Oncology Research and Treatment</i> , 2018, 41, 395-398.	0.8	1
1500	Stereotactic Body Radiotherapy Treatment for Recurrent, Previously Irradiated Head and Neck Cancer. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381878008.	0.8	11

#	ARTICLE	IF	CITATIONS
1501	Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A Retrospective Study. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2018, 127, 456-462.	0.6	2
1503	C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer. <i>Oncogene</i> , 2018, 37, 5780-5793.	2.6	45
1504	Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy. , 2019, , 1-23.		0
1505	The role of tumor DNA as a diagnostic tool for head and neck squamous cell carcinoma. <i>Seminars in Cancer Biology</i> , 2019, 55, 1-7.	4.3	43
1506	Retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia and cetuximab for carcinoma of the buccal mucosa with N3 lymph node metastasis: a case report. <i>Oral Radiology</i> , 2019, 35, 77-83.	0.9	3
1507	Bloodstream infection in patients with head and neck cancer: a major challenge in the cetuximab era. <i>Clinical and Translational Oncology</i> , 2019, 21, 187-196.	1.2	12
1508	Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEK Prospective Study. <i>Clinical Chemistry</i> , 2019, 65, 1267-1275.	1.5	38
1509	Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients. <i>Oral Science International</i> , 2019, 16, 49-68.	0.3	2
1510	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
1512	Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 616-622.	0.3	3
1513	Challenges in the re-irradiation of locally advanced head and neck cancers: outcomes and toxicities. <i>Journal of Radiation Oncology</i> , 2019, 8, 259-266.	0.7	1
1514	The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions. <i>Frontiers in Oncology</i> , 2019, 9, 668.	1.3	33
1515	Identification and analysis of genes associated with head and neck squamous cell carcinoma by integrated bioinformatics methods. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e857.	0.6	27
1516	Pembrolizumab for the treatment of head and neck squamous cell cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 879-885.	1.4	8
1517	Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer. <i>Journal of Inorganic Biochemistry</i> , 2019, 199, 110780.	1.5	33
1518	An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1379-1389.	2.0	26
1519	Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1295-1305.	5.1	87
1520	Palbociclib: a new partner for cetuximab?. <i>Lancet Oncology</i> , The, 2019, 20, 1195-1196.	5.1	1

#	ARTICLE	IF	CITATIONS
1521	Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. <i>Oral Oncology</i> , 2019, 96, 7-14.	0.8	45
1522	A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab. <i>Biomarker Research</i> , 2019, 7, 14.	2.8	6
1523	Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance. <i>Cancer Biology and Medicine</i> , 2019, 16, 264.	1.4	24
1524	Clinical and translational advances in esophageal squamous cell carcinoma. <i>Advances in Cancer Research</i> , 2019, 144, 95-135.	1.9	140
1525	The role of salvage surgery with interstitial brachytherapy for the Management of Regionally Recurrent Head and Neck Cancers. <i>Cancers of the Head & Neck</i> , 2019, 4, 4.	6.2	8
1526	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019, 25, 5221-5230.	3.2	115
1528	ATR inhibition sensitizes HPV ⁻ and HPV ⁺ head and neck squamous cell carcinoma to cisplatin. <i>Oral Oncology</i> , 2019, 95, 35-42.	0.8	34
1529	Palliative Radiation Therapy for Head and Neck Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 254-266.	0.4	52
1530	Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3266-3274.	0.8	70
1531	Immune gene expression in head and neck squamous cell carcinoma patients. <i>European Journal of Cancer</i> , 2019, 121, 210-223.	1.3	45
1532	Advances in Diagnosis and Multidisciplinary Management of Oropharyngeal Squamous Cell Carcinoma: State of the Art. <i>Radiographics</i> , 2019, 39, 2055-2068.	1.4	19
1534	Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). <i>European Journal of Cancer</i> , 2019, 122, 53-60.	1.3	16
1535	Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 849.	1.3	117
1536	Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer. <i>Clinical Therapeutics</i> , 2019, 41, 2517-2528.e28.	1.1	2
1537	A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study—Part 3 (Medical Oncology). <i>Frontiers in Oncology</i> , 2019, 9, 1127.	1.3	1
1539	Immunotherapy in head and neck cancer: The great challenge of patient selection. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102829.	2.0	14
1540	The 100 most cited manuscripts in head and neck cancer: a bibliometric analysis. <i>Journal of Laryngology and Otology</i> , 2019, 133, 936-942.	0.4	9
1541	Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. <i>British Journal of Cancer</i> , 2019, 121, 897-903.	2.9	32

#	ARTICLE	IF	CITATIONS
1542	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 1915-1928.	6.3	1,804
1543	Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5399.	1.8	35
1545	Immunotherapy for head and neck cancer: Recent advances and future directions. <i>Oral Oncology</i> , 2019, 99, 104460.	0.8	202
1546	Treatment Strategy for Distant Synchronous Metastatic Head and Neck Squamous Cell Carcinoma. <i>Current Oncology Reports</i> , 2019, 21, 102.	1.8	16
1549	A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer. <i>Head and Neck</i> , 2019, 41, 3842-3849.	0.9	18
1550	Novel immune-modulating drugs for advanced head and neck cancer. <i>Head and Neck</i> , 2019, 41, 46-56.	0.9	5
1551	Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions. <i>Head and Neck</i> , 2019, 41, 4-18.	0.9	40
1552	Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy. <i>Head and Neck</i> , 2019, 41, 19-45.	0.9	70
1553	Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study. <i>European Journal of Cancer</i> , 2019, 123, 36-47.	1.3	21
1554	Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 44-51.	1.3	34
1555	Oral Cancer: Integration of Studies for Diagnostic and Therapeutic Precision. <i>Advances in Dental Research</i> , 2019, 30, 45-49.	3.6	13
1556	Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 1084.	1.3	60
1557	Changing functional status within 6 months posttreatment is prognostic of overall survival in patients with head and neck cancer: NRG Oncology Study. <i>Head and Neck</i> , 2019, 41, 3924-3932.	0.9	6
1558	Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma. , 2019, 7, 79.		28
1559	ADAM17: An Emerging Therapeutic Target for Lung Cancer. <i>Cancers</i> , 2019, 11, 1218.	1.7	57
1560	The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2019, 8, 5969-5978.	1.3	26
1561	Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 881-889.	1.1	7
1562	Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?. <i>Journal of Clinical Oncology</i> , 2019, 37, 2807-2814.	0.8	5

#	ARTICLE	IF	CITATIONS
1563	Cetuximab in the management of nasopharyngeal carcinoma – a narrative review. <i>Journal of Laryngology and Otology</i> , 2019, 133, 843-855.	0.4	3
1564	Clinical, pathophysiologic, and genomic analysis of the outcomes of primary head and neck malignancy after pulmonary metastasectomy. <i>Scientific Reports</i> , 2019, 9, 12913.	1.6	7
1565	<p>The relevance between the immune response-related gene module and clinical traits in head and neck squamous cell carcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7455-7472.	0.9	37
1566	Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma. <i>Cancers</i> , 2019, 11, 1317.	1.7	28
1567	Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 815.	1.3	53
1568	Carbon Ion Reirradiation for Recurrent Head and Neck Cancer: A Single-Institutional Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 803-811.	0.4	40
1569	Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3032-3041.	0.8	51
1570	Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. <i>Targeted Oncology</i> , 2019, 14, 505-525.	1.7	40
1571	Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz055.	1.4	34
1572	Quality Assessment in Supportive Care in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 926.	1.3	8
1573	EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4693.	1.8	25
1574	Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2019, 121, 123-129.	1.3	115
1575	Progress in targeted therapeutic drugs for oral squamous cell carcinoma. <i>Surgical Oncology</i> , 2019, 31, 90-97.	0.8	59
1576	Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI. <i>Oncogenesis</i> , 2019, 8, 54.	2.1	12
1577	Propagermanium Induces NK Cell Maturation and Tends to Prolong Overall Survival of Patients With Refractory Cancer. <i>Anticancer Research</i> , 2019, 39, 4687-4698.	0.5	7
1578	Analyzing expression and phosphorylation of the EGF receptor in HNSCC. <i>Scientific Reports</i> , 2019, 9, 13564.	1.6	32
1579	Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial. <i>Annals of Oncology</i> , 2019, 30, 637-643.	0.6	37
1580	Head and Neck Tumors. , 2019, , 627-762.		0

#	ARTICLE	IF	CITATIONS
1581	Impact of age on the overall survival benefits of anti-EGFR-containing regimens in head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 39-46.	2.0	7
1582	Growth suppression of human oral cancer cells by candidate agents for cetuximab-side effects. <i>Experimental Cell Research</i> , 2019, 376, 210-220.	1.2	5
1583	Is EGFR really a therapeutic target in head and neck cancers?. <i>Journal of Surgical Oncology</i> , 2019, 119, 685-686.	0.8	12
1584	The Effectiveness and Prognostic Factors of CT-Guided Radioactive I-125 Seed Implantation for the Treatment of Recurrent Head and Neck Cancer After External Beam Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 638-645.	0.4	37
1586	Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2019, 15, 909-923.	1.1	10
1587	Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer. <i>Head and Neck</i> , 2019, 41, 908-914.	0.9	3
1588	Post-radiotherapy PET/CT for predicting treatment outcomes in head and neck cancer after postoperative radiotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 794-800.	3.3	11
1589	<p>Role of radiotherapy in the treatment of metastatic head and neck cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 677-683.	1.0	22
1590	Treatment trends in head and neck cancer: Surveillance, Epidemiology, and End Results (SEER) Patterns of Care analysis. <i>Cancer Causes and Control</i> , 2019, 30, 721-732.	0.8	25
1591	Selectively high efficacy of eribulin against high“grade invasive recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Oncology Letters</i> , 2019, 17, 5064-5072.	0.8	0
1592	Cutaneous Squamous Cell Carcinoma. <i>Dermatologic Clinics</i> , 2019, 37, 241-251.	1.0	31
1594	The failure of cetuximab-based de-intensified regimens for HPV-positive OPSCC: A radiobiologists perspective. <i>Clinical and Translational Radiation Oncology</i> , 2019, 17, 47-50.	0.9	15
1595	Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations. <i>Trends in Cancer</i> , 2019, 5, 365-390.	3.8	11
1596	LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression. <i>BioMed Research International</i> , 2019, 2019, 1-11.	0.9	37
1597	Approach to the Patient with Recurrent/Metastatic Disease. <i>Current Treatment Options in Oncology</i> , 2019, 20, 65.	1.3	8
1598	Novel Agents and the“Future Perspectives. , 2019, , 367-378.		0
1600	Development of active tuberculosis during treatment of head and neck carcinoma: a case series. <i>Journal of Medical Case Reports</i> , 2019, 13, 162.	0.4	4
1601	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. <i>Intensive Care Medicine</i> , 2019, 45, 988-997.	3.9	18

#	ARTICLE	IF	CITATIONS
1602	A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4955-4965.	3.2	30
1603	Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Oncology</i> , 2019, 2019, 1-9.	0.6	24
1604	HNCDB: An Integrated Gene and Drug Database for Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 371.	1.3	7
1605	Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma. <i>Pharmaceutical Medicine</i> , 2019, 33, 269-289.	1.0	10
1606	The changing therapeutic landscape of head and neck cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 669-683.	12.5	454
1607	Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2019, 5, 1170.	3.4	34
1608	Oropharyngeal Cancers in the East and the West – Implications of Aetiopathogenesis on Prognosis and Research. <i>Clinical Oncology</i> , 2019, 31, 510-519.	0.6	3
1609	Head and neck cancer management and cancer stem cells implication. <i>Saudi Dental Journal</i> , 2019, 31, 395-416.	0.5	33
1610	Non-curative treatment of patients with oral tongue squamous-cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 2039-2045.	0.8	11
1611	Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	37
1612	Integration of Checkpoint Inhibitors into the Management of Locally Advanced Head and Neck Cancer – Future Perspectives. <i>Clinical Oncology</i> , 2019, 31, 424-431.	0.6	0
1613	Immunotherapy Mythbusters in Head and Neck Cancer: The Abscopal Effect and Pseudoprogression. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 352-363.	1.8	28
1614	Real-World Systemic Therapy Treatment Patterns for Squamous Cell Carcinoma of the Head and Neck in Canada. <i>Current Oncology</i> , 2019, 26, 167-174.	0.9	11
1615	Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. <i>European Journal of Cancer</i> , 2019, 115, 4-12.	1.3	18
1616	Nivolumab in the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN): A Report of 16 Cases at a Single Institution. <i>International Journal of Practical Otolaryngology</i> , 2019, 02, e7-e10.	0.2	0
1617	Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy. <i>Trends in Cancer</i> , 2019, 5, 208-232.	3.8	54
1618	Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. <i>Biochemical Pharmacology</i> , 2019, 166, 128-138.	2.0	12
1619	Electrochemotherapy of superficial tumors – Current status:. <i>Seminars in Oncology</i> , 2019, 46, 173-191.	0.8	80

#	ARTICLE	IF	CITATIONS
1620	Salvage Treatment Options after Failed Primary Treatment of Hypopharyngeal Cancer. <i>Advances in Oto-Rhino-Laryngology</i> , 2019, 83, 135-147.	1.6	4
1621	Platinum rechallenge in recurrent head and neck squamous cell carcinoma after primary chemoradiation. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2019, 136, 257-261.	0.4	8
1622	Phase I/II Pilot Study of Wilms' Tumor 1 Peptide- Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer. <i>Therapeutic Apheresis and Dialysis</i> , 2019, 23, 279-288.	0.4	24
1623	Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 41-52.	2.0	7
1624	Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 383.	1.3	90
1625	Nimotuzumab Plus Paclitaxel and Cisplatin as a 1 st -Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study. <i>Journal of Cancer</i> , 2019, 10, 1409-1416.	1.2	12
1626	Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2019, 93, 46-51.	0.8	10
1627	Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?. <i>Cancers</i> , 2019, 11, 472.	1.7	24
1628	Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. <i>Oncolmmunology</i> , 2019, 8, e1593805.	2.1	110
1629	Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries. <i>Journal of Medical Economics</i> , 2019, 22, 698-705.	1.0	5
1630	<p>Management of recurrent nasopharyngeal carcinoma: current perspectives</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1583-1591.	1.0	72
1631	Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives. <i>Cancers</i> , 2019, 11, 367.	1.7	23
1632	Molecular Diagnostics in Head and Neck Squamous Cell Carcinoma. , 2019, , 165-185.		3
1633	Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2019, 41, 2591-2601.	0.9	12
1634	Salvage of Recurrence after Surgery and Adjuvant Therapy: A Multi- Institutional Study. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 161, 74-81.	1.1	16
1635	Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity. <i>Anticancer Research</i> , 2019, 39, 1275-1282.	0.5	10
1636	Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1357-1366.	1.1	19
1637	Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 823-833.	1.9	27

#	ARTICLE	IF	CITATIONS
1638	Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets. <i>Frontiers in Oncology</i> , 2019, 9, 74.	1.3	17
1639	Highly Uniform Synthesis of Selenium Nanoparticles with EGFR Targeting and Tumor Microenvironment-Responsive Ability for Simultaneous Diagnosis and Therapy of Nasopharyngeal Carcinoma. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 11177-11193.	4.0	56
1640	Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab. <i>Head and Neck</i> , 2019, 41, 2574-2580.	0.9	9
1641	Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma. <i>Molecular Pharmacology</i> , 2019, 95, 528-536.	1.0	17
1642	Immunotherapy Approaches Beyond PD-1 Inhibition: the Future of Cellular Therapy for Head and Neck Squamous Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 31.	1.3	10
1643	Immunotherapy for Head and Neck Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 301-321.	0.9	19
1644	A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors. <i>International Journal of Cancer</i> , 2019, 145, 2450-2458.	2.3	5
1645	Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 1003-1006.	2.9	109
1647	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 535-540.	0.6	19
1648	PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2019, 91, 69-78.	0.8	25
1649	Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. <i>Molecular Cancer</i> , 2019, 18, 69.	7.9	78
1650	Undifferentiated carcinoma of the oral tongue treated with cetuximab: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 10, 446-450.	0.4	0
1651	Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2019, 9, 155.	1.3	14
1652	Monitoring the dynamics of hemeoxygenase-1 activation in head and neck cancer cells in real-time Using plasmonically enhanced Raman spectroscopy. <i>Chemical Science</i> , 2019, 10, 4876-4882.	3.7	16
1653	Systemic Therapy, Palliation and Supportive Care of Patients with Hypopharyngeal Cancer. <i>Advances in Oto-Rhino-Laryngology</i> , 2019, 83, 148-158.	1.6	0
1654	Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1753-1774.	0.8	204
1655	Electrochemotherapy as palliative treatment in patients with advanced head and neck tumours: Outcome analysis in 93 patients treated in a single institution. <i>Oral Oncology</i> , 2019, 92, 77-84.	0.8	14
1656	Oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy: Single institution outcomes. <i>Head and Neck</i> , 2019, 41, 2309-2314.	0.9	37

#	ARTICLE	IF	CITATIONS
1657	Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients. <i>Acta Oto-Laryngologica</i> , 2019, 139, 201-205.	0.3	10
1659	The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial. <i>Radiotherapy and Oncology</i> , 2019, 134, 74-80.	0.3	14
1660	The role of age in treatment-related adverse events in patients with head and neck cancer: A systematic review. <i>Head and Neck</i> , 2019, 41, 2410-2429.	0.9	24
1661	MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. <i>International Journal of Cancer</i> , 2019, 145, 748-762.	2.3	20
1662	<p></p>Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma<p></p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1321-1336.	0.9	19
1663	Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models. <i>Targeted Oncology</i> , 2019, 14, 223-235.	1.7	8
1664	Importance of the immune system in head and neck cancer. <i>Head and Neck</i> , 2019, 41, 2789-2800.	0.9	28
1665	Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinomaâ€”A single institution analysis of 54 patients. <i>Clinical Otolaryngology</i> , 2019, 44, 639-643.	0.6	5
1666	Tumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 17.	1.3	19
1667	Emerging patient-specific treatment modalities in head and neck cancer â€” a systematic review. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 365-376.	1.9	3
1668	Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 351-363.	1.9	14
1669	How I treat squamous ENT cancer. <i>ESMO Open</i> , 2019, 4, e000542.	2.0	4
1670	High-Grade Salivary Gland Ductal Carcinoma With Unusual EGFR Amplification Responsive to Afatinib. <i>JCO Precision Oncology</i> , 2019, 3, 1-5.	1.5	1
1671	Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. <i>Molecular Pharmacology</i> , 2019, 96, 862-870.	1.0	10
1672	Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1909-1915.	1.9	21
1673	MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation. <i>Oncologist</i> , 2019, 24, 1305-1308.	1.9	3
1674	Rare entities in head-and-neck cancer: salvage re-irradiation with carbon ions. <i>Radiation Oncology</i> , 2019, 14, 202.	1.2	6
1675	Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma. <i>Cell Death and Disease</i> , 2019, 10, 867.	2.7	29

#	ARTICLE	IF	CITATIONS
1676	14 Carcinoma of the Hypopharynx. , 2019, , .		0
1677	Bypassing pro-survival and resistance mechanisms of autophagy in EGFR-positive lung cancer cells by targeted delivery of 5FU using theranostic Ag ₂ S quantum dots. Journal of Materials Chemistry B, 2019, 7, 7363-7376.	2.9	28
1678	Rechallenge en sels de platine aprÃs radiochimiothÃrapie pour les rÃcidives de carcinome ÃpidermoÃde des voies aÃrodigestives supÃrieures. Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale, 2019, 136, 255-260.	0.0	0
1679	SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Journal of Translational Medicine, 2019, 17, 429.	1.8	5
1680	Molecular genetics of head and neck squamous cell carcinoma. Current Opinion in Oncology, 2019, 31, 131-137.	1.1	30
1681	Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance. World Journal of Surgical Oncology, 2019, 17, 198.	0.8	31
1683	Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics. Stem Cells International, 2019, 2019, 1-15.	1.2	44
1684	Ten-year Clinical Trends among 575 Consecutive Oral Cancer Patients at Tokyo Dental College Oral Cancer Center. Bulletin of Tokyo Dental College, The, 2019, 60, 251-260.	0.1	1
1685	Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies. Pharmacology Research and Perspectives, 2019, 7, e00519.	1.1	2
1686	Treatment of syncope in tongue cancer with palliative chemotherapy in the intensive care unit. Medicine (United States), 2019, 98, e16998.	0.4	3
1687	Treatment of inoperable elderly head and neck cancer patients. Current Opinion in Oncology, 2019, 31, 152-159.	1.1	11
1688	Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck. Current Opinion in Oncology, 2019, 31, 146-151.	1.1	25
1689	Hyperthermia and immunotherapy: clinical opportunities. International Journal of Hyperthermia, 2019, 36, 4-9.	1.1	51
1690	C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma. Anti-Cancer Drugs, 2019, 30, 846-853.	0.7	17
1691	Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice. Current Opinion in Otolaryngology and Head and Neck Surgery, 2019, 27, 142-150.	0.8	24
1692	Real-world Treatment Outcomes of the EXTREME Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multi-center Retrospective Cohort Study in Japan. Anticancer Research, 2019, 39, 6819-6827.	0.5	21
1693	Maintenance Therapy in Metastatic Solid Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 615-623.	0.6	4
1694	A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma. Medicine (United States), 2019, 98, e17486.	0.4	3

#	ARTICLE	IF	CITATIONS
1696	33 Targeted Therapy for the Treatment of Advanced Squamous Cell Carcinoma of the Larynx. , 2019, , .		0
1697	Cancers of the Head and Neck. , 2019, , 103-114.		0
1698	Isolated gluteal metastasis 3 years after sufficiently treated oral squamous cell carcinoma: Case report and literature review. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2019, 127, e51-e55.	0.2	1
1699	Co-targeting EGFR and IKK β /NF- κ B signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer. British Journal of Cancer, 2019, 120, 306-316.	2.9	12
1700	JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer. Future Oncology, 2019, 15, 687-694.	1.1	41
1701	The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma. Medical Oncology, 2019, 36, 8.	1.2	16
1702	Survival and prognostic factors after pulmonary metastasectomy of head and neck cancer: what are the clinically informative prognostic indicators?. European Journal of Cardio-thoracic Surgery, 2019, 55, 942-947.	0.6	23
1703	Immunotherapy for Head and Neck Cancer. Oral and Maxillofacial Surgery Clinics of North America, 2019, 31, 85-100.	0.4	36
1704	Current Concepts in Chemotherapy for Head and Neck Cancer. Oral and Maxillofacial Surgery Clinics of North America, 2019, 31, 145-154.	0.4	34
1705	Efficacy of anti-PD-1 therapy in a patient with brain metastasis of parotid carcinoma: A case report. Auris Nasus Larynx, 2019, 46, 813-817.	0.5	4
1706	A descriptive epidemiological study on the treatment options for head and neck cancer: Transition before and after approval of cetuximab. Pharmacoepidemiology and Drug Safety, 2019, 28, 330-336.	0.9	4
1707	Electrochemotherapy " A locoregional therapy with well-established palliative effect in patient with large recurrent lesion of head and neck. Journal of Cranio-Maxillo-Facial Surgery, 2019, 47, 41-46.	0.7	11
1708	Prognostic factors and selection criteria in the retreatment of head and neck cancers. Oral Oncology, 2019, 88, 85-90.	0.8	7
1709	Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma. BMC Cancer, 2019, 19, 68.	1.1	44
1710	Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. Head and Neck, 2019, 41, 1895-1902.	0.9	10
1711	Benefit of cetuximab addition to a platinum-fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers. European Archives of Oto-Rhino-Laryngology, 2019, 276, 541-550.	0.8	2
1712	CheckMate 141 trial: all that glitters is not gold. Expert Opinion on Biological Therapy, 2019, 19, 169-171.	1.4	11
1713	Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial. Head and Neck, 2019, 41, 1703-1712.	0.9	13

#	ARTICLE	IF	CITATIONS
1714	26 Systemic Therapies in the Management of Head and Neck Cancer. , 2019, , .		0
1715	An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes. <i>Journal of Investigative Dermatology</i> , 2019, 139, 213-223.	0.3	19
1716	Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. <i>Clinical Cancer Research</i> , 2019, 25, 487-495.	3.2	11
1717	Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 903-917.	0.5	5
1718	Gene Therapy in Head and Neck Cancer. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2019, 31, 117-124.	0.4	18
1719	Immunotherapeutic Approaches in Cancer. , 2019, , 19-44.		4
1720	Outcomes after up-front surgery and metronomic neoadjuvant chemotherapy with S-1 or UFT for early tongue squamous cell carcinoma. <i>Clinical Oral Investigations</i> , 2019, 23, 2593-2598.	1.4	5
1721	The value of immunotherapy in head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 35-43.	1.4	14
1722	Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2019, 15, 739-751.	1.1	14
1723	Second infield re-irradiation with a resulting cumulative equivalent dose (EQD2 max) of >180 Gy for patients with recurrent head and neck cancer. <i>Head and Neck</i> , 2019, 41, E48-E54.	0.9	4
1724	Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 163-170.	2.0	26
1725	Cancer Immunotherapy: The Dawn of Antibody Cocktails. <i>Methods in Molecular Biology</i> , 2019, 1904, 11-51.	0.4	25
1726	Genomic Applications in Head and Neck Cancers. , 2019, , 309-324.		0
1727	A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1486-1493.	3.2	174
1728	Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer. <i>Tumori</i> , 2019, 105, 151-154.	0.6	0
1729	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 393, 156-167.	6.3	1,153
1730	Glucocorticoids reduce chemotherapeutic effectiveness on OSCC cells via glucose-dependent mechanisms. <i>Journal of Cellular Physiology</i> , 2019, 234, 2013-2020.	2.0	16
1731	Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 747-759.	3.2	35

#	ARTICLE	IF	CITATIONS
1732	Ras and Rap1: A tale of two GTPases. <i>Seminars in Cancer Biology</i> , 2019, 54, 29-39.	4.3	121
1733	Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2020, 47, 116-122.	0.5	33
1734	Therapeutic Antibodies and Immunologic Conjugates. , 2020, , 486-499.e8.		2
1735	Long-term disease control in a metastatic squamous cell carcinoma of the oral cavity treated with maintenance metronomic capecitabine. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 240-243.	0.5	3
1736	Translational genomics and recent advances in oral squamous cell carcinoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 71-83.	4.3	150
1737	Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 261-268.	0.8	11
1738	Unexpected Response to Nivolumab in a "Fast Progressor" Head and Neck Cancer Patient. <i>Case Reports in Oncology</i> , 2020, 12, 709-714.	0.3	3
1739	Current Immunotherapeutic Strategies in Cancer. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	4
1740	Current Development of Monoclonal Antibodies in Cancer Therapy. <i>Recent Results in Cancer Research</i> , 2020, 214, 1-70.	1.8	16
1741	Selection of systemic therapy in patients with locally advanced and recurrent/metastatic head and neck cancer: RAND-based expert opinion by an Italian multidisciplinary panel. <i>Tumori</i> , 2020, 106, 177-189.	0.6	1
1742	Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting. <i>Oral Oncology</i> , 2020, 102, 104440.	0.8	6
1743	Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. <i>Annals of Palliative Medicine</i> , 2020, 9, 4430-4445.	0.5	0
1744	Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 163-170.	0.9	7
1746	Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase II randomized phase II study Commence. <i>Head and Neck</i> , 2020, 42, 828-838.	0.9	12
1747	Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients. <i>Head and Neck</i> , 2020, 42, 625-635.	0.9	2
1748	Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Indian tertiary care retrospective analysis. <i>Head and Neck</i> , 2020, 42, 955-962.	0.9	3
1749	Molecular biology of oral cavity squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 102, 104552.	0.8	20
1750	Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 17-29.	1.1	17

#	ARTICLE	IF	CITATIONS
1751	Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. PLoS ONE, 2020, 15, e0227261.	1.1	6
1752	Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer". Radiation Oncology, 2020, 15, 7.	1.2	28
1753	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. Seminars in Cancer Biology, 2020, 65, 51-64.	4.3	63
1754	Head and Neck Cancer. New England Journal of Medicine, 2020, 382, 60-72.	13.9	1,197
1755	Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology, 2020, 101, 104523.	0.8	38
1756	Cancer of the Head and Neck. , 2020, , 999-1033.e7.		3
1757	Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity, 2020, 52, 183-199.e9.	6.6	383
1758	Improved survival among patients enrolled in oncology phase 1 trials in recent decades. Cancer Chemotherapy and Pharmacology, 2020, 85, 449-459.	1.1	1
1759	Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. Oral Oncology, 2020, 101, 104492.	0.8	44
1760	MUC1 as a target for CAR-T therapy in head and neck squamous cell carcinoma. Cancer Medicine, 2020, 9, 640-652.	1.3	51
1761	The Evolving Role of Radiotherapy for Head and Neck Cancer. Hematology/Oncology Clinics of North America, 2020, 34, 91-108.	0.9	13
1762	Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer. BMC Cancer, 2020, 20, 933.	1.1	11
1763	Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Auris Nasus Larynx, 2020, 47, 676-686.	0.5	11
1764	DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Auris Nasus Larynx, 2020, , .	0.5	1
1765	Analysis of chemotherapy effect on the second primary malignancy for head and neck cancer patients by a nomogram based on SEER database. Cancer Medicine, 2020, 9, 8029-8042.	1.3	11
1766	Combination therapy and outcomes in head and neck cancer. , 2020, , 143-163.		0
1767	Nimotuzumab plus platinum-based chemotherapy <i>versus</i> platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095373.	1.4	6
1768	FOLFIRINOX De-escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. Oncologist, 2020, 25, e1701-e1710.	1.9	10

#	ARTICLE	IF	CITATIONS
1769	Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7621.	1.8	12
1770	Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis. <i>Clinical Drug Investigation</i> , 2020, 40, 1137-1146.	1.1	10
1771	Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHS&E"ESMO&E"ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1462-1475.	0.6	359
1772	Pairing a prognostic target with potential therapeutic strategy for head and neck cancer. <i>Oral Oncology</i> , 2020, 111, 105035.	0.8	6
1773	Further clinical interpretation and implications of KEYNOTE-048 findings &E" Authors' reply. <i>Lancet</i> , The, 2020, 396, 379-380.	6.3	5
1774	Mitochondrial ROS1 Increases Mitochondrial Fission and Respiration in Oral Squamous Cancer Carcinoma. <i>Cancers</i> , 2020, 12, 2845.	1.7	9
1775	Squamous cell carcinoma of the buccal mucosa with multiple distant metastases. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2020, 32, 488-492.	0.2	1
1776	Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes. <i>Oral Oncology</i> , 2020, 111, 105024.	0.8	7
1777	Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. <i>Oral Oncology</i> , 2020, 109, 104977.	0.8	10
1778	Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell Cancer. <i>Clinical Oncology</i> , 2020, 32, 490-492.	0.6	5
1779	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , 2020, 26, 5153-5161.	3.2	58
1780	Complete and enduring response in an elderly patient with repeated recurrent gingival squamous cell carcinoma treated by combined toripalimab and single agent chemotherapy: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 6968-6973.	0.5	4
1781	Trials and tribulations: Clinical trials and the future. , 2020, , 197-215.		0
1782	Gold Nanoparticles Enhance EGFR Inhibition and Irradiation Effects in Head and Neck Squamous Carcinoma Cells. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	11
1783	Head and neck squamous cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2020, 6, 93.	18.1	1
1784	Head and neck squamous cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2020, 6, 92.	18.1	1,649
1785	Emerging immune checkpoint inhibitors for the treatment of head and neck cancers. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 501-514.	1.0	7
1786	Established treatment concepts for recurrent or metastatic head and neck squamous cell carcinoma (R/M&HNSC). <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 395-399.	0.3	1

#	ARTICLE	IF	CITATIONS
1787	Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 559596.	1.3	9
1788	Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2020, 11, 591139.	2.2	23
1789	Molecular targeted therapy: novel therapeutic approach for head and neck cancer. <i>Therapeutic Delivery</i> , 2020, 11, 637-651.	1.2	4
1790	Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer: Her1 and c-Met in Conjunction with the Clinical Features and Human Papillomavirus (p16) Status. <i>Cancers</i> , 2020, 12, 3358.	1.7	5
1791	Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial. <i>Radiation Oncology</i> , 2020, 15, 190.	1.2	10
1792	Radiation therapy on primary tumour of synchronous metastatic head and neck squamous cell carcinomas. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 559-566.	0.6	6
1793	Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. <i>BMC Cancer</i> , 2020, 20, 727.	1.1	17
1794	Long-term outcomes in patients with recurrent human papillomavirus-positive oropharyngeal cancer after upfront transoral robotic surgery. <i>Head and Neck</i> , 2020, 42, 3490-3496.	0.9	6
1795	Molecular margins in head and neck cancer: Current techniques and future directions. <i>Oral Oncology</i> , 2020, 110, 104893.	0.8	13
1796	Tricetin Suppresses Migration and Presenilin-1 Expression of Nasopharyngeal Carcinoma through Akt/GSK-3 β Pathway. <i>The American Journal of Chinese Medicine</i> , 2020, 48, 1203-1220.	1.5	8
1797	Salvage surgery with second free flap reconstruction for recurrent oral squamous cell carcinoma. <i>Heliyon</i> , 2020, 6, e04014.	1.4	3
1798	Tipifarnib as a Precision Therapy for KRAS-Mutant Head and Neck Squamous Cell Carcinomas. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1784-1796.	1.9	72
1799	NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 2390.	1.0	20
1800	Head and Neck Cancer Metastasis and the Effect of the Local Soluble Factors, from the Microenvironment, on Signalling Pathways: Is It All about the Akt?. <i>Cancers</i> , 2020, 12, 2093.	1.7	8
1801	TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection. <i>EBioMedicine</i> , 2020, 58, 102905.	2.7	27
1802	Role of programmed death-ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 3275-3281.	0.9	8
1803	Survival and Prognostic Analysis after Pulmonary Metastasectomy for Head and Neck Cancer. <i>Thoracic and Cardiovascular Surgeon</i> , 2021, 69, 666-671.	0.4	5
1804	Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies. <i>Cancers of the Head & Neck</i> , 2020, 5, 9.	6.2	25

#	ARTICLE	IF	CITATIONS
1805	Immunotherapy for squamous cell carcinoma of the head and neck. Japanese Journal of Clinical Oncology, 2020, 50, 1089-1096.	0.6	39
1806	Further clinical interpretation and implications of KEYNOTE-048 findings. Lancet, The, 2020, 396, 378.	6.3	0
1807	Cetuximab and paclitaxel combination therapy for recurrent basaloid squamous cell carcinoma in the ethmoid sinus. Auris Nasus Larynx, 2020, 48, 1189-1192.	0.5	2
1808	Genomic-based treatment of patients with head and neck cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 401-408.	0.4	0
1809	Management of cisplatin-associated toxicities in bladder cancer patients. Current Opinion in Supportive and Palliative Care, 2020, 14, 286-292.	0.5	9
1810	Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial). Cancers, 2020, 12, 3110.	1.7	11
1812	<p>Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect</p>. OncoTargets and Therapy, 2020, Volume 13, 10207-10220.	1.0	12
1813	Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. Frontiers in Oncology, 2020, 10, 571304.	1.3	10
1814	Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma. Anticancer Research, 2020, 40, 5277-5283.	0.5	24
1815	Baseline Computed Tomography Radiomic and Genomic Assessment of Head and Neck Squamous Cell Carcinoma. Journal of Computer Assisted Tomography, 2020, 44, 546-552.	0.5	4
1816	Resensitization to Nivolumab after Intratumoral Chemotherapy in Recurrent Head and Neck Squamous Cell Cancer: A Report of 2 Cases. Case Reports in Oncology, 2020, 13, 835-842.	0.3	1
1817	Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers, 2020, 12, 2691.	1.7	39
1818	Parameter control and property analysis in the preparation of platinum iodide nanocolloids through the electrical spark discharge method. RSC Advances, 2020, 10, 30169-30175.	1.7	5
1819	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibodyâ€Drug Conjugate. Molecular Cancer Therapeutics, 2020, 19, 2117-2125.	1.9	30
1820	Translating KEYNOTE-048 into practice recommendations for head and neck cancer. Annals of Translational Medicine, 2020, 8, 975-975.	0.7	25
1821	An update on the immune landscape in lung and head and neck cancers. Ca-A Cancer Journal for Clinicians, 2020, 70, 505-517.	157.7	93
1822	Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. In Vivo, 2020, 34, 2653-2657.	0.6	7
1823	Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance. Frontiers in Cell and Developmental Biology, 2020, 8, 732.	1.8	22

#	ARTICLE	IF	CITATIONS
1825	Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. <i>The Lancet Global Health</i> , 2020, 8, e1213-e1222.	2.9	57
1826	Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer. <i>Molecular Carcinogenesis</i> , 2020, 59, 1147-1158.	1.3	18
1828	Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2299.	1.7	26
1829	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in patients with human papillomavirus-associated malignancies. , 2020, 8, e001395.		79
1830	Comparative efficacy and safety of radiotherapy/cetuximab versus radiotherapy/chemotherapy for locally advanced head and neck squamous cell carcinoma patients: a systematic review of published, primarily non-randomized, data. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097535.	1.4	12
1831	Primary squamous cell carcinoma of major salivary gland: Sapienza Head and Neck Unit's clinical recommendations. <i>Rare Tumors</i> , 2020, 12, 203636132097352.	0.3	12
1832	Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 3743.	1.7	19
1833	The role of IgE specific for galactose-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis. <i>Scientific Reports</i> , 2020, 10, 21355.	1.6	10
1834	New first-line treatment for recurrent or metastatic squamous cell carcinoma of head and neck: does one size fit all?. <i>Therapeutic Radiology and Oncology</i> , 0, 4, 5-5.	0.2	1
1835	Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development. <i>Cancers</i> , 2020, 12, 3577.	1.7	4
1836	Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes. <i>Cancers</i> , 2020, 12, 2935.	1.7	4
1837	Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis. <i>Cancer Management and Research</i> , 2020, Volume 12, 11383-11390.	0.9	10
1838	Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8229.	1.8	7
1839	Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 3197.	1.7	16
1840	Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report. <i>Annals of Translational Medicine</i> , 2020, 8, 402-402.	0.7	8
1841	A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. <i>Cancer</i> , 2020, 126, 3237-3243.	2.0	12
1842	Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 16-19.	0.9	6
1843	Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC. <i>British Journal of Cancer</i> , 2020, 123, 288-297.	2.9	16

#	ARTICLE	IF	CITATIONS
1844	Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that <i>PTEN</i> Loss Contributes to Cetuximab Resistance in Head and Neck Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1562-1571.	1.9	17
1845	Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 777-789.	1.9	17
1848	Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy. <i>Future Oncology</i> , 2020, 16, 1359-1370.	1.1	4
1849	Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 927-934.	1.0	5
1850	Overlapping volumes in re-irradiation for head and neck cancer – an important factor for patient selection. <i>Radiation Oncology</i> , 2020, 15, 147.	1.2	9
1851	Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status. <i>British Journal of Cancer</i> , 2020, 123, 752-761.	2.9	25
1852	Phase I Study of Ficlatazumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 1537.	1.7	19
1853	Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 102984.	2.0	36
1854	Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma. <i>Facial Plastic Surgery</i> , 2020, 36, 186-193.	0.5	5
1855	The Evolution of Care of Cancers of the Head and Neck Region: State of the Science in 2020. <i>Cancers</i> , 2020, 12, 1543.	1.7	18
1856	Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck. <i>Frontiers in Oncology</i> , 2020, 10, 817.	1.3	24
1857	Stereotactic ablative radiotherapy (SABR) for recurrent and previously irradiated head and neck cancers. <i>BJR Open</i> , 2020, 2, 20190051.	0.4	4
1858	Icotinib: efficacy in different solid tumors and gene mutations. <i>Anti-Cancer Drugs</i> , 2020, 31, 205-210.	0.7	3
1859	Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immunotherapy. <i>Head and Neck</i> , 2020, 42, 2030-2038.	0.9	1
1860	The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC. <i>Cancers of the Head & Neck</i> , 2020, 5, 4.	6.2	30
1861	A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. <i>Investigational New Drugs</i> , 2020, 38, 1483-1494.	1.2	15
1862	Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. <i>Oncologist</i> , 2020, 25, 46-54.	1.9	7
1863	Oligometastatic head and neck cancer: Comprehensive review. <i>Head and Neck</i> , 2020, 42, 2194-2201.	0.9	30

#	ARTICLE	IF	CITATIONS
1864	Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. <i>Oral Oncology</i> , 2020, 104, 104641.	0.8	16
1865	A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma. <i>Nature Communications</i> , 2020, 11, 1556.	5.8	12
1866	Effect of HPV Status on Survival of Oropharynx Cancer with Distant Metastasis. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 372-374.	1.1	6
1867	Exploiting antibody biology for the treatment of cancer. <i>Immunotherapy</i> , 2020, 12, 255-267.	1.0	7
1868	CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 1273-1280.	0.8	25
1869	Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 268.	1.3	68
1870	Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. <i>Head and Neck</i> , 2020, 42, 1939-1953.	0.9	29
1872	Most Cited Articles in Head and Neck Oncology. <i>Ear, Nose and Throat Journal</i> , 2020, 100, 014556132093492.	0.4	2
1873	Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen. <i>Frontiers in Oncology</i> , 2020, 10, 1011.	1.3	9
1874	Dihydroartemisinin: from malaria to the treatment of relapsing head and neck cancers. <i>Annals of Translational Medicine</i> , 2020, 8, 612-612.	0.7	3
1875	Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell. <i>Medicine (United States)</i> , 2020, 99, e20944.	0.4	13
1876	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- β 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. , 2020, 8, e000664.		48
1877	Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 340-347.	0.7	9
1878	Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. <i>Radiotherapy and Oncology</i> , 2020, 150, 62-69.	0.3	3
1879	The 5-Whs of immunotherapy in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103041.	2.0	13
1880	Immunotherapy combinations for the treatment of patients with solid tumors. <i>Future Oncology</i> , 2020, 16, 1715-1736.	1.1	6
1881	HSP27 regulates viability and migration of cancer cell lines following irradiation. <i>Journal of Proteomics</i> , 2020, 226, 103886.	1.2	6
1882	TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 339.	1.7	39

#	ARTICLE	IF	CITATIONS
1883	A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma. <i>Investigational New Drugs</i> , 2020, 38, 1550-1558.	1.2	17
1884	Oncolytic effect of Midkine promoterâ€“based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891. <i>Cancer Reports</i> , 2020, 3, e1231.	0.6	4
1885	Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN). <i>Cancer Treatment Reviews</i> , 2020, 85, 101992.	3.4	17
1886	ErbB3, a possible prognostic factor of head and neck squamous cell carcinoma. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2020, 129, 377-387.	0.2	2
1887	A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>Cancer</i> , 2020, 126, 2146-2152.	2.0	24
1888	Mesenchymal stem cell transplantation attenuates growth of chemotherapy treated oral squamous cell carcinoma in an animal model. <i>Journal of Oral Pathology and Medicine</i> , 2020, 49, 655-664.	1.4	7
1889	Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis. <i>In Vivo</i> , 2020, 34, 479-488.	0.6	53
1891	Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2020, 47, 650-657.	0.5	16
1892	Active Porous Electrodes Prepared by Ultrasonicâ€“bath and their Application in Glucose/O ₂ Electrochemical Reactions. <i>Electroanalysis</i> , 2020, 32, 1084-1092.	1.5	4
1893	Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. <i>Journal of Medical Economics</i> , 2020, 23, 442-447.	1.0	16
1894	Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). <i>Annals of Oncology</i> , 2020, 31, 228-235.	0.6	60
1895	Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study. <i>Oral Oncology</i> , 2020, 102, 104526.	0.8	37
1896	Administration sequence for multi-agent oncolytic regimens. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 933-942.	0.5	1
1897	Prospective feasibility analysis of salvage surgery in recurrent oral cancer in terms of quality of life. <i>Oral Oncology</i> , 2020, 102, 104580.	0.8	19
1898	Anti-EGFR plus chemotherapy in unselected advanced oesophageal squamous cell carcinoma: less POWERful than expected. <i>Annals of Oncology</i> , 2020, 31, 161-162.	0.6	1
1899	LINC00312/YBX1 Axis Regulates Myofibroblast Activities in Oral Submucous Fibrosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2979.	1.8	14
1900	Grade 3 infusion-related reaction because of cetuximab administered with 5-fluorouracil and cisplatin chemotherapy for a recurrent and metastatic head and neck cancer patient who received chlorpheniramine 5â€“mg, dexamethasone 13.2â€“mg, and aprepitant 125â€“mg premedication. <i>European Journal of Oncology Pharmacy</i> , 2020, 3, e21.	0.5	1
1901	Effect of Small-molecule Tyrosine Kinase Inhibitors on PDGF-AA/BB and PDGFR β Expression in SCC According to HPV16 Status. <i>Anticancer Research</i> , 2020, 40, 825-835.	0.5	7

#	ARTICLE	IF	CITATIONS
1902	Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. <i>Annals of Oncology</i> , 2020, 31, 942-950.	0.6	240
1903	Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity. <i>Oral Oncology</i> , 2020, 105, 104673.	0.8	17
1904	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. <i>Vaccines</i> , 2020, 8, 191.	2.1	10
1905	Efficacy and safety of panitumumab alone or in association with radiotherapy in unresectable cutaneous squamous cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2789-2794.	1.3	9
1906	Is Chemotherapy with Carboplatin and 5-Fluorouracil Effective, Worthwhile Palliative Treatment in Recurrent/Metastatic Non-oral Cavity Head and Neck Carcinoma?. <i>Clinical Oncology</i> , 2020, 32, 546.	0.6	1
1907	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. <i>Experimental Hematology and Oncology</i> , 2020, 9, 7.	2.0	11
1908	Management Practices of Head and Neck Cancer in Chinese Tertiary Care Hospitals: A Multicenter Questionnaire-Based Survey Among Oncologists. <i>Cancer Control</i> , 2020, 27, 107327482090226.	0.7	1
1909	An update on angiogenesis targeting in head and neck squamous cell carcinoma. <i>Cancers of the Head & Neck</i> , 2020, 5, 5.	6.2	31
1910	Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102966.	2.0	45
1911	Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks. <i>Oral Oncology</i> , 2020, 105, 104684.	0.8	104
1912	Epidermal growth factor-induced COX-2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin-like 4. <i>Cancer Science</i> , 2020, 111, 2004-2015.	1.7	13
1913	The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer. <i>Radiation Oncology</i> , 2020, 15, 81.	1.2	21
1914	Metabolic Imaging Using Hyperpolarized Pyruvate-Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts. <i>Clinical Cancer Research</i> , 2020, 26, 1932-1943.	3.2	8
1915	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. <i>Clinical Cancer Research</i> , 2020, 26, 3211-3219.	3.2	64
1916	<p></p>Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3047-3059.	1.0	25
1917	Overcoming head and neck cancer stem cells. , 2020, , 135-158.		1
1918	Comprehensive immunogenomic landscape analysis of prognosis-related genes in head and neck cancer. <i>Scientific Reports</i> , 2020, 10, 6395.	1.6	25
1919	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 27-37.	3.0	17

#	ARTICLE	IF	CITATIONS
1920	<sc>Anti-CEACAM5 Autoantibody Is a Novel Prognostic Biomarker for Patients With Head and Neck Cancer. Laryngoscope, 2021, 131, E196-E202.	1.1	2
1921	Staging more important than grading? Evaluation of malignancy grading, depth of invasion, and resection margins in oral squamous cell carcinoma. Clinical Oral Investigations, 2021, 25, 1169-1182.	1.4	17
1922	Combinatorial approaches targeting the EGFR family and c-Met in SCCHN. Oral Oncology, 2021, 112, 105074.	0.8	12
1923	Predictors of early progression after curative resection followed by platinum-based adjuvant chemoradiotherapy in oral cavity squamous cell carcinoma. Postgraduate Medicine, 2021, 133, 377-384.	0.9	4
1924	PD-L1 expression in tongue squamous cell carcinoma. Medical Molecular Morphology, 2021, 54, 52-59.	0.4	6
1925	Panitumumab as an effective maintenance treatment in metastatic squamous cell carcinoma of the head and neck. Oral Oncology, 2021, 112, 104984.	0.8	1
1926	Modifying gap junction communication in cancer therapy. Current Research in Translational Medicine, 2021, 69, 103268.	1.2	4
1927	Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria. Cancer, 2021, 127, 219-228.	2.0	16
1929	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. British Journal of Cancer, 2021, 124, 721-727.	2.9	5
1930	Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. International Journal of Clinical Oncology, 2021, 26, 494-506.	1.0	40
1931	The head and neck cancer genome in the era of immunotherapy. Oral Oncology, 2021, 112, 105040.	0.8	13
1932	Defining the needs of patients with recurrent and/or metastatic head and neck cancer: An expert opinion. Critical Reviews in Oncology/Hematology, 2021, 157, 103200.	2.0	9
1933	Evolving multidisciplinary treatment of squamous cell carcinoma of the head and neck in India. Cancer Treatment and Research Communications, 2021, 26, 100269.	0.7	4
1934	Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. Cancer Reports, 2021, 4, e1322.	0.6	4
1935	Importance of dose in palliative treatment for incurable head and neck cancer with radiotherapy. Head and Neck, 2021, 43, 798-804.	0.9	6
1936	Prospective practice survey of management of cetuximab-related skin reactions. Supportive Care in Cancer, 2021, 29, 3497-3506.	1.0	1
1937	Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck. International Journal of Clinical Oncology, 2021, 26, 51-58.	1.0	0
1938	Reprint of "Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Oral Oncology, 2021, 113, 105042.	0.8	18

#	ARTICLE	IF	CITATIONS
1939	Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2). <i>International Journal of Clinical Oncology</i> , 2021, 26, 316-325.	1.0	7
1940	Oral cancer adjacent to dental implants mimicking benign lesions: a case series study. <i>Australian Dental Journal</i> , 2021, 66, 112-118.	0.6	2
1941	HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 26-31.	1.0	6
1943	NFAT5 promotes oral squamous cell carcinoma progression in a hyperosmotic environment. <i>Laboratory Investigation</i> , 2021, 101, 38-50.	1.7	16
1944	The roles of extracellular vesicles in the development, microenvironment, anticancer drug resistance, and therapy of head and neck squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 35.	3.5	30
1945	Systemic therapy for recurrent and/or metastatic head and neck cancer: a population-based healthcare research study in Thuringia, Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2625-2635.	1.2	0
1946	Salvage brachytherapy with or without external beam radiotherapy for oral or oropharyngeal squamous cell carcinomas in previously irradiated areas: carcinologic and toxicity outcomes of 25 patients. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 402-409.	0.4	1
1947	Surgical oncology of the head and neck district during COVID-19 pandemic. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 3107-3111.	0.8	6
1948	Mechanisms of Cetuximab Resistance and How to Overcome It. , 2021, , 21-51.		1
1949	Changes in Protein Glycosylation in Head and Neck Squamous Cell Carcinoma. <i>Journal of Cancer</i> , 2021, 12, 1455-1466.	1.2	22
1950	Regulation of Glycolysis in Head and Neck Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1280, 219-230.	0.8	3
1952	Radiotherapy, Chemotherapy, and Quality of Life. , 2021, , 329-342.		0
1953	Analysis of HRAS mutations in Japanese patients with oral squamous cell carcinoma. <i>Advances in Oral and Maxillofacial Surgery</i> , 2021, 1, 100021.	0.1	4
1954	A pre-operative prognostic score for the selection of patients for salvage surgery after recurrent head and neck squamous cell carcinomas. <i>Scientific Reports</i> , 2021, 11, 502.	1.6	9
1955	Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592094941.	1.4	35
1956	Emerging role of circulating tumor cells in immunotherapy. <i>Theranostics</i> , 2021, 11, 8057-8075.	4.6	19
1957	Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 338.	1.7	70
1958	Complications Related to Radical Neck Dissections and Management of Recurrent Neck Disease. , 2021, , 111-141.		0

#	ARTICLE	IF	CITATIONS
1960	Complex Interaction Among Immune, Inflammatory, and Carcinogenic Mechanisms in the Head and Neck Squamous Cell Carcinoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1335, 11-35.	0.8	11
1961	Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). <i>JCO Precision Oncology</i> , 2021, 5, 215-226.	1.5	22
1962	MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies. <i>Translational Cancer Research</i> , 2021, 10, 3090-3110.	0.4	15
1963	Update of Immune Therapies in Recurrent/Metastatic Head and Neck Cancer. , 2021, , 297-306.		0
1964	Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma. <i>Medicine (United States)</i> , 2021, 100, e24339.	0.4	7
1965	Effect of <i>Berberis vulgaris</i> L. root extract on ifosfamide-induced in vivo toxicity and in vitro cytotoxicity. <i>Scientific Reports</i> , 2021, 11, 1708.	1.6	16
1966	Prognostic analysis of 152 patients with distant metastasis after intensity-modulated radiotherapy for nasopharyngeal carcinoma. <i>Annals of Palliative Medicine</i> , 2021, 10, 0-0.	0.5	1
1967	Circulating Biomarkers in Head and Neck Cancer. , 2021, , 123-142.		0
1968	Oral metronomic therapy in head and neck cancer. <i>The Lancet Global Health</i> , 2021, 9, e20.	2.9	1
1969	Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 555-565.	1.1	3
1971	Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1307-1313.	1.2	24
1972	Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100375.	0.7	6
1973	A case of recurrent oral cancer treated with interchangeable administrations of immune checkpoint inhibitors and chemotherapy agents. <i>Journal of Japanese Society of Oral Oncology</i> , 2021, 33, 75-80.	0.0	1
1975	Efficacy of second and subsequent lines of chemotherapy for recurrent and metastatic head and neck cancer. <i>Auris Nasus Larynx</i> , 2021, 48, 161-165.	0.5	0
1976	Monoclonal Antibodies: A Prospective and Retrospective View. <i>Current Medicinal Chemistry</i> , 2021, 28, 435-471.	1.2	8
1977	Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2741-2750.	1.2	4
1978	Myocardial Metastasis of Tongue Cancer: A Rare Localization. <i>American Journal of Case Reports</i> , 2021, 22, e927459.	0.3	1
1979	Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient. <i>Auris Nasus Larynx</i> , 2022, 49, 721-726.	0.5	7

#	ARTICLE	IF	CITATIONS
1980	One Size Does Not Fit All: The Need for Population-Specific Palliative Care Interventions. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1449-1450.	3.0	1
1981	Elective neck dissection versus positron emission tomography- ¹⁸ F-fluorodeoxyglucose-guided management of the neck in clinically node-negative early oral cavity cancer: A cost-utility analysis. <i>Cancer</i> , 2021, 127, 1993-2002.	2.0	2
1983	Drug-induced interstitial lung disease in recurrent and/or metastatic head and neck cancer patients treated with cetuximab and/or nivolumab. <i>Oral Oncology</i> , 2021, 113, 105129.	0.8	6
1984	New Insights Into Oral Squamous Cell Carcinoma: From Clinical Aspects to Molecular Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2252.	1.8	44
1985	Surveillance and Monitoring Techniques for HPV-Related Head and Neck Squamous Cell Carcinoma: Circulating Tumor DNA. <i>Current Treatment Options in Oncology</i> , 2021, 22, 21.	1.3	6
1986	BÃ¡o cÃ¡o case lÃ¡m sÃ¡ng Äu trá» miá»...n dá»ch ung thÆ° biá»fu mÃ vá»y vÃng Äu cá»• giai Än di cÃfn. <i>Journal of Clinical Medicine- Hue Central Hospital</i> , 2021, , .	0.0	0
1987	Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab. <i>Scientific Reports</i> , 2021, 11, 2741.	1.6	16
1988	Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 614332.	1.3	33
1989	Clinical and histopathological risk factors for distant metastasis in head and neck cancer patients. <i>Acta Otorhinolaryngologica Italica</i> , 2021, 41, 6-17.	0.7	11
1990	Genetic alterations associated with 18F-fluorodeoxyglucose positron emission tomography/computed tomography in head and neck squamous cell carcinoma. <i>Translational Oncology</i> , 2021, 14, 100988.	1.7	4
1991	LncRNA FER1L4 Promotes Oral Squamous Cell Carcinoma Progression via Targeting miR-133a-5p/Prx1 Axis. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 795-806.	1.0	10
1992	SEOM clinical guidelines for the treatment of head and neck cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 913-921.	1.2	40
1993	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 361-379.e16.	7.7	189
1995	Modifications of Plasma Membrane Organization in Cancer Cells for Targeted Therapy. <i>Molecules</i> , 2021, 26, 1850.	1.7	19
1996	Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway. <i>BioMed Research International</i> , 2021, 2021, 1-6.	0.9	4
1997	Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck. <i>Cancers</i> , 2021, 13, 1251.	1.7	5
1998	Surgical outcomes of pulmonary metastasectomy for head and neck cancer in the current era of advances in chemotherapy and immunotherapy. <i>General Thoracic and Cardiovascular Surgery</i> , 2021, 69, 1214-1221.	0.4	3
1999	Cancro dell'ipofaringe. <i>EMC - Otorinolaringoiatria</i> , 2021, 20, 1-19.	0.0	0

#	ARTICLE	IF	CITATIONS
2000	The role of the tumor matrix environment in progression of head and neck cancer. <i>Current Opinion in Oncology</i> , 2021, 33, 168-174.	1.1	13
2001	At the Crossroads of Molecular Biology and Immunology: Molecular Pathways for Immunological Targeting of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oral Health</i> , 2021, 2, 647980.	1.2	4
2002	Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 361-367.	0.6	17
2003	Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers. <i>Investigational New Drugs</i> , 2021, 39, 1315-1323.	1.2	2
2004	Percutaneous Management of Recurrent Head and Neck Cancer: Current Role and Evolving Principles in the Multidisciplinary Setting. <i>Current Oncology Reports</i> , 2021, 23, 52.	1.8	3
2005	Oxidative Stress and the Intersection of Oncogenic Signaling and Metabolism in Squamous Cell Carcinomas. <i>Cells</i> , 2021, 10, 606.	1.8	3
2006	Risk factors for distant metastasis in locoregionally controlled oral squamous cell carcinoma: a retrospective study. <i>Scientific Reports</i> , 2021, 11, 5213.	1.6	16
2007	Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. <i>Cancers</i> , 2021, 13, 1413.	1.7	13
2009	Prolonged cetuximab treatment promotes p27Kip1-mediated G1 arrest and autophagy in head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 5259.	1.6	12
2010	Radioterapia dei cancro oto-rino-laringoiatrici. <i>EMC - Otorinolaringoiatria</i> , 2021, 20, 1-10.	0.0	0
2011	Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites?. <i>Radiation Oncology</i> , 2021, 16, 62.	1.2	13
2012	Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study. <i>Cancers</i> , 2021, 13, 1180.	1.7	29
2013	Comprehending the crosstalk between Notch, Wnt and Hedgehog signaling pathways in oral squamous cell carcinoma - clinical implications. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 473-494.	2.1	19
2014	Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes. <i>Current Opinion in Oncology</i> , 2021, 33, 160-167.	1.1	9
2015	Lymphoepithelial carcinoma of the larynx: An unusual response to EXTREME regimen therapy. A new option for treatment?. <i>Translational Medicine Reports</i> , 2021, 5, .	0.8	2
2016	Total Laryngectomyâ€”Still Cutting-Edge?. <i>Cancers</i> , 2021, 13, 1405.	1.7	13
2017	Molecular targets for the management of cancer using <i>Curcuma longa</i> Linn. phytoconstituents: A Review. <i>Biomedicine and Pharmacotherapy</i> , 2021, 135, 111078.	2.5	39
2018	Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188523.	3.3	25

#	ARTICLE	IF	CITATIONS
2019	Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study. <i>Clinical and Translational Oncology</i> , 2021, 23, 1666-1677.	1.2	6
2020	Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma. <i>Medicinal Research Reviews</i> , 2022, 42, 112-155.	5.0	24
2021	A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 157, 203-209.	0.3	12
2022	Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC). <i>Journal of Clinical Oncology</i> , 2022, 40, 463-475.	5.1	95
2023	Oral Tongue Cancer in a Patient with Fanconi Anemia: A Case Report and Literature Review. <i>Cancer Management and Research</i> , 2021, Volume 13, 3145-3154.	0.9	5
2024	Distinct Outcomes of Oropharyngeal Squamous Cell Carcinoma Patients after Distant Failure According to p16 Status: Implication in Therapeutic Options. <i>Current Oncology</i> , 2021, 28, 1673-1680.	0.9	6
2025	Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial. <i>Oral Oncology</i> , 2021, 115, 105173.	0.8	15
2026	Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma. <i>Oral Oncology</i> , 2021, 115, 105133.	0.8	1
2027	Modified TPEX as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer. <i>Anticancer Research</i> , 2021, 41, 2045-2051.	0.5	3
2028	Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. <i>Oral Oncology</i> , 2021, 115, 105192.	0.8	22
2029	Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. <i>Nature Communications</i> , 2021, 12, 2383.	5.8	39
2030	Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer. <i>South Asian Journal of Cancer</i> , 2021, 10, 72-75.	0.2	3
2031	The role of pulmonary metastasectomy for pulmonary metastasis from head and neck cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 2643-2648.	0.6	10
2032	Addition of Nimotuzumab to Standard TPF Regimen in Locally Advanced Head and Neck Cancer: A Single Institutional Study. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	3
2033	Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina. <i>Advances in Therapy</i> , 2021, 38, 2613-2630.	1.3	7
2034	Safety considerations with new treatment regimens for anal cancer. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 889-902.	1.0	2
2035	Proton re-irradiation of unresectable recurrent head and neck cancers. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 203-210.	0.3	11
2036	Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1188-1195.	1.0	4

#	ARTICLE	IF	CITATIONS
2037	Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1049-1056.	1.0	4
2038	Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 1714.	1.7	14
2039	Decreasing treatment burden in HPV-related OPSCC: A systematic review of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103243.	2.0	10
2040	Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1525.	1.0	16
2041	Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era. <i>Lancet Oncology</i> , The, 2021, 22, 413-415.	5.1	12
2042	Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4981.	1.8	33
2043	The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2021, 158, 13-20.	0.3	3
2044	The prognostic impact of daytime and seasonality of radiotherapy on head and neck cancer. <i>Radiotherapy and Oncology</i> , 2021, 158, 293-299.	0.3	4
2045	Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 2573.	1.7	12
2046	Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: A single-center cohort study. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 71-78.	0.9	6
2047	Development of Exhaustion and Acquisition of Regulatory Function by Infiltrating CD8+CD28 ^{hi} T Lymphocytes Dictate Clinical Outcome in Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 2234.	1.7	8
2048	EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas. <i>Pathology and Oncology Research</i> , 2021, 27, 620256.	0.9	1
2049	Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. <i>Cancers</i> , 2021, 13, 2371.	1.7	35
2050	Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient. <i>Frontiers in Immunology</i> , 2021, 12, 678028.	2.2	5
2051	Progress of molecular targeted therapy for head and neck cancer in clinical aspects. <i>Molecular Biomedicine</i> , 2021, 2, 15.	1.7	4
2052	Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. <i>Cancers</i> , 2021, 13, 2210.	1.7	6
2053	Survival Outcomes and Treatment Decision by Human Papillomavirus Status Among Patients With Stage IVC Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 668066.	1.3	7
2054	Platinum-induced nausea and vomiting in patients treated for head and neck cancer. <i>Bulletin Du Cancer</i> , 2021, 108, 449-454.	0.6	1

#	ARTICLE	IF	CITATIONS
2055	Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 640392.	1.3	31
2056	A Case of DILD Likely Induced by Molecular-Targeted Therapy Following Administration of an Immune Checkpoint Inhibitor Against Metastatic Lung Lesions from Tongue Cancer. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1809-1812.	0.3	1
2057	Designation Products: Boron Neutron Capture Therapy for Head and Neck Carcinoma. <i>Oncologist</i> , 2021, 26, e1250-e1255.	1.9	31
2058	Texture analysis of [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography for predicting the treatment response of postoperative recurrent or metastatic oral squamous cell carcinoma treated with cetuximab. <i>Annals of Nuclear Medicine</i> , 2021, 35, 871-880.	1.2	5
2059	Brain metastasis in head and neck squamous cell carcinoma after immune check point inhibitors treatment. <i>Oral Oncology</i> , 2021, 116, 105138.	0.8	1
2060	A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study. <i>Diagnostics</i> , 2021, 11, 979.	1.3	5
2061	<sc>lncRNA PVT1</sc> promotes cetuximab resistance of head and neck squamous cell carcinoma cells by inhibiting <sc>miR</sc>. <i>Head and Neck</i> , 2021, 43, 2712-2723.	0.9	11
2062	Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab. <i>Frontiers in Oncology</i> , 2021, 11, 635096.	1.3	3
2063	Molecular landscape of head and neck cancer and implications for therapy. <i>Annals of Translational Medicine</i> , 2021, 9, 915-915.	0.7	51
2064	Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. <i>Cancer Medicine</i> , 2021, 10, 3952-3963.	1.3	5
2065	Advances in pharmacotherapy for head and neck cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2007-2018.	0.9	5
2066	Tracking the dropout patients of neoadjuvant chemotherapy with locally advanced oral cavity cancer. <i>BMC Cancer</i> , 2021, 21, 663.	1.1	1
2067	Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. <i>Cancer Treatment Reviews</i> , 2021, 97, 102172.	3.4	27
2069	Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 699668.	1.3	10
2070	Observational, prospective, phase 4 study in patients with firstâ€line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinumâ€based therapy: <sc>DIRECT</sc>. <i>Cancer Reports</i> , 2022, 5, e1467.	0.6	4
2071	Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors. <i>Viruses</i> , 2021, 13, 1234.	1.5	10
2072	Bleeding complications in patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2021, 43, 2844-2858.	0.9	12
2073	Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3038.	1.7	7

#	ARTICLE	IF	CITATIONS
2074	Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review. <i>Cancers</i> , 2021, 13, 3126.	1.7	12
2075	Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1822-1830.	1.0	5
2076	Metronomic Therapy in Oral Squamous Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 2818.	1.0	5
2077	Is This the Dawn of Precision Oncology in Head and Neck Cancer?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1839-1841.	0.8	1
2078	Genomic Landscape of Head and Neck Squamous Cell Carcinoma Across Different Anatomic Sites in Chinese Population. <i>Frontiers in Genetics</i> , 2021, 12, 680699.	1.1	13
2079	Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2021, 12, 1214-1229.	0.8	37
2080	Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review. <i>Advances in Therapy</i> , 2021, 38, 3674-3693.	1.3	12
2081	Long Intergenic Non-Coding RNAs in HNSCC: From "Junk DNA" to Important Prognostic Factor. <i>Cancers</i> , 2021, 13, 2949.	1.7	17
2082	A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1812-1821.	1.0	43
2083	Modified bi-weekly cetuximab-cisplatin and 5-FU /leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients. <i>Cancer Reports</i> , 2021, , e1479.	0.6	5
2084	Inmunoterapia en oncología de las vías aerodigestivas superiores. <i>EMC - Otorrinolaringología</i> , 2021, 50, 1-20.	0.0	0
2085	A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 3413.	1.7	6
2086	Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress. <i>Cancers</i> , 2021, 13, 3822.	1.7	3
2087	Tumour infiltrating lymphocytes in oropharyngeal carcinoma: prognostic value and evaluation of a standardised method. <i>Pathology</i> , 2021, 53, 836-843.	0.3	7
2088	Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Cancers</i> , 2021, 13, 3545.	1.7	9
2089	Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 805-812.	1.1	0
2090	Real-World Treatment Patterns and Outcomes in Patients with Head and Neck Cancer: Point-in-Time Survey of Oncologists in Italy and Spain. <i>Advances in Therapy</i> , 2021, 38, 4722-4735.	1.3	3
2091	Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. <i>Journal of Translational Medicine</i> , 2021, 19, 303.	1.8	1

#	ARTICLE	IF	CITATIONS
2092	CDH11 Regulates Adhesion and Transcellular Migration of Tongue Squamous Cell Carcinoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4211-4222.	1.0	4
2093	Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2021, 13, 3781.	1.7	10
2094	Possible Therapeutic Strategy Involving the Purine Synthesis Pathway Regulated by ITK in Tongue Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3333.	1.7	4
2095	Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study. <i>Head and Neck</i> , 2021, 43, 3331-3344.	0.9	15
2096	Current status of systemic therapy in head and neck cancer. <i>Journal of Chemotherapy</i> , 2021, , 1-16.	0.7	1
2097	Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma. <i>Journal of Genetics and Genomics</i> , 2021, 48, 582-594.	1.7	12
2098	Choosing the Right Treatment Option for the Right R/M HNSCC Patient: Should We Adhere to PFE for First-Line Therapy?. <i>Frontiers in Oncology</i> , 2021, 11, 715297.	1.3	0
2099	Epidemiological Trends of Head and Neck Cancer: A Population-Based Study. <i>BioMed Research International</i> , 2021, 2021, 1-14.	0.9	23
2100	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 651.	1.1	28
2101	Cisplatin Plus Cetuximab Inhibits Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Migration and Proliferation but Does Not Enhance Apoptosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8167.	1.8	9
2102	Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. <i>Annals of Translational Medicine</i> , 2021, 9, 1189-1189.	0.7	8
2103	Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. <i>Cancer Research and Treatment</i> , 2021, 53, 671-677.	1.3	14
2104	PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 1966-1978.	2.9	17
2105	Outcome of patients with recurrent/metastatic squamous cell head and neck cancer treated with platinum-based chemotherapy with or without cetuximab in real-world practice. <i>Molecular and Clinical Oncology</i> , 2021, 15, 190.	0.4	0
2106	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. <i>Kidney International</i> , 2021, 100, 196-205.	2.6	95
2107	Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 712944.	1.3	7
2108	Cigarette Smoke Containing Acrolein Upregulates EGFR Signaling Contributing to Oral Tumorigenesis In Vitro and In Vivo. <i>Cancers</i> , 2021, 13, 3544.	1.7	10
2109	The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 649963.	1.3	4

#	ARTICLE	IF	CITATIONS
2110	Risk factors and survival outcomes of laryngeal squamous cell carcinoma patients with lung metastasis: A population-based study. <i>Auris Nasus Larynx</i> , 2021, 48, 723-730.	0.5	1
2111	Epidermal Growth Factor Receptor-Targeted Therapy for Head and Neck Cancer. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 743-749.	0.5	7
2112	Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab ϵ) ₂ in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab ϵ) ₂ ϵ implications for a PET theranostic strategy. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 25.	1.8	5
2113	Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103424.	2.0	19
2115	Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery. <i>ESMO Open</i> , 2021, 6, 100178.	2.0	15
2116	Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival. <i>Oral Oncology</i> , 2021, 119, 105380.	0.8	8
2117	A Transcriptomic Analysis of Head and Neck Squamous Cell Carcinomas for Prognostic Indications. <i>Journal of Personalized Medicine</i> , 2021, 11, 782.	1.1	5
2119	Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice. <i>Cancer Management and Research</i> , 2021, Volume 13, 6689-6703.	0.9	6
2120	Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors. <i>Biomedicines</i> , 2021, 9, 1045.	1.4	4
2121	Anti ϵ PD-1 and Anti ϵ PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 705096.	2.2	47
2122	Immunotherapeutic Strategies for Head and Neck Cancer. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 729-742.	0.5	3
2123	Long-term survivor of metastatic squamous-cell head and neck carcinoma with occult primary after cetuximab-based chemotherapy: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 7092-7098.	0.3	3
2124	Durable complete response to immunotherapy with anti ϵ PD ϵ 1 antibody nivolumab in a patient with oral squamous cell carcinoma presenting with lung metastasis: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04545.	0.2	5
2125	Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer. <i>Oral Oncology</i> , 2021, 119, 105369.	0.8	5
2126	Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 221.	0.4	2
2127	The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 719650.	2.2	3
2128	Utilizing feline oral squamous cell carcinoma patients to develop NQO1-targeted therapy. <i>Neoplasia</i> , 2021, 23, 811-822.	2.3	3
2129	Tumor microenvironment is not an ϵ innocent bystander ϵ TM in the resistance to treatment of head and neck cancers (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1128.	0.8	5

#	ARTICLE	IF	CITATIONS
2130	The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy. <i>Frontiers in Oncology</i> , 2021, 11, 697967.	1.3	11
2131	Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 727433.	1.3	57
2132	Weekly vs. weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer. <i>Molecular and Clinical Oncology</i> , 2021, 15, 240.	0.4	0
2133	Recurrence Patterns After IMRT/VMAT in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 720052.	1.3	6
2134	éééf“ç™Œã~3/4ã™ã,ã...ç—«ãfã,Sãffã,ãfã,ãfãf~é»ã®3è—→. <i>Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaiho</i> , 2021, 124, 1251-1255.		
2135	FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1. <i>Oral Diseases</i> , 2021, , .	1.5	5
2136	The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 737311.	2.2	28
2137	Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113854.	6.6	12
2139	Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells. <i>Scientific Reports</i> , 2021, 11, 19051.	1.6	18
2140	The potential role of imaging techniques in avoiding neck dissection during salvage surgery after head and neck carcinoma treated with bioradiotherapy. <i>Journal of Laryngology and Otolaryngology</i> , 2021, 135, 970-975.	0.4	1
2141	A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 7012-7020.	1.3	8
2143	Prognostic factors for bone metastases from head and neck squamous cell carcinoma: A case series of 97 patients. <i>Molecular and Clinical Oncology</i> , 2021, 15, 246.	0.4	6
2144	Revisiting <sc>EXTREME</sc> in the <sc>Immuno-Oncology</sc> Era: How to Improve Its Outcomes. <i>Oncologist</i> , 2021, 26, 899-901.	1.9	4
2145	Outcomes of salvage treatment in patients with recurrent oral squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 3764-3774.	0.9	3
2146	Nitrate increases cisplatin chemosensitivity of oral squamous cell carcinoma via REDD1/AKT signaling pathway. <i>Science China Life Sciences</i> , 2021, 64, 1814-1828.	2.3	6
2147	Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2021, 11, 705614.	1.3	19
2148	Head and neck cancer. <i>Lancet</i> , The, 2021, 398, 2289-2299.	6.3	280
2149	Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial. <i>Medical Oncology</i> , 2021, 38, 128.	1.2	11

#	ARTICLE	IF	CITATIONS
2150	Cancer of the Larynx and Hypopharynx. Hematology/Oncology Clinics of North America, 2021, 35, 933-947.	0.9	7
2151	A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study. ESMO Open, 2021, 6, 100242.	2.0	5
2152	First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial. European Journal of Cancer, 2021, 156, 35-45.	1.3	16
2153	Managing Recurrent Metastatic Head and Neck Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 1009-1020.	0.9	10
2154	Immunotherapy for Head and Neck Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 1021-1037.	0.9	8
2155	Efficacy and safety of systemic treatments for patients with recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and network meta-analysis. Pharmacological Research, 2021, 173, 105866.	3.1	10
2156	Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck. European Journal of Cancer, 2021, 157, 190-197.	1.3	6
2157	miR-30a attenuates drug sensitivity to 5-FU by modulating cell proliferation possibly by downregulating cyclin E2 in oral squamous cell carcinoma. Biochemistry and Biophysics Reports, 2021, 28, 101114.	0.7	2
2158	Effectiveness of cetuximab as preemptive postsurgical therapy for oral squamous cell carcinoma patients with major risk: a single-center retrospective cohort study. Investigational New Drugs, 2021, 39, 846-852.	1.2	8
2159	Oral metronomic therapy in head and neck cancer. The Lancet Global Health, 2021, 9, e19.	2.9	1
2160	Is there a Role for Adjuvant Targeted and Immunotherapies in Patients with Locoregionally-Advanced Head and Neck Cancer?. , 2021, , 205-219.		1
2161	Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer. , 2021, , 155-179.		1
2162	Carboplatin in combination with 3-weekly paclitaxel as first-line therapy in patients with recurrent/metastatic head-and-neck cancers: A regional cancer center experience. Oncology Journal of India, 2021, 5, 71.	0.1	0
2163	Tumors: Oto-Rhino-Laryngology. , 2021, , 1-12.		0
2164	Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Practica Otologica, 2021, 114, 405-411.	0.0	0
2165	Immune checkpoint inhibitors for recurrent or metastatic head and neck cancer :. Japanese Journal of Head and Neck Cancer, 2021, 47, 10-14.	0.0	0
2166	Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response. Journal of Translational Medicine, 2021, 19, 43.	1.8	17
2167	New and Promising Targeted Therapies in First and Second-Line Settings. , 2021, , 277-296.		0

#	ARTICLE	IF	CITATIONS
2168	Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma. <i>In Vivo</i> , 2021, 35, 1253-1259.	0.6	5
2169	Screening the key genes of prognostic value in the microenvironment for head and neck squamous cell carcinoma. <i>Medicine (United States)</i> , 2021, 100, e24184.	0.4	5
2170	Engineering nanomedicine for glutathione depletion-augmented cancer therapy. <i>Chemical Society Reviews</i> , 2021, 50, 6013-6041.	18.7	342
2171	Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 598-613.	2.3	77
2172	Multidisciplinary Management of Oral Cavity and Maxillary Sinus Cancers. , 2011, , 363-380.		2
2173	Multidisciplinary Management of Hypopharyngeal Carcinoma. , 2011, , 431-455.		2
2174	Cervical Lymph Node Metastases of Squamous Cell Carcinoma from an Unknown Primary Site. , 2011, , 547-553.		1
2175	Treatment of the Elderly Head and Neck Cancer Patient. , 2011, , 581-588.		1
2176	Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. , 2011, , 651-664.		4
2177	Overview: The Pathobiology of Head and Neck Cancer. , 2014, , 1-5.		3
2178	DNA Damage Proteins and Response to Therapy in Head and Neck Cancer. , 2014, , 259-282.		1
2179	Molecular Features and Treatment Modalities of "Classic" Versus Human Papilloma Virus-Associated Head and Neck Cancer. , 2014, , 7-21.		2
2180	Targeting Receptor Tyrosine Kinases in Cancer. , 2015, , 225-278.		11
2181	Treatment Strategies in Head and Neck Cancers. , 2020, , 273-294.		1
2183	Biomarkers for Individualized Oral Cancer Therapy. , 2015, , 43-60.		1
2184	Chemotherapy in Head and Neck Squamous Cell Cancer. , 2016, , 53-68.		2
2185	The Value of Anti-angiogenics in Head and Neck Cancer Therapy. , 2019, , 477-494.		1
2186	Molecular Imaging in Head and Neck Squamous Cell Carcinoma Patients. , 2017, , 77-96.		1

#	ARTICLE	IF	CITATIONS
2187	Stratifying Cancer Therapies by Molecular Interactions and Imaging. , 2017, , 315-358.		1
2188	Molecular Signaling Pathways in Nasopharyngeal Cancer. Medical Radiology, 2010, , 27-40.	0.0	2
2189	Drugs to Treat Head and Neck Cancers: Mechanisms of Action. , 2013, , 861-913.		1
2190	Antibody Therapies in Cancer. Advances in Experimental Medicine and Biology, 2016, 909, 1-67.	0.8	8
2191	The role of molecularly targeted therapies and immunotherapy in head and neck cancer. , 2020, , 33-47.		1
2192	Nonsurgical Treatment of Head and Neck Cancer. , 2011, , 2893-2914.		3
2193	Biologics and Their Interactions with Radiation. , 2012, , 83-94.		1
2194	Malignome des Kopf- und Halsbereichs. , 2020, , 609-633.		1
2195	Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective. Oral Oncology, 2020, 107, 104754.	0.8	7
2196	Reirradiation using stereotactic body radiotherapy in the management of recurrent or second primary head and neck cancer: A meta-analysis and systematic review. Oral Oncology, 2020, 107, 104757.	0.8	17
2197	Mild pulmonary emphysema a risk factor for interstitial lung disease when using cetuximab for squamous cell carcinoma of the head and neck. Acta Oto-Laryngologica, 2017, 137, 1288-1291.	0.3	6
2198	Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study. Anti-Cancer Drugs, 2021, 32, 95-101.	0.7	16
2199	Clinicopathologic Significance of EGFR Mutation and HPV Infection in Sinonasal Squamous Cell Carcinoma. American Journal of Surgical Pathology, 2021, 45, 108-118.	2.1	27
2201	MicroRNA-361 is a potent therapeutic target for oral squamous cell carcinoma. Cancer Science, 2020, 111, 1645-1651.	1.7	17
2202	Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers. Cancer Science, 2020, 111, 1943-1957.	1.7	24
2203	Squamous cell carcinoma of external auditory canal lacking epidermal growth factor receptor protein overexpression, in an elderly Omani with oculocutaneous albinism treated with palliative radiotherapy. BMJ Case Reports, 2014, 2014, bcr2013203226-bcr2013203226.	0.2	2
2204	Landscape of natural killer cell activity in head and neck squamous cell carcinoma. , 2020, 8, e001523.		36
2205	AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 4349-4359.	3.2	26

#	ARTICLE	IF	CITATIONS
2206	Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 632-644.	3.2	49
2207	Epidemiology and Molecular Biology of Head and Neck Cancer. <i>Oncology Research and Treatment</i> , 2017, 40, 328-332.	0.8	112
2208	Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	44
2209	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. <i>JCI Insight</i> , 2017, 2, e90449.	2.3	45
2210	Molecular Pathways in Head and Neck Cancer: EGFR, PI3K, and More. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 246-255.	1.8	48
2211	Management of Immune-Related Dermatitis and Mucositis Associated With Pembrolizumab in Metastatic Human Papillomavirus-Associated Squamous Cell Carcinoma of the Oropharynx. <i>JCO Oncology Practice</i> , 2020, 16, 20s-24s.	1.4	8
2212	Advances in the management of squamous cell carcinoma of the head and neck. <i>F1000prime Reports</i> , 2014, 6, 44.	5.9	77
2213	1, 9-Pyrazoloanthrones Downregulate HIF-1 α and Sensitize Cancer Cells to Cetuximab-Mediated Anti-EGFR Therapy. <i>PLoS ONE</i> , 2010, 5, e15823.	1.1	16
2214	Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer. <i>PLoS ONE</i> , 2012, 7, e38557.	1.1	32
2215	Infectious Complications in Head and Neck Cancer Patients Treated with Cetuximab: Propensity Score and Instrumental Variable Analysis. <i>PLoS ONE</i> , 2012, 7, e50163.	1.1	15
2216	Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia. <i>PLoS ONE</i> , 2013, 8, e69368.	1.1	18
2217	Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0143132.	1.1	13
2218	Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0146551.	1.1	11
2219	Selective Killing Effects of Cold Atmospheric Pressure Plasma with NO Induced Dysfunction of Epidermal Growth Factor Receptor in Oral Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0150279.	1.1	43
2220	Metastatic disease in head & neck oncology. <i>Acta Otorhinolaryngologica Italica</i> , 2020, 40, S1-S86.	0.7	83
2221	Influence of the results of international studies on the choice of treatment tactics for unresectable forms of squamous cell carcinoma of the head and neck. <i>Opuholi Golovy I Sei</i> , 2020, 10, 10-21.	0.1	4
2222	Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies. <i>Medical Research Archives</i> , 2015, 3, .	0.1	15
2223	Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas. <i>Oncotarget</i> , 2016, 7, 47418-47430.	0.8	13

#	ARTICLE	IF	CITATIONS
2224	Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 74362-74379.	0.8	149
2225	Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. <i>Oncotarget</i> , 2017, 8, 11020-11029.	0.8	9
2226	Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03. <i>Oncotarget</i> , 2017, 8, 51830-51839.	0.8	2
2227	Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. <i>Oncotarget</i> , 2014, 5, 298-308.	0.8	44
2228	Molecular dissection of effector mechanisms of <i>RAS</i> -mediated resistance to anti-EGFR antibody therapy. <i>Oncotarget</i> , 2017, 8, 45898-45917.	0.8	12
2229	Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation. <i>Oncotarget</i> , 2017, 8, 61786-61799.	0.8	16
2230	Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model. <i>Oncotarget</i> , 2017, 8, 92090-92105.	0.8	20
2231	The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism. <i>Oncotarget</i> , 2014, 5, 5428-5438.	0.8	17
2232	Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review. <i>Oncotarget</i> , 2017, 8, 113120-113128.	0.8	19
2233	Protein methyltransferases and demethylases dictate CD8+ T-cell exclusion in squamous cell carcinoma of the head and neck. <i>Oncotarget</i> , 2017, 8, 112797-112808.	0.8	9
2234	Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 22480-22497.	0.8	32
2235	Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule. <i>Oncotarget</i> , 2018, 9, 22038-22046.	0.8	14
2236	FGFR signaling regulates resistance of head and neck cancer stem cells to cisplatin. <i>Oncotarget</i> , 2018, 9, 25148-25165.	0.8	39
2237	² -deoxy- ² -[¹⁸ F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck. <i>Oncotarget</i> , 2018, 9, 28572-28585.	0.8	6
2238	The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. <i>Oncotarget</i> , 2014, 5, 11133-11142.	0.8	102
2239	EGFR overexpression is not common in patients with head and neck cancer. Cell lines are not representative for the clinical situation in this indication. <i>Oncotarget</i> , 2018, 9, 28965-28975.	0.8	18
2240	Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer. <i>Oncotarget</i> , 2018, 9, 37581-37588.	0.8	3
2241	Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer. <i>Oncotarget</i> , 2020, 11, 3688-3697.	0.8	13

#	ARTICLE	IF	CITATIONS
2242	Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation. <i>Oncotarget</i> , 2015, 6, 1723-1739.	0.8	26
2243	Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck. <i>Oncotarget</i> , 2011, 2, 599-609.	0.8	69
2244	Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 6029-6039.	0.8	29
2245	PTX3 gene activation in EGF-induced head and neck cancer cell metastasis. <i>Oncotarget</i> , 2015, 6, 7741-7757.	0.8	62
2246	Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer. <i>Oncotarget</i> , 2015, 6, 12481-12492.	0.8	10
2247	Interleukin-1 beta transactivates epidermal growth factor receptor via the CXCL1-CXCR2 axis in oral cancer. <i>Oncotarget</i> , 2015, 6, 38866-38880.	0.8	43
2248	Therapeutic potential of targeting cell division cycle associated 5 for oral squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 2343-2353.	0.8	42
2249	Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 11651-11663.	0.8	14
2250	Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 13167-13181.	0.8	14
2251	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. <i>Oncotarget</i> , 2016, 7, 25050-25063.	0.8	6
2252	Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. <i>Oncotarget</i> , 2016, 7, 33391-33407.	0.8	17
2253	Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 42988-42995.	0.8	64
2254	Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 18726-18734.	0.8	6
2255	Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses. , 2018, 1, 118-125.		13
2256	Immunotherapy for head and neck cancer: where are we now and where are we going?. <i>Annals of Translational Medicine</i> , 2019, 7, S75-S75.	0.7	35
2257	Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, 651-651.	0.7	18
2258	Immunotherapy in Head and Neck Squamous Cell Cancer. <i>Clinical and Experimental Otorhinolaryngology</i> , 2018, 11, 217-223.	1.1	18
2259	Oropharyngeal cancer: an emergent disease?. <i>Salud Publica De Mexico</i> , 2016, 58, 285-290.	0.1	6

#	ARTICLE	IF	CITATIONS
2260	Molecular characterization of head and neck cancer: how close to personalized targeted therapy?. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 209-22.	1.6	14
2261	Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review. <i>Current Genomics</i> , 2016, 18, 60-74.	0.7	7
2262	Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 290-303.	0.9	14
2263	Radiotherapy-associated Furin Expression and Tumor Invasiveness in Recurrent Laryngeal Cancer. <i>Anticancer Research</i> , 2016, 36, 5117-5126.	0.5	14
2264	Cilengitide and Cetuximab Reduce Cytokine Production and Colony Formation of Head and Neck Squamous Cell Carcinoma Cells Ex Vivo. <i>Anticancer Research</i> , 2017, 37, 521-528.	0.5	11
2265	Hypofractionated Palliative Radiotherapy with Concurrent Radiosensitizing Chemotherapy for Advanced Head and Neck Cancer Using the "QUAD-SHOT Regimen". <i>Anticancer Research</i> , 2017, 37, 685-692.	0.5	29
2266	Spheroid-based 3D Cell Cultures Enable Personalized Therapy Testing and Drug Discovery in Head and Neck Cancer. <i>Anticancer Research</i> , 2017, 37, 2201-2210.	0.5	79
2267	Association of eIF4E and SPARC Expression with Lymphangiogenesis and Lymph Node Metastasis in Hypopharyngeal Cancer. <i>Anticancer Research</i> , 2018, 38, 699-706.	0.5	9
2268	Re-irradiation Using Intensity-modulated Radiotherapy for Recurrent and Second Primary Head and Neck Cancer. <i>Anticancer Research</i> , 2018, 38, 3165-3173.	0.5	9
2269	Continuous infusion of 5-FU with split-dose cisplatin: An effective treatment for advanced squamous-cell carcinoma of the head and neck. <i>Clinical and Investigative Medicine</i> , 2011, 34, 8.	0.3	5
2270	Systemic therapy strategies for head-neck carcinomas: Current status. <i>GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery</i> , 2012, 11, Doc03.	0.8	21
2271	Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. <i>GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery</i> , 2012, 11, Doc09.	0.8	54
2272	Actinic Keratosis and Cutaneous Squamous Cell Carcinoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2019, 116, 616-626.	0.6	15
2273	Unseiin, a Kampo medicine, Reduces the Severity and Manifestations of Skin Toxicities Induced by Cetuximab: A Case Report. <i>Yonago Acta Medica</i> , 2020, 63, 379-384.	0.3	2
2274	Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 240.	1.8	101
2275	Recurrent Nasopharyngeal Carcinoma: A Clinical Dilemma and Challenge. <i>Current Oncology</i> , 2013, 20, 406-419.	0.9	102
2276	Rash Rates with EGFR Inhibitors: Meta-Analysis. <i>Current Oncology</i> , 2011, 18, 54-63.	0.9	19
2277	Reirradiation of head and neck cancer in the era of intensity-modulated radiotherapy: patient selection, practical aspects, and current evidence. <i>Radiation Oncology Journal</i> , 2017, 35, 1-15.	0.7	49

#	ARTICLE	IF	CITATIONS
2278	H2Mabâ€™19, an antiâ€™human epidermal growth factor receptorâ€™2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 846-853.	0.8	25
2279	Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study. <i>International Journal of Oncology</i> , 2017, 51, 1471-1481.	1.4	6
2280	Gene targets of sulforaphane in head and neck squamous cell carcinoma. <i>Molecular Medicine Reports</i> , 2019, 20, 5335-5344.	1.1	6
2281	A novel antiâ€™EGFR monoclonal antibody (EMabâ€™17) exerts antitumor activity against oral squamous cell carcinomas via antibodyâ€™dependent cellular cytotoxicity and complementâ€™dependent cytotoxicity. <i>Oncology Letters</i> , 2020, 19, 2809-2816.	0.8	21
2282	Selective inhibition of PI3K110Î± as a novel therapeutic strategy for cetuximabâ€™resistant oral squamous cell carcinoma. <i>Oncology Reports</i> , 2020, 44, 863-872.	1.2	6
2283	Monoclonal Antibodies as Treatment Modalities in Head and Neck Cancers. <i>AIMS Medical Science</i> , 2015, 2, 347-359.	0.2	1
2284	Current status of novel agents in advanced gastroesophageal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 60-74.	0.6	19
2285	EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice?. <i>Translational Lung Cancer Research</i> , 2012, 1, 145-6.	1.3	6
2286	Chemotherapy for advanced cancers. <i>Annals of Palliative Medicine</i> , 2014, 3, 203-28.	0.5	11
2287	Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?. <i>Annals of Translational Medicine</i> , 2016, 4, 80.	0.7	7
2288	Indian clinical practice consensus guidelines for the management of very advanced disease of squamous cell carcinoma of head and neck. <i>Indian Journal of Cancer</i> , 2020, 57, 22.	0.2	4
2289	Indian Council of Medical Research consensus document for the management of tongue cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 140-145.	0.1	10
2290	Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 161-165.	0.1	20
2291	Palliative low dose fortnightly methotrexate in oral cancers: Experience at a rural cancer centre from India. <i>South Asian Journal of Cancer</i> , 2014, 03, 166-170.	0.2	8
2292	An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients. <i>South Asian Journal of Cancer</i> , 2016, 05, 048-051.	0.2	12
2293	Metronomic palliative chemotherapy in maxillary sinus tumor. <i>South Asian Journal of Cancer</i> , 2016, 05, 056-058.	0.2	5
2294	A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers. <i>South Asian Journal of Cancer</i> , 2017, 06, 011-014.	0.2	11
2295	Comparison of paclitaxel-cetuximab chemotherapy versus metronomic chemotherapy consisting of methotrexate and celecoxib as palliative chemotherapy in head and neck cancers. <i>Indian Journal of Cancer</i> , 2017, 54, 20.	0.2	7

#	ARTICLE	IF	CITATIONS
2296	Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer. Indian Journal of Cancer, 2017, 54, 25.	0.2	11
2297	Is pulmonary metastasectomy beneficial in head and neck squamous cell carcinoma? A review of literature. Indian Journal of Cancer, 2017, 54, 2.	0.2	4
2298	Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma. Indian Journal of Cancer, 2019, 56, 4.	0.2	3
2299	Efficacy and tolerability of nimotuzumab in combination with chemotherapy in recurrent and metastatic squamous cell carcinoma of head and neck at a cancer center in Northern India. Indian Journal of Cancer, 2020, 57, 76.	0.2	4
2300	Metronomic chemotherapy for scheduling oral cancer surgery during the COVID-19 pandemic. Indian Journal of Cancer, 2020, 57, 481-484.	0.2	2
2301	Immunotherapy in oral cancer. Journal of Pharmacy and Bioallied Sciences, 2019, 11, 107.	0.2	37
2302	Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients. South Asian Journal of Cancer, 2018, 07, 249-252.	0.2	8
2303	Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence. South Asian Journal of Cancer, 2018, 07, 188-192.	0.2	9
2304	Management of Cutaneous Toxicity and Radiation Dermatitis in Patients with Squamous Cancer of the Head and Neck Undergoing Concurrent Treatment with Cetuximab and Radiotherapy. Journal of Cancer Science & Therapy, 2009, 01, 028-033.	1.7	3
2305	Drug Combinations in Cancer Treatments. Clinical & Experimental Pharmacology, 2013, 03, .	0.3	6
2306	New Oncological Drugs: Analysis of Survival Gain. Global & Regional Health Technology Assessment, 2014, 1, GRHTA.2014.1235.	0.2	4
2307	Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches. World Journal of Clinical Oncology, 2016, 7, 15.	0.9	14
2308	Next generation of antibody therapy for cancer. Chinese Journal of Cancer, 2011, 30, 293-302.	4.9	10
2309	Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit. Chinese Journal of Cancer, 2012, 31, 319-326.	4.9	14
2310	Molecular targeted therapy for EGFR and VEGF in head and neck squamous cell carcinomas. Japanese Journal of Head and Neck Cancer, 2010, 36, 436-441.	0.0	3
2311	Clinical experience with cetuximab in our hospital. Japanese Journal of Head and Neck Cancer, 2016, 42, 76-80.	0.0	2
2312	Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 873-898.	2.3	633
2313	Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 899-906.	2.3	24

#	ARTICLE	IF	CITATIONS
2314	Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. <i>Cancer Biology and Medicine</i> , 2013, 10, 192-205.	1.4	45
2315	Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. <i>ELife</i> , 2020, 9, .	2.8	31
2316	Induction of the Abscopal Effect with Immunotherapy and Palliative Radiation in Metastatic Head and Neck Squamous Cell Carcinoma: A Case Report and Review of the Literature. <i>Cureus</i> , 2019, 11, e4201.	0.2	14
2317	Head and Neck Cancers. <i>UNIPA Springer Series</i> , 2021, , 707-729.	0.1	0
2318	Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. <i>Cancer Science</i> , 2021, 112, 5020-5033.	1.7	19
2319	Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis. <i>Biology</i> , 2021, 10, 1011.	1.3	1
2320	DLEU1 promotes oral squamous cell carcinoma progression by activating interferon-stimulated genes. <i>Scientific Reports</i> , 2021, 11, 20438.	1.6	10
2321	The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells. <i>Cell Death and Disease</i> , 2021, 12, 988.	2.7	27
2323	Epidermal Growth Factor Receptor Inhibitor-Induced Hypomagnesaemia: Is There a Best Replacement Strategy?. <i>European Medical Journal (Chelmsford, England)</i> , 0, , .	3.0	0
2324	The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 761379.	1.3	38
2325	Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial. , 2021, 9, e002998.		14
2326	Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Medicina (Lithuania)</i> , 2021, 57, 1151.	0.8	8
2327	Ultrasound-Mediated Drug Delivery With a Clinical Ultrasound System: In Vitro Evaluation. <i>Frontiers in Pharmacology</i> , 2021, 12, 768436.	1.6	12
2328	Pembrolizumab in the first-line treatment of advanced head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1321-1331.	1.1	11
2329	Perineural invasion/lymphovascular invasion double positive predicts distant metastasis and poor survival in T3â€“4 oral squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 19770.	1.6	14
2330	Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients. <i>Frontiers in Oncology</i> , 2021, 11, 714551.	1.3	2
2331	Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. <i>PeerJ</i> , 2021, 9, e12338.	0.9	7
2332	NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11057.	1.8	4

#	ARTICLE	IF	CITATIONS
2333	Phase 1/2a, open-label, multicenter study of C^{1929} photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 3875-3887.	0.9	64
2334	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , 2021, 158, 17-26.	1.3	33
2335	Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC). <i>Oral Oncology</i> , 2021, 122, 105546.	0.8	4
2336	Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Uses of Monoclonal Antibodies. , 2009, , 321-363.		0
2337	Onkologie II. , 2009, , 311-354.		0
2340	Biologisch zielgerichtete medikamentöse Therapie. , 2010, , 265-275.		0
2341	Targeting EGFR in HPV-Associated Cancer. , 2010, , 211-234.		0
2342	Chemotherapy and Biologic Therapy for Squamous Cell Cancers of the Head and Neck. <i>Otorhinolaryngology Clinics</i> , 2010, 2, 33-41.	0.1	0
2343	Chemotherapy for head and neck cancer: Current status and problems in Japan. <i>Japanese Journal of Head and Neck Cancer</i> , 2010, 36, 273-277.	0.0	0
2345	Molecular-Targeted Chemotherapy for Head and Neck Squamous Cell Carcinoma. , 2011, , 365-382.		0
2346	Targeted Therapeutics in Cancer Treatment. , 2011, , 403-461.		0
2347	Metastasi linfonodali del collo a sede primitiva ignota. , 2011, , 421-430.		0
2348	Terapia medica integrata nei carcinomi squamocellulari. , 2011, , 195-207.		0
2349	Translational Research in Head and Neck Oncology. , 2011, , 179-189.		0
2350	Treatment of Disseminated Non-Melanoma Skin Cancers. , 2011, , 526-531.		0
2351	Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers. , 2011, , 471-481.		0
2352	Multidisciplinary Management of Oropharynx Carcinomas. , 2011, , 401-430.		0
2353	Biomarkers in Head and Neck Cancer. , 2011, , 157-167.		0

#	ARTICLE	IF	CITATIONS
2354	The Role of Chemotherapy and Radiotherapy in the Treatment of Penile Cancer. , 2011, , 259-272.		0
2357	Les cancers de la sphère ORL. , 2011, , 199-216.		0
2360	Carcinoma del cavo orale. , 2011, , 361-370.		0
2361	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
2362	Oropharyngeal Cancer. , 2012, , 585-617.		0
2363	Potential Molecular Targets: From Bench to Bedside. Head and Neck Cancer Clinics, 2012, , 1-16.	0.0	0
2364	Moving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck. Journal of Cancer Research Updates, 0, , .	0.3	0
2365	Salivary Gland Malignancies. , 2012, , 691-706.		0
2366	Understanding the characteristics of molecular targeting agents for proper usage. Japanese Journal of Head and Neck Cancer, 2012, 38, 399-402.	0.0	2
2367	Chemotherapy and Radiotherapy for Elderly Head and Neck Cancer Patients. Nihon Kikan Shokudoka Gakkai Kaiho, 2012, 63, 367-373.	0.0	1
2368	Malignome des Kopf- und Halsbereichs. , 2012, , 533-555.		0
2369	Head and Neck Tumours. , 2012, , 19-59.		0
2371	Individualized Cancer Chemotherapy by Detecting Cancer Biomarkers. Metabolomics: Open Access, 2012, 02, .	0.1	4
2372	Current Research into Head and Neck Cancer Molecular Targeted Therapy and Human Papilloma Virus Infection in Head and Neck Squamous Cell Carcinoma. Practica Otologica, 2012, 105, 183-191.	0.0	0
2373	Systemic Therapies in the Management of Head and Neck Cancer. Head and Neck Cancer Clinics, 2012, , 99-113.	0.0	0
2374	Novel Chemoradiotherapy Regimens Incorporating Targeted Therapies in Locally Advanced Head and Neck Cancers. , 0, , .		0
2375	Clinical trial design in advanced head and neck cancer: from past experiences to future perspectives. Clinical Investigation, 2012, 2, 473-481.	0.0	1
2376	Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy. Journal of the Advanced Practitioner in Oncology, 2012, 3, 161-9.	0.2	2

#	ARTICLE	IF	CITATIONS
2377	Predictive Markers in Lung Cancer. , 2013, , 43-68.		0
2378	Capturing and Deciphering the Molecular Signatures of Head and Neck Cancer. , 2013, , 97-130.		0
2379	Molecular Targeting Drugs for Head and Neck Cancer: EGFR Signaling and its Crosstalk. Practica Otologica, 2013, 106, 89-93.	0.0	0
2380	EGFR, Immunology. , 2013, , 1-10.		0
2381	Salvage surgery for the recurrence of oropharyngeal carcinoma after definitive radiotherapy or chemoradiotherapy. Journal of Japan Society for Head and Neck Surgery, 2013, 23, 343-348.	0.0	0
2382	Salivary duct carcinoma in the submandibular gland: a report of four cases. Journal of Japan Society for Head and Neck Surgery, 2013, 23, 403-408.	0.0	1
2383	Medical Oncology: Planning Considerations and Practices. , 2013, , 495-507.		0
2384	Regionale Chemotherapie bei Kopf-Hals-Tumoren. , 2013, , 79-120.		0
2385	Cancer-Specific Ligandâ€“Receptor Interactions. , 2013, , 461-507.		0
2387	The Efficacy and Cost of Biological Targeted Agents in Oncology. SSRN Electronic Journal, 0, , .	0.4	0
2388	From polychemotherapy regimens to molecular targeting strategies. Biomedical Journal, 2013, 36, 257.	1.4	0
2389	Salvage surgery following combined radiation and cetuximab therapy. Japanese Journal of Head and Neck Cancer, 2013, 39, 496-499.	0.0	1
2396	Chemotherapy for Squamous Cell Carcinoma of the Lip. , 2014, , 51-57.		0
2397	Andere Tumoren. , 2014, , 143-178.		0
2398	Current Surgical Treatment for Thoracic Esophageal Cancer. Nihon Ika Daigaku Igakkai Zasshi, 2014, 10, 134-141.	0.0	0
2399	Palliative radiotherapy for primary lesions of head and neck cancer with uncontrolled distant metastases. Japanese Journal of Head and Neck Cancer, 2014, 40, 473-478.	0.0	3
2400	Angiogenesis in Head and Neck Cancer. Journal of Cancer Science & Therapy, 2014, 06, .	1.7	0
2401	Safety profile and efficacy of Chemotherapy with Docetaxel and Cisplatin (DC) for Recurrent or Metastatic Head and Neck Cancer^ ^ndash;A Retrospective Analysis in a Single Institution. Japanese Journal of Head and Neck Cancer, 2014, 40, 490-496.	0.0	2

#	ARTICLE	IF	CITATIONS
2402	Projections: Novel Therapies for HPV-Negative Cancers of the Head and Neck. , 2014, , 343-359.		0
2403	Overcoming Inherent Resistance to Proteasome Inhibitors in Head and Neck Cancer: Challenges and New Approaches. Resistance To Targeted Anti-cancer Therapeutics, 2014, , 205-231.	0.1	0
2404	Sustained Efficacy of Cetuximab after Therapy Discontinuation in a Patient with Advanced Colorectal Cancer. Journal of Carcinogenesis & Mutagenesis, 2014, S10, .	0.3	0
2405	Outcome of radiotherapy combined with cetuximab for head and neck squamous cell carcinoma. Japanese Journal of Head and Neck Cancer, 2014, 40, 479-484.	0.0	0
2406	Therapeutic Antibodies and Immunologic Conjugates. , 2014, , 508-518.e7.		2
2407	Personalized Cancer Therapy: A Perspective. Clinical & Experimental Pharmacology, 2014, 04, .	0.3	2
2408	Treatment of Malignant Neoplasms of the Nasal and Paranasal Sinuses by Photodynamic Laser Therapy (PDT) With Temoporfin. Journal of Otology & Rhinology, 2014, 03, .	0.1	0
2409	Cancer of the Head and Neck. , 2014, , 1037-1070.e6.		1
2410	Clinical Analysis of Laryngeal Carcinoma Over Ten Years. Practica Otologica, 2014, 107, 405-409.	0.0	0
2411	Current Status of Immunotherapy in Gastroesophageal Cancer. , 2014, , 179-191.		0
2412	Head and Neck Cancer Treatment in the Elderly. Nihon Kikan Shokudoka Gakkai Kaiho, 2014, 65, 388-394.	0.0	2
2413	Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2014, 32, TPS3123-TPS3123.	0.8	0
2415	Current Systemic Therapy Options for Head and Neck Cancers. , 2015, , 17-31.		0
2418	Carcinomas of the Head and Neck. , 2015, , 605-627.		0
2419	Head and Neck Cancers. , 2015, , 373-379.		0
2420	Cetuximab-induced acneiform rash is an early predictor of survival in patients with recurrent or metastatic head and neck cancer. Japanese Journal of Head and Neck Cancer, 2015, 41, 401-405.	0.0	2
2421	Pharmacogenomics for Oral Disease. , 2015, , 363-388.		0
2422	Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck. Current Clinical Pathology, 2015, , 81-87.	0.0	0

#	ARTICLE	IF	CITATIONS
2423	A Case of an Elderly Patient of Hypopharyngeal Carcinoma Developed Thrombocytopenia during Radiotherapy with Cetuximab. <i>Practica Otológica</i> , 2015, 108, 63-69.	0.0	0
2424	Head and Neck Tumors: Viewpointâ€”Fractionated Radiation Therapy and Chemotherapy. , 2015, , 549-562.		0
2425	Frequent Copy Gain of the <i>MET&i> Gene in Hypopharyngeal and Laryngeal Cancer in the Japanese Population. <i>Journal of Cancer Therapy</i> , 2015, 06, 1093-1102.	0.1	0
2426	Opportunities and Challenges for the Future of Personalized Oral Healthcare. , 2015, , 145-153.		1
2427	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
2428	éééf”ç™(Eè”ç™,ã,-ã,ãf%ãf©ã,ãf³. <i>Japanese Journal of Head and Neck Cancer</i> , 2015, 41, 23-25.	0.0	0
2429	Targeted Therapies for Gastric Cancer. <i>Current Clinical Pathology</i> , 2015, , 103-126.	0.0	0
2430	A Case of Metastatic Head and Neck Squamous Cell Carcinoma with Multiple Treatments Including Stereotactic Ablative Body Radiotherapy Alone for Oligometastases to the Parotid Gland. <i>Cureus</i> , 2015, 7, e438.	0.2	2
2431	First-line chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma with or without cetuximab: a single institution experience. <i>Japanese Journal of Head and Neck Cancer</i> , 2016, 42, 432-437.	0.0	1
2432	Adverse Events of Cetuximab Plus Radiotherapy and Countermeasures. <i>Practica Otológica</i> , 2016, 109, 511-517.	0.0	0
2433	Neues aus der Forschung. , 2016, , 289-306.		0
2434	Salvage Surgeries for Patients with Recurrent Head and Neck Cancer after Bioradiotherapy. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2016, 67, 264-271.	0.0	1
2435	Future Directions and Clinical Trials in Penile Cancer. , 2016, , 311-324.		0
2436	Treatment of the Elderly Head and Neck Cancer Patient. , 2016, , 743-751.		0
2437	A Case of Oropharyngeal Squamous Cell Carcinoma who Developed Sigmoid Colon Perforation after Cetuximab Treatment. <i>Practica Otológica</i> , 2016, 109, 803-808.	0.0	0
2438	Immunological Effect of Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies in Squamous Cell Carcinoma of the Head and Neck (HNSCC): the Present and the Future. <i>Journal of Cancer Research and Immuno-Oncology</i> , 2016, 02, .	0.0	0
2439	Two Cases of Nasal and Paranasal Verrucous Carcinoma. <i>Practica Otológica</i> , 2016, 109, 333-342.	0.0	1
2440	Induction Chemotherapy in Head and Neck Cancers. , 2016, , 73-122.		0

#	ARTICLE	IF	CITATIONS
2441	Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers. , 2016, , 555-567.		0
2442	Multidisciplinary Management of Oral Cavity and Maxillary Sinus Cancers. , 2016, , 405-428.		0
2443	Onkologie. , 2016, , 177-212.		0
2444	Management of High-Risk Primary Tumors Including Nodal Staging. , 2016, , 149-174.		0
2445	Head and Neck Quality Assurance 2014. , 2016, , 845-859.		0
2446	Molecular Targeted Therapies in Head and Neck Cancer. , 2016, , 349-372.		0
2447	Multidisciplinary Management of Hypopharyngeal Carcinoma. , 2016, , 511-537.		0
2448	Cervical Lymph Node Metastases of Squamous Cell Carcinoma from an Unknown Primary Site. , 2016, , 665-672.		0
2449	Introduction of chemotherapy (Molecular targeting agentäf»Chemotherapy). Japanese Journal of Head and Neck Cancer, 2016, 42, 309-315.	0.0	1
2450	Two Cases of Nasal and Paranasal Verrucous Carcinoma. Practica Otologica, Supplement, 2016, 147, 94-95.	0.0	0
2451	Translational Research in Head and Neck Oncology. , 2016, , 215-227.		0
2452	Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through activation of the EGFR/AKT pathway. Nihon Koku Geka Gakkai Zasshi, 2016, 62, 476-486.	0.0	0
2453	Phase I Study to Determine the Starting Dose for Estimating the Individualized Maximum Repeatable Dose in Tumor Dormancy Therapy with Weekly Paclitaxel for Recurrent and Metastatic Head and Neck Cancer. Practica Otologica, 2016, 109, 883-888.	0.0	0
2454	Principles of Systemic Chemotherapy for Squamous Cell Head and Neck Cancer. , 2016, , 337-348.		0
2455	Reirradiation in Head and Neck Cancer: A Curative Intent in Recurrence or Second Tumors. Journal of Nuclear Medicine & Radiation Therapy, 2016, 07, .	0.2	0
2456	Conformal re-irradiation of recurrent head and neck tumors. Onkologiya Zhurnal Imeni P A Gertsena, 2016, 5, 54.	0.0	1
2457	Multidisciplinary Management of Oropharynx Carcinomas. , 2016, , 475-510.		0
2458	Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 27-107.	0.1	0

#	ARTICLE	IF	CITATIONS
2459	Systemic Treatments: Chemotherapy and Targeted Therapies. , 2017, , 221-231.		0
2460	Palliative Care in Patients with Head and Neck Cancer. , 2017, , 263-271.		0
2462	Salvage Treatment for Recurrent Oral Cancer. , 2017, , 271-290.		0
2463	Current and Emerging Role of Chemotherapy in Oral Cancer. , 2017, , 127-146.		1
2464	Treatment in the Elderly. , 2017, , 251-261.		0
2465	The effects of transoral surgery for the recurrent hypopharyngeal cancer after radiation therapy with cetuximab. Japanese Journal of Head and Neck Cancer, 2017, 43, 28-32.	0.0	1
2466	Angiogenesis and Nonmelanoma Skin Cancer. , 2017, , 67-79.		0
2467	Envoi"An Appraisal of Targeted Therapies for Head and Neck Cancer. , 2017, , 217-278.		0
2468	Two Cases of Squamous Cell Carcinoma Successfully Treated with Cetuximab-Based Chemotherapy or Radiotherapy. Nishinohon Journal of Dermatology, 2017, 79, 55-58.	0.0	0
2469	Hoofd-halstumoren. , 2017, , 251-291.		0
2470	The Value of Anti-angiogenics in Head and Neck Cancer Therapy. , 2017, , 1-17.		0
2471	Phase I Study to Determine the Starting Dose for Estimating the Individualized Maximum Repeatable Dose in Tumor Dormancy Therapy with Weekly Paclitaxel for Recurrent and Metastatic Head and Neck Cancer. Practica Otologica, Supplement, 2017, 148, 100-101.	0.0	0
2472	Adverse Events of Cetuximab Plus Radiotherapy and Countermeasures. Practica Otologica, Supplement, 2017, 148, 68-69.	0.0	0
2473	Kopf-Hals-Tumoren beim alten und geriatrischen Patienten. , 2017, , 1-11.		0
2474	Malignome des Kopf- und Halsbereichs. , 2017, , 581-604.		0
2475	A case of whole body pneumatosis after radiotherapy with cetuximab. Japanese Journal of Head and Neck Cancer, 2017, 43, 393-396.	0.0	2
2476	Effectiveness and prognostic factors of Cetuximab plus chemotherapy for recurrent or metastatic head and neck cancer. Japanese Journal of Head and Neck Cancer, 2017, 43, 493-498.	0.0	1
2477	Cetuximab ^{1/4} FP therapy may enable radical resection of metastases in patients with tongue small cell carcinoma. Japanese Journal of Head and Neck Cancer, 2017, 43, 377-382.	0.0	3

#	ARTICLE	IF	CITATIONS
2478	Utility of chemoradiotherapy for head and neck cancer with distant metastases at initial presentation. Japanese Journal of Head and Neck Cancer, 2017, 43, 488-492.	0.0	1
2479	To review the role and issue of pharmacotherapy for head and neck cancer clarified from previous clinical trials. Japanese Journal of Head and Neck Cancer, 2017, 43, 425-429.	0.0	0
2480	A Case of Oropharyngeal Squamous Cell Carcinoma who Developed Sigmoid Colon Perforation after Cetuximab Treatment. Practica Otologica, Supplement, 2017, 148, 86-87.	0.0	0
2481	Single Fraction Stereotactic Radiosurgery for Retreatment of Skull Base Recurrent Head and Neck Malignancies. Cureus, 2017, 9, e1206.	0.2	4
2482	Oncology gold standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck. South Asian Journal of Cancer, 2017, 06, 154-160.	0.2	3
2483	Cetuximab for Squamous Cell Carcinoma of the Head and Neck. International Journal of Cancer Management, 2017, 10, .	0.2	1
2484	Do We Still Need Phase 2 Trials? Late Obituary for Panitumumab and the SPECTRUM-Trial. Annals of Hematology & Oncology, 2017, 4, .	0.0	0
2485	Enfermedad ganglionar residual tras quimiorradioterapia con intención radical en pacientes con tumores de faringolaringe. Revista ORL, 2017, 8, 205.	0.0	0
2486	Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program. Journal of Japanese Society of Oral Oncology, 2018, 30, 144-150.	0.0	0
2487	Utility of lateral temporal bone resection for stage T1 and T2 squamous cell carcinoma of external auditory canal. Journal of Japan Society for Head and Neck Surgery, 2018, 28, 143-147.	0.0	0
2488	Kopf-Hals-Tumoren beim alten und geriatrischen Patienten. , 2018, , 299-309.		0
2489	Immune check point inhibitors for head and neck cancer. Japanese Journal of Head and Neck Cancer, 2018, 44, 336-341.	0.0	0
2490	The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma. Current Cancer Research, 2018, , 397-438.	0.2	0
2491	Overview: The Pathobiology of Head and Neck Cancer. Current Cancer Research, 2018, , 1-5.	0.2	0
2492	Angiogenesis and Anti-angiogenic Therapy in Head and Neck Cancer. Current Cancer Research, 2018, , 439-467.	0.2	1
2493	A Case of Head and Neck Cancer Died of Lung Failure after a Single Administration of Nivolumab. Practica Otologica, 2018, 111, 693-699.	0.0	0
2494	Targeting the ErbB Family in Head and Neck Cancer. Current Cancer Research, 2018, , 7-61.	0.2	1
2495	Drug Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Plans. Practica Otologica, 2018, 111, 577-582.	0.0	0

#	ARTICLE	IF	CITATIONS
2496	Besides and beyond histopathology; for adjuvant treatment in early tongue cancer. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 355.	0.1	1
2497	Chemotherapy for Temporal Bone Cancer. , 2018, , 403-410.		0
2498	Targeted Therapy in Recurrent or Metastatic Head and Neck Carcinoma. Hospice and Palliative Medicine International Journal, 2018, 2, .	0.2	1
2499	Anticorps monoclonaux en oncologie : d'élucider une réponse immunitaire en plus de la réduction tumorale spécifique.. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 707-735.	0.0	0
2500	The Synergistic Effect of Immune Checkpoint Blockade and Radiotherapy in Recurrent/Metastatic Sinonasal Cancer. Cureus, 2018, 10, e3519.	0.2	7
2501	Validity of Treatment for Patients with Head and Neck Squamous Cell Carcinoma with Distant Metastasis Detected at the First Examination. Journal of Otolaryngology of Japan, 2018, 121, 1288-1293.	0.1	0
2502	IMPACT OF VIRAL INFECTION ON EFFECTIVENESS OF ANTITUMOR TREATMENT FOR LARYNGEAL CANCER. Malignant Tumours, 2018, 8, 49-56.	0.1	1
2503	Interstitial Lung Disease Associated With Cetuximab in Patients With Head and Neck Carcinoma: A Single-Institution Experience in Japan. International Surgery, 2018, 103, 528-533.	0.0	0
2504	ééfç™Eäã ¼ã™ä,è—ç%o Çç™,æ³•ã®é€²æ©. Journal of Otolaryngology of Japan, 2018, 121, 1458-1462.	0.1	0
2505	First-line chemotherapy for head and neck squamous cell carcinoma. Optimal strategy. Opuholi Golovy I Sei, 2019, 8, 14-20.	0.1	1
2506	Nivolumab in the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN): A Report of 16 Cases at a Single Institution. Practica Otologica, 2019, 112, 625-628.	0.0	0
2507	Elective neck dissection is useful in what cases?. Journal of Japanese Society of Oral Oncology, 2019, 31, 122-130.	0.0	0
2508	Carboplatin plus Paclitaxel in patients with recurrent/metastatic head and neck carcinoma. Japanese Journal of Head and Neck Cancer, 2019, 45, 420-425.	0.0	0
2509	Response to salvage chemotherapy after progression on nivolumab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Japanese Journal of Head and Neck Cancer, 2019, 45, 41-45.	0.0	1
2510	The role of surgical resection for distant metastasis of head and neck squamous cell carcinoma. Japanese Journal of Head and Neck Cancer, 2019, 45, 314-317.	0.0	0
2511	Clinicopathological analysis of local recurrence of oral squamous cell carcinoma. Journal of Japanese Society of Oral Oncology, 2019, 31, 143-149.	0.0	0
2512	Testing alternate biochemotherapy combinations in recurrent/metastatic head and neck cancer - Putting the best foot forward. Indian Journal of Cancer, 2019, 56, 2.	0.2	0
2513	Outcome of Combination Chemotherapy of Cetuximab, Platinum and Fluorouracil to Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Japanese Journal of Head and Neck Cancer, 2019, 45, 294-299.	0.0	0

#	ARTICLE	IF	CITATIONS
2514	A Case of Lung Metastasis from Laryngeal Cancer Showing a Good Response to Chemotherapy with Docetaxel. <i>Practica Otologica</i> , 2019, 112, 405-410.	0.0	0
2515	Head and Neck Tumors in Older Adults: Systemic Treatments and Combination with Local Strategies. , 2019, , 1-13.		0
2516	Targeted and Immune Therapy for Periocular and Orbital Malignancies. <i>Current Practices in Ophthalmology</i> , 2019, , 83-97.	0.1	0
2517	Clinical analysis of palliative care alone in end-stage head and neck cancer treatment. <i>Japanese Journal of Head and Neck Cancer</i> , 2019, 45, 34-40.	0.0	0
2518	A prospective observation study of Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated by radiotherapy with cetuximab i14^JROSG12-2i14%: interim appraisal of the safety and treatment compliance. <i>Japanese Journal of Head and Neck Cancer</i> , 2019, 45, 330-336.	0.0	0
2519	Clinical features of 10 patients with recurrent and/or metastatic head and neck carcinomas treated by Nivolumab:. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2019, 28, 313-318.	0.0	1
2520	Chemotherapy and Biologic Therapy in Rectal Cancer: An Update. , 2019, , 407-444.		0
2521	Andere Tumoren. , 2019, , 191-239.		0
2522	Squamous Cell Carcinoma of the Head and Neck. , 2019, , 697-720.		1
2523	Carcinoma of base of tongue with disseminated nonregional lymph nodal metastases clinically mimicking lymphoma: The first reported case and review of literature. <i>Journal of Medical Sciences (Taiwan)</i> , 2019, 39, 243.	0.1	0
2524	Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. <i>Journal of the Advanced Practitioner in Oncology</i> , 2019, 10, 37-46.	0.2	5
2526	Immunotherapy in head and neck cancer. <i>Pomeranian Journal of Life Sciences</i> , 2019, 65, 15-19.	0.1	2
2527	Secreted amphiregulin promotes vincristine resistance in oral squamous cell carcinoma. <i>International Journal of Oncology</i> , 2019, 55, 949-959.	1.4	8
2528	â...ç-«ãfã,Sãffã,ãfã,ãfãf^é»â©3è-ãCEã~ã,Šæ«ãã†ç™ãf»è»ççS»éé,éç™CEæ2»ç™,. <i>Journal of Otolaryngology of Japan</i> , 2019, 12		1
2529	Current Development and Research Trend of Chemotherapeutic Agents for Head and Neck Squamous Cell Carcinoma. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , 2019, 62, 487-498.	0.0	1
2530	OPTIMAL TREATMENT STRATEGY FOR PATIENTS WITH PROGRESSIVE SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. <i>Issledovaniã I Praktika V Medicine</i> , 2019, 6, 115-128.	0.1	0
2531	Recurrent Oral Cancer and Salvage Options. , 2020, , 155-164.		0
2532	Immunotherapy in Oral Cancer: A Fourth Dimension of Cancer Treatment. , 2020, , 129-154.		1

#	ARTICLE	IF	CITATIONS
2533	Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Korean Society for Head and Neck Oncology, 2019, 35, 1-10.	0.1	0
2534	Identification of the optimal cetuximab concentration that is effective against oral squamous cell carcinoma in collagen gel droplet embedded culture drug sensitivity testing. Molecular and Clinical Oncology, 2020, 12, 51-56.	0.4	2
2535	The MET receptor as a therapeutic target in head and neck squamous cell carcinomas. , 2020, , 263-280.		0
2536	Immunotherapy for cancer of the oral cavity and oropharynx. The use of monoclonal antibodies. Bukovinian Medical Herald, 2020, 24, 178-186.	0.1	0
2537	A Cross-Sectional, Retrospective Study of Clinicopathological Profile of Oral Malignancies in King George Hospital, Visakhapatnam, India. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 1480-1483.	0.0	0
2538	PD-1 ⁺ Treg cells in oral squamous cell carcinoma. Nihon Kikan Shokudoka Gakkai Kaiho, 2020, 71, 338-340.	0.0	1
2539	A defucosylated anti-CD44 monoclonal antibody 5G2A exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. Oncology Reports, 2020, 44, 1949-1960.	1.2	28
2540	FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus. Anticancer Research, 2020, 40, 5621-5630.	0.5	2
2541	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 5471.	1.7	18
2542	Targeting Cancer Stem Cell Markers or Pathways: A Potential Therapeutic Strategy for Oral Cancer Treatment. International Journal of Stem Cells, 2021, 14, 386-399.	0.8	3
2543	EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. Communications Biology, 2021, 4, 1237.	2.0	20
2544	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clinical Immunology, 2021, 232, 108873.	1.4	19
2545	Targeting TP53 to augment therapeutic response in head and neck cancer. , 2020, , 65-88.		1
2546	Molecular Targeted Therapy for Advanced Oral Cancer. Textbooks in Contemporary Dentistry, 2020, , 359-385.	0.2	0
2547	Duration of Oral Antibiotics Administration for Cetuximab-Induced Acneiform Eruption. Dermatology, 2021, 237, 457-463.	0.9	3
2548	F-18 FDG PET Tests in Head and Neck Cancer. , 2021, , 51-69.		0
2549	Principles of Management of Head and Neck Cancers. , 2021, , 409-425.		0
2550	Neoplasms of the Oral Cavity and Oropharynx. , 2021, , 427-447.		0

#	ARTICLE	IF	CITATIONS
2551	Gastrointestinal Toxicities of Targeted Therapy. , 2020, , 119-132.		0
2552	Fibroblast growth factor receptors as therapeutic targets in head and neck squamous cell carcinomas. , 2020, , 235-261.		0
2553	Chemotherapy: Where we have been and where we are going. , 2020, , 17-38.		0
2554	Immunotherapy-Based Approaches for Treatment of Oral and Oropharyngeal Cancers. Textbooks in Contemporary Dentistry, 2020, , 387-397.	0.2	0
2555	Hoofd-halskanker. , 2020, , 261-291.		0
2556	Dermatological Toxicities of Targeted Therapy. , 2020, , 147-164.		1
2557	Head and Neck Tumors in Older Adults: Systemic Treatments and Combination with Local Strategies. , 2020, , 759-771.		0
2558	Immunotherapeutic approaches in HNSCC. , 2020, , 117-142.		1
2559	The knowledge and management of steroid side effects for head and neck cancer oncology treatment physician. Japanese Journal of Head and Neck Cancer, 2020, 46, 26-30.	0.0	1
2560	Clinical Study on recurrent and metastatic head and neck cancer patients treated with Nivolumab. Japanese Journal of Head and Neck Cancer, 2020, 46, 278-283.	0.0	1
2561	Chemotherapy for older patients with head and neck cancer. Journal of Japanese Society of Oral Oncology, 2020, 32, 186-192.	0.0	0
2562	Autophagy in head and neck cancer therapy. , 2020, , 281-300.		0
2563	ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
2564	Pharmacogenomics of Antitumor Targeted Agent and Immunotherapy. , 2020, , 55-82.		0
2565	Introduction: Leaps and bounds. , 2020, , 1-15.		0
2566	Targeted therapy: Precision comes to life. , 2020, , 39-51.		0
2567	Cancer des voies aérodigestives et supérieures. , 2020, , 178-189.e4.		0
2568	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0

#	ARTICLE	IF	CITATIONS
2569	Development of chemotherapy for head and neck cancer, and current status of treatment strategy in clinical practice. Journal of Japanese Society of Oral Oncology, 2020, 32, 130-133.	0.0	0
2570	Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592098371.	1.4	7
2571	Moving towards the Future of Radio-Immunotherapy: Could We "Tailor" the Abscopal Effect on Head and Neck Cancer Patients?. Immuno, 2021, 1, 410-423.	0.6	1
2572	Contrasting functions of the epithelial-stromal interaction 1 gene, in human oral and lung squamous cell cancers. Oncology Reports, 2021, 47, .	1.2	5
2573	Stereotactic body radiotherapy plus cetuximab for previously irradiated un-resectable head and neck cancer. Biomedical Journal, 2022, 45, 838-846.	1.4	8
2574	Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma. Anticancer Research, 2021, 41, 5785-5791.	0.5	6
2575	Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma. European Journal of Cancer, 2021, 159, 125-132.	1.3	11
2576	Quimioterapia y terapias dirigidas en otorrinolaringología. EMC - Otorrinolaringología, 2020, 49, 1-6.	0.0	0
2577	Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 982-984.	2.3	0
2578	Combining Systemic Therapy With Radiation: Head and Neck Cancer Treatments in an Era of Targeted Agents and Immunotherapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 907-913.	2.3	3
2579	«çç\$»âf»â†ç™°éé,éf"âCEâ, "â«â-3/4âªMâ,â†âæ™çš,,è-âªâ...ç-«âfâ,Sâffâ,âfâ,âfâf^é»â®³è-âªâ,"âf"âf†âf³â,1. Journal of Otolaryngology	0.1	0
2582	Squamous cell carcinoma of head and neck: what internists should know. Korean Journal of Internal Medicine, 2020, 35, 1031-1044.	0.7	19
2584	Immunotherapy for regional, recurrent and metastatic head and neck cancer: recent advances and future directions. Medical Alphabet, 2020, , 60-69.	0.0	0
2585	Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study. PeerJ, 2020, 8, e9862.	0.9	3
2586	THE EFFECTS OF SULINDAC ON CELL VIABILITY, CELL CYCLE AND ANGIOGENESIS IN PHARYNGEAL CANCER CELL. Ent Updates, 0, , .	0.0	0
2587	Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma. Auris Nasus Larynx, 2020, 47, 864-869.	0.5	1
2588	Minocycline-induced black thyroid with black pigmentation of the thyroid cartilage, cricoid cartilage, and trachea found during reconstructive surgery for hypopharyngeal cancer. Auris Nasus Larynx, 2020, , .	0.5	2
2589	The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospective economic assessment from a single-center experience. Tumori, 2012, 98, 408-12.	0.6	2

#	ARTICLE	IF	CITATIONS
2590	Targeted therapy: a new approach for the treatment of locally advanced oropharyngeal cancer. <i>Acta Naturae</i> , 2012, 4, 82-5.	1.7	0
2592	Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). <i>Anticancer Research</i> , 2011, 31, 249-53.	0.5	66
2594	Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis. <i>American Journal of Cancer Research</i> , 2015, 5, 1017-31.	1.4	29
2595	Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. <i>American Journal of Cancer Research</i> , 2015, 5, 1921-38.	1.4	19
2596	IKK phosphorylation of NF- κ B at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 3098-110.	1.4	11
2598	Advances in Collaborative Practice for Patients With Head and Neck Cancers. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 261-265.	0.2	0
2599	STOML2 as a novel prognostic biomarker modulates cell proliferation, motility and chemo-sensitivity via IL6-Stat3 pathway in head and neck squamous cell carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 683-695.	0.0	7
2600	Mechanisms of resistance in head and neck cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 2742-2751.	1.4	17
2601	Nimotuzumab combined with radiotherapy for the treatment of hypopharyngeal cancer - A case report from a tertiary cancer center. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 285-288.	0.3	0
2602	SOD2 Enhancement by Long-Term Inhibition of the PI3K Pathway Confers Multi-Drug Resistance and Enhanced Tumor-Initiating Features in Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, .	1.8	0
2603	Objective Quantitation of EGFR Protein Levels using Quantitative Dot Blot Method for the Prognosis of Gastric Cancer Patients. <i>Journal of Gastric Cancer</i> , 2021, 21, 335.	0.9	2
2604	Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study. <i>Oral Oncology</i> , 2022, 124, 105634.	0.8	9
2605	Tumoren im Kopf-Hals-Bereich. , 2022, , 230-241.		0
2606	SOD2 Enhancement by Long-Term Inhibition of the PI3K Pathway Confers Multi-Drug Resistance and Enhanced Tumor-Initiating Features in Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11260.	1.8	4
2607	Functional Profiling of Head and Neck/Esophageal Squamous Cell Carcinoma to Predict Cetuximab Response. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, , .	0.7	2
2608	Immunotherapy Approaches in HPV-Associated Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 5889.	1.7	21
2610	Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists. <i>Cancers</i> , 2021, 13, 5716.	1.7	13
2611	Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 779779.	1.6	3

#	ARTICLE	IF	CITATIONS
2612	Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 750852.	1.3	6
2613	Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 114-131.	12.5	76
2614	Autophagy awakens the myriad roles of autophagy in head and neck cancer development and therapeutic response. <i>Molecular Carcinogenesis</i> , 2022, 61, 243-253.	1.3	1
2615	Head and Neck Cancers Are Not Alike When Tared with the Same Brush: An Epigenetic Perspective from the Cancerization Field to Prognosis. <i>Cancers</i> , 2021, 13, 5630.	1.7	11
2616	Radioimmunotherapy and Targeted Radiotherapy of Squamous Cell Carcinoma of the Head and Neck. , 2022, , 457-469.		0
2617	Determining ADCC Activity of Antibody-Based Therapeutic Molecules using Two Bioluminescent Reporter-Based Bioassays. <i>Current Protocols</i> , 2021, 1, e296.	1.3	11
2618	Immuno-Oncology. <i>Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaishi</i> , 2021, 11, 1-10.		0
2619	Pan-Asian adaptation of the EHSO/ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. <i>ESMO Open</i> , 2021, 6, 100309.	2.0	29
2620	Kutane Plattenepithelkarzinome: Maligne Tumoren mit hoher Mutationslast. , 0, , .		0
2621	Genome-Wide Copy Number Variation of Circulating Cell-Free DNA As a Biomarker in Head and Neck Cancer Patients Treated With Immunotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2622	Alcohol and Head and Neck Cancer: Updates on the Role of Oxidative Stress, Genetic, Epigenetics, Oral Microbiota, Antioxidants, and Alkylating Agents. <i>Antioxidants</i> , 2022, 11, 145.	2.2	25
2623	Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. <i>Oncologist</i> , 2022, 27, e194-e198.	1.9	18
2624	PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2022, 43, 103324.	0.6	8
2625	Tumors: <i>Oto-Rhino-Laryngology</i> . , 2021, , 5279-5291.		0
2626	Post hoc analysis of the screening log of phase III investigator-initiated randomized clinical trial comparing palliative oral metronomic versus intravenous chemotherapy in head-and-neck cancer. <i>Cancer Research Statistics and Treatment</i> , 2021, 4, 642.	0.1	0
2627	Rapid response of locally advanced oral squamous cell carcinoma to apatinib: A case report. <i>Open Medicine (Poland)</i> , 2021, 16, 1668-1672.	0.6	2
2628	OUP accepted manuscript. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, , .	0.6	4
2629	Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma. <i>Oncologist</i> , 2022, 27, e340-e349.	1.9	8

#	ARTICLE	IF	CITATIONS
2630	Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 812702.	1.1	2
2632	Prediction Model of Distant Metastasis in Oral Cavity Squamous Cell Carcinoma With or Without Regional Lymphatic Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 713815.	1.3	5
2633	Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine. <i>Drug Resistance Updates</i> , 2022, 60, 100806.	6.5	41
2634	Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 629.	1.7	10
2636	Current status and future outlooks on therapeutic drug monitoring of fluorouracil. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1407-1422.	1.5	2
2637	Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines. <i>Cells</i> , 2022, 11, 154.	1.8	9
2638	Upfront DPYD Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress. <i>Current Oncology</i> , 2022, 29, 497-509.	0.9	4
2639	A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 761428.	1.3	4
2640	NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models. <i>Cancers</i> , 2022, 14, 506.	1.7	4
2641	Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1335-1344.	3.2	14
2642	Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group. <i>Frontiers in Oncology</i> , 2022, 12, 730785.	1.3	1
2643	Management of elderly patients with head and neck cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 313-321.	0.6	3
2644	Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2022, 12, 2025.	1.6	5
2645	Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases. <i>Cancers</i> , 2022, 14, 792.	1.7	8
2646	How I Treat Advanced Head Neck Cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.1	0
2647	Impact of HPV status on metastatic patterns and survival in non-oropharyngeal head and neck cancer with distant metastasis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 3029-3039.	0.8	5
2648	Retreatment with nivolumab for patients with recurrent and/or metastatic head and neck cancer. <i>Acta Oto-Laryngologica</i> , 2022, 142, 206-212.	0.3	2
2649	Curative intent Stereotactic Ablative Radiation Therapy (SABR) for treatment of lung oligometastases from head and neck squamous cell carcinoma (HNSCC): a multi-institutional retrospective study. <i>British Journal of Radiology</i> , 2022, 95, 20210033.	1.0	5

#	ARTICLE	IF	CITATIONS
2650	Baseline Neutrophil-to-Lymphocyte Ratio and Glasgow Prognostic Score are Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab. <i>Acta Medica Okayama</i> , 2021, 75, 335-343.	0.1	5
2651	Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy. <i>In Vivo</i> , 2022, 36, 907-917.	0.6	10
2652	Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer. <i>In Vivo</i> , 2022, 36, 979-984.	0.6	4
2653	Total accumulated dose of cisplatin and EXTREME regimen for recurrent and metastatic head and neck carcinoma. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2022, 31, 223-228.	0.0	0
2655	The role of partial-EMT in the progression of head and neck squamous cell carcinoma. <i>Journal of Oral Biosciences</i> , 2022, 64, 176-182.	0.8	10
2656	Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2022, 44, 1192-1205.	0.9	5
2657	Reirradiation for Rare Head and Neck Cancers: Orbit, Auditory Organ, and Salivary Glands. <i>Cureus</i> , 2022, 14, e22727.	0.2	1
2658	Discovery of a potent cytotoxic agent that promotes G ₂ /M phase cell cycle arrest and apoptosis in a malignant human pharyngeal squamous carcinoma cell line. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	2
2659	Autophagy and Skin Diseases. <i>Frontiers in Pharmacology</i> , 2022, 13, 844756.	1.6	20
2660	Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era. <i>Cancers</i> , 2022, 14, 1202.	1.7	5
2661	Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2022, 42, 1607-1613.	0.5	1
2663	First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study. <i>World Journal of Clinical Oncology</i> , 2022, 13, 147-158.	0.9	2
2664	Choice of optimal therapeutic sequence in treatment of patients with progressive / metastatic squamous cell cancer of the head and neck in the light of TPEX study results. <i>Opuholi Golovy I Sei</i> , 2022, 11, 58-63.	0.1	0
2665	Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 254-267.	1.3	4
2666	Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy. <i>Current Oncology Reports</i> , 2022, 24, 475-491.	1.8	4
2667	Anti-PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 781348.	1.3	6
2668	MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. , 2022, 10, e003917.		19
2669	EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 813732.	2.2	9

#	ARTICLE	IF	CITATIONS
2670	Regulation of Ferroptosis by Non-Coding RNAs in Head and Neck Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3142.	1.8	6
2671	Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Hypopharynx, Larynx, Trachea and Parapharyngeal Space. <i>Head and Neck Pathology</i> , 2022, 16, 31-39.	1.3	13
2672	Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2329-2338.	3.2	31
2673	Treatment for Locoregionally Recurrent Head and Neck Cancers. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , 2022, 65, 133-142.	0.0	0
2674	Long non-coding RNA LINC00472 inhibits oral squamous cell carcinoma via miR-4311/GNG7 axis. <i>Bioengineered</i> , 2022, 13, 6371-6382.	1.4	2
2675	Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 73.	7.1	9
2676	Unexpected response to fourth-line paclitaxel in a patient with metastatic oropharyngeal squamous cell carcinoma, immunotherapy-refractory. <i>Anti-Cancer Drugs</i> , 2022, Publish Ahead of Print, .	0.7	1
2677	ACK1 upregulated the proliferation of head and neck squamous cell carcinoma cells by promoting p27 phosphorylation and degradation. <i>Journal of Cell Communication and Signaling</i> , 2022, 16, 567-578.	1.8	2
2678	Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib. <i>Cancer Biology and Therapy</i> , 2022, 23, 309-317.	1.5	3
2680	A single-arm, multicenter, phase II clinical study of tislelizumab plus albumin-bound paclitaxel/cisplatin as neoadjuvant therapy for borderline resectable esophageal squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 263-263.	0.7	3
2681	Treatment of Recurrent and Metastatic HPV-Associated Squamous Cell Carcinoma. <i>Current Otorhinolaryngology Reports</i> , 0, , 1.	0.2	0
2682	Retreatment of Recurrent or Second Primary Head and Neck Cancer After Prior Radiation: Executive Summary of the American Radium Society Appropriate Use Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 759-786.	0.4	20
2683	Percutaneous Cryoablation for Recurrent Head and Neck Tumors. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 791-799.	0.9	2
2684	Glycoprotein NMB promotes tumor formation and malignant progression of laryngeal squamous cell carcinoma. <i>Cancer Science</i> , 2022, 113, 3244-3254.	1.7	5
2685	Paclitaxel and Cisplatin with or without Cetuximab in metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label Phase II trial. <i>Innovation(China)</i> , 2022, 3, 100239.	5.2	2
2686	¹⁸ F-FDG-PET/CT can be used to predict distant metastasis in hypopharyngeal squamous cell carcinoma. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2022, 51, 13.	0.9	1
2687	Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma. <i>Biology</i> , 2022, 11, 54.	1.3	13
2688	Anticancer effects of picrasidine I on oral squamous cell carcinoma. <i>Environmental Toxicology</i> , 2022, 37, 627-636.	2.1	2

#	ARTICLE	IF	CITATIONS
2689	Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. Exploration of Targeted Anti-tumor Therapy, 2021, 2, .	0.5	3
2691	Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFICID Trial. Oncology Research and Treatment, 2022, 45, 319-325.	0.8	1
2692	Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism. Cell Death and Disease, 2022, 13, 350.	2.7	4
2693	PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 93-99.	1.4	6
2694	A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. Investigational New Drugs, 2022, 40, 782-788.	1.2	5
2695	Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies. Oral Oncology, 2022, 128, 105806.	0.8	4
2696	Therapeutic approaches for the treatment of head and neck squamous cell carcinomaAn update on clinical trials. Translational Oncology, 2022, 21, 101426.	1.7	33
2715	Salvage stereotactic re-irradiation with CyberKnife for locally recurrent head and neck cancer: a single center experience. Tumori, 2014, 100, 278-83.	0.6	6
2716	Treatment Outcomes of Pulmonary Metastases from Head and Neck Squamous Cell Carcinoma. Acta Medica Okayama, 2021, 75, 31-37.	0.1	1
2717	New challenge of developing combined radio-drug therapy. Chinese Clinical Oncology, 2014, 3, 18.	0.4	3
2719	A multi-institutional analysis of outcomes following stereotactic body radiation therapy for management of metastases from squamous cell carcinomas of the head and neck.. Journal of Radiosurgery and SBRT, 2022, 8, 11-19.	0.2	0
2720	Real world evidence of nivolumab in Japanese patients with head and neck cancer. Japanese Journal of Head and Neck Cancer, 2022, 48, 1-6.	0.0	0
2721	In Vivo Models for Studying Interstitial Photodynamic Therapy of Locally Advanced Cancer. Methods in Molecular Biology, 2022, 2451, 151-162.	0.4	1
2722	BaÅ-Boyun SkuamÅz HÅcreli KarsinomlarÅnda EGFR, P16 ve Ki67 Ekspresyonunun Prognozu Etkisi. Online TÅrk SaÅk Bilimleri Dergisi, 0, .	0.1	0
2723	Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 527-540.	1.8	9
2724	Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients: A systematic review and meta-analysis. Oral Diseases, 2023, 29, 1905-1919.	1.5	2
2725	Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head and Neck, 2022, 44, 1777-1786.	0.9	3
2726	Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 511-526.	1.8	9

#	ARTICLE	IF	CITATIONS
2727	Effectiveness of Pembrolizumab in Patients with HNSCC in Japanese Real-World Clinical Practice. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 78-79.	0.0	0
2728	Current trends of targeted therapy for oral squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2169-2186.	1.2	23
2729	Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa. <i>Cancers</i> , 2022, 14, 2351.	1.7	0
2730	Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 687-692.	0.6	3
2731	EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 2407.	1.7	1
2732	Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma. <i>BMC Medicine</i> , 2022, 20, 175.	2.3	3
2733	Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 2355.	1.7	6
2734	Bleeding complications and possible resistance patterns of anti-angiogenesis treatments in recurrent/metastatic head-and-neck squamous cell carcinoma – Reflections from a phase II study of pazopanib in recurrent/metastatic head-and-neck squamous cell carcinoma. <i>Journal of Cancer Research and Practice</i> , 2022, 9, 52.	0.2	1
2735	Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. <i>World Journal of Clinical Oncology</i> , 2022, 13, 388-411.	0.9	13
2736	New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Vaccines</i> , 2022, 10, 885.	2.1	2
2737	Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 131, 105939.	0.8	5
2738	Head and neck cancers. , 2023, , 376-382.		0
2740	Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?. <i>Current Opinion in Oncology</i> , 2022, 34, 196-203.	1.1	3
2741	The impact of patient preference in the treatment algorithm for recurrent/metastatic head and neck squamous cell carcinoma. <i>Radiologia Medica</i> , 2022, 127, 866-871.	4.7	4
2742	Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
2743	Palliative Care Therapies. , 0, , .		0
2744	Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2022, 24, 1890-1902.	1.2	3
2745	A Case of Complete Remission of Nasal Cavity Poorly Differentiated Carcinoma With Targeted Therapy, to Which Surgery and Concurrent Chemoradiotherapy Was Ineffective. <i>Korean Journal of Otorhinolaryngology-Head and Neck Surgery</i> , 2023, 66, 192-197.	0.0	0

#	ARTICLE	IF	CITATIONS
2746	Preoperative prediction model to evaluate salvage surgery in patients with recurrent or second primary oral cavity squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 131, 105951.	0.8	5
2747	Biochemistry of biomarkers in cardiotoxicity induced in chemotherapeutic drugs. , 2022, , 65-82.		0
2748	Palliative tumor surgery for incurable head and neck cancer: indications and outcomes: A retrospective case review. <i>Precision and Future Medicine</i> , 2022, 6, 146-153.	0.5	0
2749	Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States. <i>Journal of Medical Economics</i> , 2022, 25, 954-965.	1.0	4
2750	The role of palliative care in relapsed and metastatic head and neck cancer patients in a single ESMO integrated oncology and palliative care centre. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 5897-5902.	0.8	1
2751	An Integrated Analysis of Prognostic Signature and Immune Microenvironment in Tongue Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
2752	Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7889.	1.8	18
2753	Oligometastasis in head and neck squamous cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, , .	0.4	2
2754	Verification and validation of the anti-PD-L1 antibody, Clone 22C ₃ on a laboratory-developed test. <i>Journal of Clinical Pathology</i> , 2023, 76, 678-683.	1.0	0
2755	The potential role of immunity in the development of early distant metastases in locoregionally treated oral squamous cell carcinoma. <i>Medical Hypotheses</i> , 2022, 166, 110900.	0.8	0
2756	The story of EGFR: from signaling pathways to a potent anticancer target. <i>Future Medicinal Chemistry</i> , 2022, 14, 1267-1288.	1.1	11
2757	Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study. <i>Oncologist</i> , 2022, 27, 1016-1024.	1.9	5
2758	Diversity of the Origin of Cancer Stem Cells in Oral Squamous Cell Carcinoma and Its Clinical Implications. <i>Cancers</i> , 2022, 14, 3588.	1.7	7
2759	Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma. <i>Communications Biology</i> , 2022, 5, .	2.0	12
2760	PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 0, , .	0.8	0
2761	ééf”ç™Ĉå…ç–«ç™,æ³•ã@ã,“ãfã,»ãf³ã,¹. <i>Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaiho</i> , 2022, 125, 1062-1066.	0.0	0
2762	Patients with Pulmonary Metastases from Head and Neck Cancer Benefit from Pulmonary Metastasectomy, A Systematic Review. <i>Medicina (Lithuania)</i> , 2022, 58, 1000.	0.8	7
2763	Free three-dimensional image software in local extension assessment of oral squamous cell carcinoma: a pilot study. <i>Brazilian Journal of Otorhinolaryngology</i> , 2022, 88, S117-S123.	0.4	1

#	ARTICLE	IF	CITATIONS
2764	Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study. <i>PLoS ONE</i> , 2022, 17, e0271907.	1.1	5
2765	Design, Synthesis, and Characterization of Novel Coordination Compounds of Benzimidazole Derivatives with Cadmium. <i>Pharmaceutics</i> , 2022, 14, 1626.	2.0	3
2766	Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1. <i>Cancer Research Communications</i> , 2022, 2, 1061-1074.	0.7	4
2767	Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan. <i>Anticancer Research</i> , 2022, 42, 4477-4484.	0.5	8
2768	Clinical applications of mass spectrometry-based proteomics in cancer: Where are we?. <i>Proteomics</i> , 2023, 23, .	1.3	20
2769	Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study. <i>Acta Oncologica</i> , 2022, 61, 972-978.	0.8	1
2770	Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor. <i>Anticancer Research</i> , 2022, 42, 4273-4283.	0.5	1
2771	Combined taxane, platinum, and cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study. <i>Head and Neck</i> , 2022, 44, 2040-2045.	0.9	3
2772	Current perspectives on recurrent HPV-mediated oropharyngeal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
2773	Genome-Wide Super-Enhancer-Based Analysis: Identification of Prognostic Genes in Oral Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9154.	1.8	2
2774	Therapy of head and neck cancer in China: Introduction to the special issue. <i>Head and Neck</i> , 2022, 44, 2007-2008.	0.9	1
2775	Radiotherapy plus cetuximab or cisplatin in head and neck squamous cell carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. <i>European Archives of Oto-Rhino-Laryngology</i> , 2023, 280, 11-22.	0.8	3
2776	Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1669-1674.	1.0	3
2777	Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 918.	1.2	4
2778	Exosomes at the crossroad between therapeutic targets and therapy resistance in head and neck squamous cell carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188784.	3.3	6
2779	Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2). <i>International Journal of Clinical Oncology</i> , 2022, 27, 1675-1683.	1.0	2
2780	Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: A Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Revista Espanola De Patologia</i> , 2022, , .	0.6	0
2781	Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study. <i>Head and Neck</i> , 0, , .	0.9	2

#	ARTICLE	IF	CITATIONS
2782	Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature. International Journal of Nanomedicine, 0, Volume 17, 4293-4306.	3.3	10
2783	HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer. Cancer Journal (Sudbury, Mass), 2022, 28, 339-345.	1.0	3
2784	Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer. Cancer Journal (Sudbury, Mass) Tj ETQq0 0 0 rgBT /Overlock 10	1.0	67
2785	Current Trends in Anticancer Drug Delivery System for Oral Cancer- A PRISMA complaint Systematic Review. Open Dentistry Journal, 2022, 16, .	0.2	0
2786	The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response. Cells, 2022, 11, 2866.	1.8	4
2787	Oral Cancer Management. , 2022, , 1009-1055.		0
2788	Reproduction of the Antitumor Effect of Cisplatin and Cetuximab Using a Three-dimensional Spheroid Model in Oral Cancer. International Journal of Medical Sciences, 2022, 19, 1320-1333.	1.1	7
2789	Available immunotherapies and future opportunities to prevent HPV-associated cancers. , 2022, , 165-204.		0
2790	Systemic Therapy Advances in Head and Neck Cancer. , 2022, , 61-72.		0
2791	Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status. Frontiers in Oncology, 0, 12, .	1.3	0
2792	Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China. Journal of Oncology, 2022, 2022, 1-8.	0.6	1
2793	Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine. Journal of Personalized Medicine, 2022, 12, 1544.	1.1	2
2794	PI3K Inhibition for Squamous Cell Head and Neck Carcinoma. Cancer Journal (Sudbury, Mass), 2022, 28, 369-376.	1.0	0
2795	Clinical outcome of nivolumab in older and frail patients with recurrent/metastatic head and neck squamous cell carcinoma. Journal of Geriatric Oncology, 2023, 14, 101380.	0.5	1
2796	Model-informed experimental design recommendations for distinguishing intrinsic and acquired targeted therapeutic resistance in head and neck cancer. Npj Systems Biology and Applications, 2022, 8, .	1.4	6
2797	Towards precision oncology with patient-derived xenografts. Nature Reviews Clinical Oncology, 2022, 19, 719-732.	12.5	33
2798	Plasma oncology: Adjuvant therapy for head and neck cancer using cold atmospheric plasma. Frontiers in Oncology, 0, 12, .	1.3	3
2799	A novel ligand-modified nanocomposite microparticles improved efficiency of quercetin and paclitaxel delivery in the non-small cell lung cancer. Drug Delivery, 2022, 29, 3123-3133.	2.5	5

#	ARTICLE	IF	CITATIONS
2800	Role of Molecular Targeted Therapeutic Drugs in Treatment of Oral Squamous Cell Carcinoma: Development and Current Strategies”A Review Article. <i>Global Medical Genetics</i> , 2022, 09, 242-246.	0.4	1
2801	Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
2802	A novel neutrophil extracellular trap signature to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
2803	Head and neck surgical oncology. <i>Journal of Surgical Oncology</i> , 2022, 126, 860-864.	0.8	1
2804	Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma. <i>Digestive and Liver Disease</i> , 2022, , .	0.4	3
2805	Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Clinical Oncology</i> , 2022, 34, e473-e481.	0.6	1
2806	The prognostic impact of the immune signature in head and neck squamous cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2807	Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2022, 42, 4907-4912.	0.5	2
2808	Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2023, 280, 1391-1401.	0.8	1
2809	Relationships of Ferroptosis and Pyroptosis-Related Genes with Clinical Prognosis and Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-47.	1.9	5
2810	Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck. <i>Oral Oncology</i> , 2022, 135, 106183.	0.8	4
2811	Drug Targets and Strategies in the Clinical Development of Immunotherapy for Head and Neck Cancer. , 2022, , .		0
2812	A study on treatment methods for distant metastasis of head and neck squamous cell carcinoma. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2022, 32, 125-130.	0.0	0
2813	Immunotherapy in head and neck squamous cell carcinoma: An updated review. <i>Cancer Treatment and Research Communications</i> , 2022, 33, 100649.	0.7	11
2814	Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	3
2815	Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer “ Results of a large multicenter analysis. <i>Radiotherapy and Oncology</i> , 2023, 181, 109380.	0.3	9
2816	Role of <i>TNFSF15</i> variants in oral cancer development and clinicopathologic characteristics. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 5452-5462.	1.6	4
2817	Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 222-232.	0.8	58

#	ARTICLE	IF	CITATIONS
2818	Nectin-4 is widely expressed in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2022, 13, 1166-1173.	0.8	6
2819	Essential news of current guidelines: head and neck squamous cell carcinoma. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 278-281.	0.3	1
2820	The Role of Immune Checkpoint Inhibitors in Pharyngolaryngeal Cancer: A Current Review. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 318-324.	0.0	0
2821	Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. <i>Cancers</i> , 2022, 14, 4985.	1.7	5
2822	EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188827.	3.3	7
2824	A novel nomogram and risk classification system for predicting overall survival in head and neck squamous cell cancer with distant metastasis at initial diagnosis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2023, 280, 1467-1478.	0.8	6
2825	Targeting cellular metabolism in head and neck cancer precision medicine era: A promising strategy to overcome therapy resistance. <i>Oral Diseases</i> , 2023, 29, 3101-3120.	1.5	5
2826	Anti-EGFR-Based Therapy in Recurrent or Metastatic HNSCC – What Difference Does it Make?. <i>Cancer Investigation</i> , 0, , 1-8.	0.6	0
2828	First-line pembrolizumab±chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1805-1817.	1.0	5
2829	Complete response of recurrent oral squamous cell carcinoma treated with cetuximab in combination with radiotherapy: A case series. <i>Oncology Letters</i> , 2022, 24, .	0.8	0
2830	Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
2831	Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy. <i>BMC Cancer</i> , 2022, 22, .	1.1	1
2832	<sc>SOD2</sc> confers anlotinib resistance via regulation of mitochondrial damage in <sc>OSCC</sc>. <i>Oral Diseases</i> , 0, , .	1.5	3
2833	A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2022, 135, 106219.	0.8	5
2834	Improved antitumor immunity of chemotherapy in OSCC treatment by Gasdermin-E mediated pyroptosis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2023, 28, 348-361.	2.2	5
2835	Developments on the Smart Hydrogel-Based Drug Delivery System for Oral Tumor Therapy. <i>Gels</i> , 2022, 8, 741.	2.1	12
2836	Oral Squamous Cell Carcinoma-Associated Thrombosis: What Evidence?. <i>Cancers</i> , 2022, 14, 5616.	1.7	1
2837	Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer. <i>Cancers</i> , 2022, 14, 5662.	1.7	8

#	ARTICLE	IF	CITATIONS
2838	Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma. <i>Pharmaceutics</i> , 2022, 14, 2494.	2.0	0
2839	Tumoren im Kopf-Hals-Bereich. , 2023, , 585-626.		0
2840	Updates and Controversies in the Management of Head and Neck Malignancy. , 2022, , 455-483.		0
2841	Immunotherapy and Targeted Therapy in the Management of Oral Cancers. <i>Critical Reviews in Oncogenesis</i> , 2022, , .	0.2	0
2842	Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. , 2022, , 153-172.		1
2843	Oropharyngeal and Hypopharyngeal Tumours and Their Treatment. , 2022, , 147-167.		0
2844	Interdisciplinary Approach in Head and Neck Cancers. , 2022, , .		0
2845	Complete Response to Nivolumab of Resected Adenocarcinoma NOS With Parotid Gland Origin and Lung Metastasis. <i>In Vivo</i> , 2022, 36, 2840-2843.	0.6	1
2846	Improved treatment of head and neck cancer using 3-D focused ultrasound-mediated cetuximab drug delivery. , 2022, , .		0
2848	Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
2849	Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	8
2850	Nonsurgical Treatment Strategies for Elderly Head and Neck Cancer Patients: An Emerging Subject Worldwide. <i>Cancers</i> , 2022, 14, 5689.	1.7	0
2852	Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15384.	1.8	12
2853	Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
2854	Developing a Gallium(III) Agent Based on the Properties of the Tumor Microenvironment and Lactoferrin: Achieving Two-Agent Co-delivery and Multi-targeted Combination Therapy of Cancer. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 793-803.	2.9	14
2855	Editorial: Women in head and neck cancer 2021. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2856	Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. <i>Journal of Clinical Oncology</i> , 2023, 41, 2166-2180.	0.8	32
2857	Current Indications for Intraarterial Chemotherapy in Neurointerventional Surgery. , 2023, 3, .		0

#	ARTICLE	IF	CITATIONS
2858	Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. <i>Annals of Oncology</i> , 2023, 34, 262-274.	0.6	32
2859	Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. <i>Drugs</i> , 2023, 83, 217-248.	4.9	22
2860	Targeted therapy for head and neck cancer: signaling pathways and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	27
2861	Squamous Cell Carcinoma of Head and Neck. , 0, , .		0
2862	Inhibition of human oral squamous cell carcinoma proliferation and migration by prodrug-activating suicide gene therapies. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	0.8	0
2863	Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. , 2023, 11, e005940.		12
2864	A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer. , 2023, 40, .		2
2865	Radiotherapy, Chemotherapy and Immunotherapy-Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma. <i>Diagnostics</i> , 2023, 13, 99.	1.3	2
2866	Therapeutic Cancer Vaccines for the Management of Recurrent and Metastatic Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 0, , .	1.2	0
2867	Oropharynx und Larynx. , 2022, , 171-187.		0
2868	Medikamentöse Tumorthherapie des Älteren Menschen. , 2022, , 297-315.		0
2869	Karzinome der Mundhöhle. , 2022, , 147-170.		0
2871	Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma. <i>JAMA Network Open</i> , 2023, 6, e2250607.	2.8	9
2872	Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer. <i>Journal of the Egyptian National Cancer Institute</i> , 2023, 35, .	0.6	1
2873	Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in Older Patients: Are New Agents Bringing New Hope?. <i>Drugs and Aging</i> , 2023, 40, 135-143.	1.3	2
2874	Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, 153303382211505.	0.8	7
2875	Tumor immunology. , 2023, , 245-452.		0
2876	Immunotherapy in HPV-Related Oropharyngeal Cancers. <i>Current Treatment Options in Oncology</i> , 2023, 24, 170-183.	1.3	7

#	ARTICLE	IF	CITATIONS
2877	Insight into autophagy in platinum resistance of cancer. <i>International Journal of Clinical Oncology</i> , 2023, 28, 354-362.	1.0	2
2878	High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Case Reports in Oncology</i> , 0, , 13-20.	0.3	0
2879	Prognostic Impact of Sarcopenia's Occurrence during Radiotherapy in Oropharyngeal Cancer Patients. <i>Cancers</i> , 2023, 15, 723.	1.7	2
2880	Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. , 2023, , 41-46.		0
2881	Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity. <i>Cancer Research Communications</i> , 2023, 3, 245-257.	0.7	0
2882	A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal) Tj ETQq1 1 0.784314 rgBT /Ove Medical Oncology, 2023, 15, 175883592311659.	1.4	0
2883	Immune Checkpoint Inhibition and Radiotherapy in Head and Neck Squamous Cell Carcinoma: Synergisms and Resistance Mechanisms. , 2023, , 11-21.		0
2884	æ¬¡ä,-ä»£äf³äf1/4äf€äf1/4ä@è,²æ^â•éé,éƒ"ç™CEã«ã~3/4ã™ã,ã...ç-«ç™,æ³•ã@æœ€ã%øç•šã€. Nihon Jibi Inkoka Tohokubu Gekø Gakkai Ka		
2885	Long term outcomes of phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early failure oral cancer. , 2023, 12, 100143.		1
2886	Tumor immune microenvironment alterations using induction cetuximab in a phase <sc>II</sc> trial of deintensified therapy for <sc>p16</sc>-positive</sc> oropharynx cancer. <i>Head and Neck</i> , 2023, 45, 1281-1287.	0.9	3
2888	Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial. <i>Nature Medicine</i> , 2023, 29, 880-887.	15.2	12
2889	Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2023, 184, 30-38.	1.3	5
2890	Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2023, 9, 779.	3.4	18
2892	Radio-Chemo-Therapie. , 2022, , 263-295.		0
2893	HÄmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
2894	PLODs: Novel prognostic biomarkers and potential immunotherapy targets for head and neck squamous cell carcinoma. <i>Heliyon</i> , 2023, 9, e13479.	1.4	2
2895	MiR-455-5p suppresses PDZK1IP1 to promote the motility of oral squamous cell carcinoma and accelerate clinical cancer invasion by regulating partial epithelial-to-mesenchymal transition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	5
2896	Immunotherapy for Head and Neck Cancers. , 2023, , 1-28.		0

#	ARTICLE	IF	CITATIONS
2915	Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer. <i>Cells</i> , 2023, 12, 926.	1.8	8
2916	A Case Series on Pain Accompanying Photoimmunotherapy for Head and Neck Cancer. <i>Healthcare (Switzerland)</i> , 2023, 11, 924.	1.0	3
2917	Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2023, 35, 166-177.	1.1	1
2918	Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2023, 35, 158-165.	1.1	1
2919	Novel Immune Oncology Targets Beyond PD-1/PD-L1 in Head and Neck Cancer. , 2023, , 51-61.		0
2920	Systemic Treatment Sequencing and Prediction of First-line Therapy Outcomes in Recurrent or Metastatic Head and Neck Cancer. , 2023, , 199-215.		0
2921	Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer. <i>Cancers</i> , 2023, 15, 1959.	1.7	3
2922	Neoadjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma: Expecting Its Application in Temporal Bone Squamous Cell Carcinoma. <i>Current Medical Science</i> , 2023, 43, 213-222.	0.7	2
2923	Treatment Intensification in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: What Are the Options and for Whom?. , 2023, , 129-164.		0
2924	Impact of monoclonal antibody therapy for head and neck cancer on end-of-life care utilization and costs. <i>Head and Neck</i> , 0, , .	0.9	0
2925	Editorial: Insights in head and neck cancer: 2021. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
2926	Randomized Phase II Trial of Ficlatazumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 3851-3862.	0.8	2
2927	Identification of HPV16 E1 and E2-specific T cells in the oropharyngeal cancer tumor microenvironment. , 2023, 11, e006721.		3
2928	A Novel Near-IR Absorbing Ruthenium(II) Complex as Photosensitizer for Photodynamic Therapy and its Cetuximab Bioconjugates. <i>ChemBioChem</i> , 0, , .	1.3	5
2929	Combination Immunotherapy in Head and Neck Cancer—Checkmate or a Draw?. <i>JAMA Oncology</i> , 0, , .	3.4	0
2930	Pharmacoeconomic Appraisal of Treating Head and Neck Cancer with Various Chemotherapy and Chemoradiation Regimens Using Branded and Jan-aushadhi Drugs in India. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 0, , .	0.3	0
2931	Immunotherapeutic and their immunological aspects: Current treatment strategies and agents. <i>National Journal of Maxillofacial Surgery</i> , 2022, 13, 322.	0.1	1
2932	Head and neck cancer treatment in the era of molecular medicine. <i>Advances in Cancer Research</i> , 2023, , 205-252.	1.9	2

#	ARTICLE	IF	CITATIONS
2933	Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. <i>Cancer Reports</i> , 2023, 6, .	0.6	4
2934	Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7114.	1.8	1
2935	Molecular insights into the role of electronic cigarettes in oral carcinogenesis. <i>Critical Reviews in Toxicology</i> , 2023, 53, 1-14.	1.9	2
2936	Anti-PD-1 immunotherapy with dose-adjusted ultra-hypofractionated re-irradiation in patients with locoregionally recurrent head and neck cancer. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	3
2937	Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2023, 24, 680-692.	1.3	4
2938	Firstâ€line cetuximab+â€platinumâ€based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A realâ€world observational studyâ€” <scp>ENCORE</scp>. <i>Cancer Reports</i> , 0, , .	0.6	1
2939	Immune-related adverse events following checkpoint inhibitor treatment in head and neck cancers: A comprehensive review. , 2023, 6, 100036.		4
2940	Theranostic Potential of EFN2 for Cetuximab Resistance in Head and Neck Cancer. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2023, 75, 1923-1936.	0.3	1
2943	Harnessing Phagocytosis for Cancer Treatment. <i>Physiology</i> , 0, , .	4.0	0
2952	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
2962	Palliative radiotherapy in the head and neck. , 2024, , 141-154.		0
2975	Oral Metronomic Chemotherapy in Advanced and Metastatic Oral Squamous Cell Carcinoma: A Need of the Hour. <i>Journal of Maxillofacial and Oral Surgery</i> , 0, , .	0.6	2
2980	Therapeutics: Pharmacology, Chemotherapy, Radiation Oncology. , 2023, , 187-208.		0
2990	Current systemic treatment options and new developments in palliative first-line treatment of head and neck squamous cell carcinoma. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	1
3003	Oral squamous cell carcinomas: state of the field and emerging directions. <i>International Journal of Oral Science</i> , 2023, 15, .	3.6	16
3019	Editorial: Women in head and neck cancer, volume II: 2022. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
3021	Head and neck cancer revisited. <i>Memo - Magazine of European Medical Oncology</i> , 2023, 16, 146-147.	0.3	0
3078	Oral squamous cell carcinoma. , 2024, , 1-87.		0

#	ARTICLE	IF	CITATIONS
3089	Automatic Detection and Epidemiologic Trends in Head and Neck Cancer Using Fast-R-CNN and SVM Methods. , 2023, , .		0
3091	Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis. European Archives of Oto-Rhino-Laryngology, 0, , .	0.8	0
3092	Malignome des Kopf- und Halsbereichs. , 2024, , 647-673.		0
3096	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0